

Lund, Crick et al.

**Working Paper**

## The Effects of Mental Health Interventions on Labor Market Outcomes in Low- and Middle-Income Countries

IZA Discussion Papers, No. 17071

**Provided in Cooperation with:**

IZA – Institute of Labor Economics

*Suggested Citation:* Lund, Crick et al. (2024) : The Effects of Mental Health Interventions on Labor Market Outcomes in Low- and Middle-Income Countries, IZA Discussion Papers, No. 17071, Institute of Labor Economics (IZA), Bonn

This Version is available at:

<https://hdl.handle.net/10419/300967>

**Standard-Nutzungsbedingungen:**

Die Dokumente auf EconStor dürfen zu eigenen wissenschaftlichen Zwecken und zum Privatgebrauch gespeichert und kopiert werden.

Sie dürfen die Dokumente nicht für öffentliche oder kommerzielle Zwecke vervielfältigen, öffentlich ausstellen, öffentlich zugänglich machen, vertreiben oder anderweitig nutzen.

Sofern die Verfasser die Dokumente unter Open-Content-Lizenzen (insbesondere CC-Lizenzen) zur Verfügung gestellt haben sollten, gelten abweichend von diesen Nutzungsbedingungen die in der dort genannten Lizenz gewährten Nutzungsrechte.

**Terms of use:**

*Documents in EconStor may be saved and copied for your personal and scholarly purposes.*

*You are not to copy documents for public or commercial purposes, to exhibit the documents publicly, to make them publicly available on the internet, or to distribute or otherwise use the documents in public.*

*If the documents have been made available under an Open Content Licence (especially Creative Commons Licences), you may exercise further usage rights as specified in the indicated licence.*

DISCUSSION PAPER SERIES

IZA DP No. 17071

**The Effects of Mental Health Interventions  
on Labor Market Outcomes in Low- and  
Middle-Income Countries**

Crick Lund  
Kate Orkin  
Marc Witte  
John Walker  
Thandi Davies  
Johannes Haushofer

Sarah Murray  
Judy Bass  
Laura Murray  
Wietse Tol  
Vikram Patel

JUNE 2024

## DISCUSSION PAPER SERIES

IZA DP No. 17071

# The Effects of Mental Health Interventions on Labor Market Outcomes in Low- and Middle-Income Countries

**Crick Lund\***

*King's College London and University of Cape Town*

**Kate Orkin\***

*University of Oxford, CEPR and IZA*

**Marc Witte\***

*VU Amsterdam and IZA*

**John Walker**

*University of Oxford*

**Thandi Davies**

*University of Cape Town*

**Johannes Haushofer**

*Stockholm University, National University of Singapore, NBER and BREAD*

**Sarah Murray**

*John Hopkins University*

**Judy Bass**

*John Hopkins University*

**Laura Murray**

*John Hopkins University*

**Wietse Tol**

*University of Copenhagen*

**Vikram Patel**

*Harvard University*

\* denotes joint first authors

JUNE 2024

Any opinions expressed in this paper are those of the author(s) and not those of IZA. Research published in this series may include views on policy, but IZA takes no institutional policy positions. The IZA research network is committed to the IZA Guiding Principles of Research Integrity.

The IZA Institute of Labor Economics is an independent economic research institute that conducts research in labor economics and offers evidence-based policy advice on labor market issues. Supported by the Deutsche Post Foundation, IZA runs the world's largest network of economists, whose research aims to provide answers to the global labor market challenges of our time. Our key objective is to build bridges between academic research, policymakers and society.

IZA Discussion Papers often represent preliminary work and are circulated to encourage discussion. Citation of such a paper should account for its provisional character. A revised version may be available directly from the author.

ISSN: 2365-9793

IZA – Institute of Labor Economics

Schaumburg-Lippe-Straße 5–9  
53113 Bonn, Germany

Phone: +49-228-3894-0  
Email: [publications@iza.org](mailto:publications@iza.org)

[www.iza.org](http://www.iza.org)

## ABSTRACT

---

# The Effects of Mental Health Interventions on Labor Market Outcomes in Low- and Middle-Income Countries\*

Mental health conditions are prevalent but rarely treated in low- and middle-income countries (LMICs). Little is known about how these conditions affect economic participation. This paper shows that treating mental health conditions substantially improves recipients' capacity to work in these contexts. First, we perform a systematic review and meta-analysis of all randomized controlled trials (RCTs) ever conducted that evaluate treatments for mental ill-health and measure economic outcomes in LMICs. On average, treating common mental disorders like depression with psychotherapy improves an aggregate of labor market outcomes made up of employment, time spent working, capacity to work and job search by 0.16 standard deviations. Treating severe mental disorders, like schizophrenia, improves the aggregate by 0.30 standard deviations, but effects are noisily estimated. Second, we build a new dataset, pooling all available microdata from RCTs using the most common trial design: studies of psychotherapy in LMICs that treated depression and measured days participants were unable to work in the past month. We observe comparable treatment effects on mental health and work outcomes in this sub-sample of highly similar studies. We also show evidence consistent with mental health being the mechanism through which psychotherapy improves work outcomes.

**JEL Classification:** D9, I14, O1, J24

**Keywords:** labor, development, human capital, mental health, psychotherapy

**Corresponding author:**

Marc Witte  
Forschungsinstitut zur Zukunft der Arbeit (IZA)  
Schaumburg-Lippe-Str. 5-9  
53113 Bonn  
Germany  
E-mail: [witte@iza.org](mailto:witte@iza.org)

---

\* This study was funded by the Wellspring Philanthropic Fund. We are grateful to Ondine Berland, Carrie Brooke-Sumner, Alice Cahill, Tim Deisemann, Vimbayi Mafunda, Drummond Orr and Hannah Zillesen for excellent research assistance. Our thanks to Manuela Angelucci, Victoria Baranov, Sonia Bhalotra, Daniel Bennett, Pietro Biroli, Paul Bolton, Jon de Quidt, Sandy Douglas, Michael Gechter, Supreet Kaur, Rachael Meager, Gautam Rao, Matthew Ridley, Frank Schilbach, Graham Thornicroft, and Eva Vivalt for thoughtful comments.

# 1 Introduction

Mental health conditions are highly prevalent: they are one of the ten major causes of disability globally, affecting 12% of the global population at any time (GBD 2019 Collaborators, 2022). In high-income countries (HICs), treating mental health conditions improves symptoms of mental illness and improves employment rates, reduces sick days, and enhances functioning at work, reducing output losses from mental ill-health (Chan et al., 2015, Nieuwenhuijsen et al., 2020, Salomonsson et al., 2018, van Duin et al., 2019).<sup>1</sup>

However, the effect of mental ill-health on economic outcomes in low- and middle-income countries (LMICs) remains poorly understood. Treatments developed in HICs and adapted to LMICs improve symptoms of mental illness in LMICs (Cuijpers et al., 2018, De Silva et al., 2013), but recent economic studies of depression treatments find conflicting effects on economic outcomes.<sup>2</sup> There is also little evidence on the economic effects of treatments for severe mental disorders, like schizophrenia. Evidence from HICs might have limited relevance for economic outcomes in LMICs: mental health treatments in LMICs are often modified to limit costs and labor market characteristics differ substantially.

Hence, this paper studies whether mental health treatments improve work and other economic outcomes in LMICs. We conduct the first systematic review of this literature, compiling a dataset of findings and study characteristics from all studies available online before April 2022 that 1) reported on a randomized controlled trial (RCT) testing a psychosocial or pharmacological (medication) intervention in an LMIC; 2) treated people diagnosed with a mental health disorder; and 3) measured any of a list of pre-specified economic outcomes.<sup>3</sup> We screened 15,031 papers and read 1,128 fully, yielding a sample of 39 eligible interventions. We record all effect sizes on economic outcomes and potential psychological and behavioral mechanisms for economic effects in these studies using standard meta-analysis methods.

The first part of the paper estimates the effect of psychosocial treatments for mental health conditions across all available studies. We conduct separate meta-analyses on our database of effect sizes for two theoretically distinct types of studies. First, studies of sixteen interventions test the effect of psychosocial interventions treating populations

---

<sup>1</sup>It is estimated global output losses from mental ill-health will total USD 7.3 trillion (in 2010 USD) over the period 2010-30, more than those associated with cardiovascular diseases (Bloom et al., 2011). Roughly two-thirds of these losses are attributed to lost income from the effects of mental ill-health on work outcomes, like employment, productivity and absenteeism.

<sup>2</sup>For example, Angelucci and Bennett (2024), Baranov et al. (2020), Barker et al. (2022), Bhat et al. (2022) and Haushofer et al. (2020).

<sup>3</sup>Our review protocol CRD42017058930 was registered with the Prospective Register of Systematic Reviews (PROSPERO) ([https://www.crd.york.ac.uk/prospero/display\\_record.php?RecordID=58930](https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=58930)).

experiencing diagnosed common mental disorders (CMDs), depression and anxiety, with 15,444 trial participants.<sup>4</sup> These studies usually compare treatment to no treatment. Second, nine studies test “combination” treatments for populations experiencing severe mental disorders (SMDs), like schizophrenia, with 2,096 participants. These include both a psychosocial treatment and medication and are usually compared to receiving medication alone.<sup>5</sup> Under the assumption that the combination of treatments for SMDs has additive treatment effects, we recover the effect of receiving a psychosocial treatment in both populations. For each population, we separately estimate an average effect, across studies, on each of a set of similarly measured labor market outcomes and a labor market outcome aggregate, as well as other economic outcomes. We conservatively account for heterogeneity between study populations within these two groupings using Bayesian hierarchical models, alongside their traditional frequentist random-effects meta-analysis counterparts. Reported effects are from Bayesian models unless specified. Our search also captured studies testing treatments for post-traumatic stress disorder and substance use disorders and one study that tested pharmacological interventions for depression. However, we had too few studies of each of these types for substantive inference.<sup>6</sup>

Our first finding is that psychosocial interventions improve labor market outcomes in populations experiencing CMDs. On average, these interventions improve a pre-specified set of labor market outcomes comprised of measures of whether recipients are employed, their time spent working, their capacity to work, and their engagement in job search by 0.16 SD (95% CI: [0.03, 0.31]). Point estimates under our frequentist model are similar, but more precisely estimated, consistent with observed heterogeneity in effect sizes. These interventions improve a measure of work capacity: the number of days recipients are unable to work, by 0.08 SD (95% CI: [0.01, 0.17]). Effects on other sub-groupings of work outcomes are positive but not statistically significant. Six interventions reported an effect on the specific measure “days unable to work in the last 30 days”, allowing us to report an aggregate effect size without standardization. Among these interventions, the average reduction was 1.42 days, or 13% relative to a control group mean of 11 days.<sup>7</sup>

Our second finding is that the effects on the labor market aggregate are even larger for mental health treatments in populations experiencing SMDs, averaging 0.30 SD. These effects are significant in the frequentist specification (95% CI: [0.06, 0.54]) but only sig-

---

<sup>4</sup>At any one time, 3.4% of adults internationally have depression, 3.8% have anxiety and 1% have severe mental health conditions like schizophrenia (GBD 2019 Collaborators, 2022).

<sup>5</sup>There is now strong evidence that pharmacological treatments (medication) are effective in the treatment of SMDs, so few trials evaluate this intervention alone (Leucht et al., 2013).

<sup>6</sup>For completeness, findings are reported in Appendix Table A12.

<sup>7</sup>Here, we report the coefficient from the frequentist model. The Bayesian point estimate is less representative of the magnitude of the effect due to the small sample size, as outlined on page 19.

nificant at the 90% level (95% CI: [-0.05, 0.67]) under our more conservative Bayesian specification. Standard errors are larger under the Bayesian method as it better accounts for the impact of unexplained heterogeneity in study effects.

We run robustness checks on our main findings of effects on the aggregate of work-related outcomes. First, we control for study characteristics within a meta-regression framework. Next, we compare effects across subsamples disaggregated by potentially important dimensions of heterogeneity. Effects are robust across the income level of the country and the region in which the country falls. Effects are also robust to the use of different study designs. There is some evidence that treatment effects decay over time. For the CMD sample, effects are smaller in survey rounds conducted more than a year after treatment relative to those conducted sooner, but there is limited evidence of any effect in the SMD sample. Treatments for CMDs administered by clinicians and laypeople are both effective at improving work outcomes, although clinician-administered interventions have larger effects. Effects on work outcomes are, unsurprisingly, smaller for CMD treatments delivered to women in the post-natal period and living in countries with low female labor force participation than in other populations. Using a range of methods, we find no evidence of publication bias in our sample of studies .

Studies of psychosocial interventions targeting CMDs also measure non-work economic outcomes: education expenditure, assets, income, consumption, input expenditure, and subjective poverty. Our third finding is that treatment non-significantly improves an aggregate of these outcomes by 0.08 SD (95% CI: [-0.05, 0.21]), with larger effects on education outcomes and subjective poverty measures, and smaller effects on other outcomes. While results are significant at conventional levels under the frequentist specification, they are not under the Bayesian due to effect heterogeneity.

Fourth, we present evidence that improvements in symptoms of mental ill-health and functional impairment due to mental ill-health are mechanisms through which treatments improve work outcomes. Functional impairment occurs when an individual's health condition reduces their capacity to fulfil their normal social and work roles (Edlund et al., 2018). Psychosocial treatments for both CMDs and SMDs lead to large, generally statistically significant improvements in both symptoms of mental health disorders and measures of functional impairment. Larger positive effects on work outcomes reported for a given intervention are strongly correlated with larger improvements in symptoms of mental ill-health ( $\beta = 0.70$ ) and in functioning ( $\beta = 0.63$ ).

The second part of the paper replicates these findings using individual-level data and methods more standard in economics. We also examine if mental ill-health is the mechanism causing poorer work outcomes. Our second econometric strategy leverages the high

frequency of studies of psychosocial treatments for depression identified by our review. We generate a unique new dataset, pooling and harmonizing microdata on 10,731 study participants from six studies that treat depression using psychosocial therapies, measure days participants are unable to work, and provide data publicly.<sup>8</sup>

First, we show our main findings are robust in individual-level data using standard economic methods within this subset of highly similar studies. We use OLS to test if psychosocial treatment improves mental health and ability to work in this sample and present our findings in traditional (un-standardized) units. Consistent with our meta-analysis, psychosocial treatment improves depression substantially and reduces days unable to work by 1.57 days per month (SE 0.86), or 24% relative to a control mean of 6.34 days.<sup>9</sup>

Second, we show substantial treatment effect heterogeneity by individual-level characteristics, analysis uniquely enabled by our individual-level data. Treatment yields larger improvements in mental health in groups with more severe baseline depression: treatment reduces depression by 0.12, 0.30 and 0.35 SD for those with mild, moderate and severe depression respectively and differences between groups are significant. We find suggestive evidence that treated individuals more severe depression also see larger reductions in days unable to work than those with mild depression, suggesting that mental health is a mechanism through which mental health treatment improves work outcomes. However, effects are noisily estimated. We find little evidence that treatment effects differ by age.

Finally, we estimate the individual-level elasticity of economic outcomes with respect to changes in depression symptoms. We instrument depression with assignment to a psychosocial intervention. We produce Two-Stage Least Squares (2SLS) estimates: a 0.22 SD reduction in depression symptoms (equivalent to that induced by the average treatment) is significantly associated with being unable to work 1.68 (26%) fewer days per month. In our view, this is the current best feasible test of the causal impact of mental ill-health associated with depression on work outcomes.

We contribute to the literature in economics studying the effects of mental health treatments on work outcomes. We present the first definitive evidence that treating mental health disorders improves work outcomes in LMICs, from the first meta-analysis of the economic impacts of mental health interventions in LMICs and the first analysis of microdata pooled from such interventions in any context.

The question of how mental health interventions affect work outcomes has been stud-

---

<sup>8</sup>For a subset we have repeated measurements, yielding 15,517 observations of 10,731 unique study participants. This approach mirrors [Angrist and Meager \(2023\)](#), [Meager \(2019\)](#) and [Tan and Kremer \(2020\)](#).

<sup>9</sup>This offers some evidence against violation of exchangeability (included studies plausibly arise from the same data generating process). We observe a consistent result among a more homogeneous subsample, suggesting that it is not extreme heterogeneous cases driving results.



ied in HICs. Meta-analyses find that therapies for mental ill-health improve employment rates, reduce sick days, and enhance functioning at work (Chan et al., 2015, Nieuwenhuijsen et al., 2020, Salomonsson et al., 2018, van Duin et al., 2019), although none use Bayesian methods. Individual economic studies find that improved drug availability for these conditions improves earnings and labor market participation (Biasi et al., 2021, Bütikofer et al., 2020). But treatment effects may differ by context. HIC studies focus on relatively expensive treatments administered by clinicians. In LMICs, therapies are simplified to work cross-culturally and are often administered by non-specialist workers.<sup>10</sup> Labor markets also differ: LMICs tend to have more informal work and weaker labor market regulations, like provisions for sick leave, which people may use to manage their conditions.

An emerging literature in development economics finds mixed effects of mental health treatments on economic outcomes in LMICs. Papers mainly study the effects of psychosocial interventions for depression.<sup>11</sup> Barker et al. (2022) find that a psychosocial intervention improves mental and physical health in rural Ghana after one to three months.<sup>12</sup> In contrast, Haushofer et al. (2020) find no impact of a psychosocial intervention on either mental health or economic outcomes 12 months post-treatment in rural Kenya. Baranov et al. (2020) and Bhat et al. (2022) find persistent improvements in mental health but no labor supply effects from psychosocial interventions among all or mostly female populations in South Asia multiple years after treatment.<sup>13</sup>

We contribute to this literature in three ways. First, we are able to aggregate evidence from all available clinical and economic studies in LMICs, allowing us to reconcile these conflicting findings. We show that on average, psychosocial interventions for depression and anxiety (CMD) have positive and statistically significant impacts on work outcomes, although these are much smaller in contexts with low female labor force participation and decay over time. Effects are remarkably similar to effects from high income countries.<sup>14</sup>

Second, we present the first analysis of microdata pooled from such interventions in any context. We show that meta-analytic findings and standard economic methods produce similar findings. We also provide unique evidence using individual-level data that improvements in mental health are likely to be one of the mechanisms linking mental

---

<sup>10</sup>62% of the studies in our sample report on interventions employing lay-counsellors (Table H).

<sup>11</sup>Angelucci and Bennett (2024) find slightly negative effects of antidepressants for CMDs on hours worked and earnings but no other study examines pharmacological treatments for CMDs and measures economic outcomes so we do not provide meta-analytic evidence on these interventions.

<sup>12</sup>They study a general population and measure their mental health at baseline. We include estimates only on the subsample who meet clinical thresholds for having a mental disorder at baseline.

<sup>13</sup>They find effects on other economic outcomes. Baranov et al. (2020) find large effects on women's financial empowerment and parental investments. Bhat et al. (2022) find effects on people's beliefs about themselves, with implications for economic decision-making.

<sup>14</sup>See Section 5.2 for a detailed comparison of effect sizes.

health treatments to improvements in ability to work.

Finally, there is little evidence in either HICs or LMICs on the work effects of interventions to treat SMDs. We provide some of the first, albeit suggestive, evidence that such interventions may have large, economically important effects on work outcomes. However, using Bayesian methods highlights effect heterogeneity in the existing evidence base, indicating the need for more high-quality studies.

Our work is also related to the literature on the causal relationship between mental health and poverty. Whether mental ill-health causes poverty and the mechanisms underlying this relationship remain poorly understood (Ridley et al., 2020). A small quasi-experimental literature finds that mental ill-health causally increases poverty (Alloush, 2024, Stoop et al., 2019). However, these studies rely on strong assumptions about the dynamics of the long-run relationship between mental health and economic outcomes. Relative to these studies, we leverage RCT data to provide strong evidence that mental health worsens the ability to work, which may be the first link in a causal chain leading to lower earnings and poverty. Our findings paint a coherent picture. Studies with larger effects on mental health in our meta-analysis also have larger effects on work outcomes. In individual-level data, treatments have larger effects on work for those with worse mental health and the elasticity of days able to work with respect to mental health is of an economically meaningful magnitude. However, few studies in our sample collect data on earnings, limiting conclusions on later stages of the causal chain.

Our findings have immediate policy implications. Government expenditure on mental health treatment is meager, especially in LMICs.<sup>15</sup> Over 80% of people who need treatment for common mental disorders cannot access it, a substantially higher proportion than those who cannot access treatment for major physical health conditions (Chisholm et al., 2016). Analysing data on costs in our sample where available, we find interventions are of moderate cost, although there is substantial heterogeneity in costs by region and whether interventions use professional or lay-counsellors. Our work shows that treating mental ill health likely has important economic benefits in LMICs, alongside the known positive effects on mental health. Improving access to treatment presents an opportunity to significantly improve the lives of people living with these conditions in poor countries.

Sections 2 and 3 describe the systematic review process and studies captured in the search. Sections 4, 5 and 6 present the empirical strategy, results on economic outcomes and heterogeneity analysis. Section 7 analyzes potential mechanisms. Section 8 presents an analysis of the pooled microdata. Section 9 presents cost data.

---

<sup>15</sup>Median domestic expenditure on mental health is 2.1% of health expenditure globally, but only 1.05, 1.1 and 1.60% in low, lower-middle and upper-middle income countries (World Health Organization, 2021).

## 2 Systematic review procedure

A systematic review involves collecting information on and summarising all existing research on a topic. We followed guidelines from the Cochrane Collaboration for such reviews (Higgins et al., 2022). We review all studies published before April 2022 that 1) reported on an RCT testing a psychosocial or pharmacological intervention in an LMIC; 2) treated people diagnosed with a mental disorder; and 3) measured a pre-specified economic outcome. We used the Population, Intervention, Comparison and Outcome (PICO) method to pre-specify study inclusion criteria and minimize subjective inclusion decisions. We provide additional details of the search in Appendix A.

### 2.1 Inclusion and exclusion criteria

**Population:** We include only studies in low or middle-income countries, as defined by the World Bank in 2018.<sup>16</sup> We study the effect of treatment for a clinically diagnosed mental health condition. Study participants had to have been screened for a specific mental health condition and meet clinical criteria indicating they were currently living with the disorder. Screening could include an assessment on a self-reported psychological scale measuring symptoms of a mental health condition or a diagnostic assessment based on the Diagnostic and Statistical Manual of Mental Disorders (DSM) or International Classification of Diseases (ICD) criteria. Screening did not have to be done by a clinician. Studies where participants had a history of, but no current, mental illness were excluded. Participants had to be aged 14 years or older to focus on economically active populations.

**Intervention:** Interventions could include psychotherapy, psychological or psychosocial treatments (“psychosocial interventions”); pharmacological treatment; or interventions that combined psychosocial and pharmacological treatments. We compiled a list of widely used treatments, which we searched for using specific terms. In addition, we searched broadly for terms such as “mental health services” or “psychotherapy”. Interventions could vary in dose, duration, mode of delivery, and setting.

**Comparison:** We initially screened both RCTs and non-randomized evaluations for inclusion in the meta-analysis. However, we found a sufficient number of studies which used an RCT for well-powered inference, so we restricted the sample to only include RCTs.

**Outcomes:** We searched for any study that measured employment, ability to work, labor force participation, productivity, job search, income, earnings, wages, assets, wealth, consumption, expenditure, calorie count, food security, savings, investments or input expenditure, technology adoption, expenditure on temptation goods, financial outcomes,

---

<sup>16</sup>The World Bank’s classification criteria are outlined at <https://datahelpdesk.worldbank.org/knowledgebase/articles/378834-how-does-the-world-bank-classify-countries>.

health investment, education spending (children and own), income diversification, agricultural yields, revenue or profit from own employment, social networks or subjective poverty measures.<sup>17</sup> We present results by subgroups of outcomes as well as overall.

## 2.2 Search strategy

In the primary search, one author searched 21 databases (listed in Appendix A), including all major economics, social science, and clinical databases and repositories of working papers. We included studies published in any language if its abstract was in English.<sup>18</sup> We conducted forward and backward reference tracking of the citation lists of all included papers to identify other eligible studies. To capture trials in progress that might have reported results, we searched trial registries, contacted trial authors on NIH reporter, and contacted trial funders Grand Challenges Canada and the Abdul Latif Jameel Poverty Action Lab. More details are in Figure A1 and Appendix A. We placed no restrictions on the study date, with the earliest study published in 1994. The search ended in April 2022.<sup>19</sup>

## 3 Intervention and study characteristics

This section outlines the characteristics of the studies captured in our search, and the interventions they report on. Our search identifies 39 interventions evaluated in 35 different RCTs and reported on in 40 papers. Some trials test multiple interventions (e.g. [Ran et al., 2003](#)) and in some cases, more than one paper reports on the same intervention (e.g. [Nadkarni et al., 2017b,a](#)). Table 1 and Table A2 summarize the characteristics of the 39 interventions. Details of each intervention and study are presented in Table H.

### 3.1 Interventions, target conditions and control conditions

The search found studies that differed in which conditions they targeted, their choice of treatment and their selected control group. We face a decision about whether to aggregate across all treatments for all mental health conditions or analyze treatments for different conditions separately. Aggregating across more types of studies increases power, as we have more estimates of effect sizes, but also increases heterogeneity between studies being compared. To explain our choice of how to aggregate across interventions and studies into analysis groups, we briefly define some medical terms.

“Target conditions” are the type of mental health condition experienced by the population in which a study was conducted. We find interventions targeting four broad categories

---

<sup>17</sup>We collected studies measuring contraception use but decided not to include them in the analysis.

<sup>18</sup>We found three studies in Mandarin Chinese which were translated into English and included.

<sup>19</sup>Two articles were identified after the end of the search as part of forward and backward reference tracking of citation lists.

Table 1: Interventions in included randomized controlled trials

	All		Target CMD	Target SMD
	(1) Number of interventions	(2) Share of interventions	(3) N	(4) N
<b>Panel A: All interventions</b>	39	1.00	16	9
<b>Intervention type and targeted condition combination</b> ( <i>mutually exclusive</i> )				
Psychosocial + common mental disorders (CMD)	14	0.36	14	0
Combination + common mental disorders (CMD)	2	0.05	2	0
Combination + severe mental disorders (SMD)	9	0.23	0	9
Psychosocial + post-traumatic stress disorders (PTSD)	5	0.13	0	0
Psychosocial + substance use disorders (SUD)	5	0.13	0	0
Other combinations	4	0.10	0	0
<b>Panel B: Control conditions</b> ( <i>mutually exclusive</i> )				
Enhanced usual care	12	0.31	8	1
No treatment	14	0.36	5	0
Treatment as usual (pharmacological)	13	0.33	3	8
<b>Panel C: Outcome measures</b> ( <i>not mutually exclusive</i> )				
<b>Economic outcomes</b>				
<b>Work-related outcomes</b>	34	0.87	14	9
In employment (dummy)	7	0.18	4	1
Time in work	7	0.18	3	2
Unable to work (dummy)	5	0.13	0	3
Days unable to work	13	0.33	9	1
Functioning at work	13	0.33	5	4
Job search	3	0.08	2	0
<b>Non-work-related outcomes</b>	14	0.36	6	2
Education	3	0.08	1	0
Assets	4	0.10	1	0
Income, consumption and input expenditure	7	0.18	4	0
Subjective poverty measures	4	0.10	2	1
Social networks	2	0.05	0	0
Other	3	0.08	2	1
<b>Mental health outcomes</b>				
<b>Mental health condition symptoms</b>	36	0.92	14	8
Suicide attempts or at risk of suicide	10	0.26	6	1
Relapse (dummy)	8	0.21	3	4
Recovery (dummy)	4	0.10	1	2
Rehospitalisation (dummy)	4	0.10	1	3
Diagnosed with mental health condition (dummy)	7	0.18	4	0
Qualitative assessment of mental health condition	7	0.18	3	2
Substance use	6	0.15	0	0
CMD symptoms	23	0.59	13	0
PTSD symptoms	6	0.15	0	0
SMD symptoms	6	0.15	0	4
<b>Functioning and disability aggregate</b>	31	0.79	12	8
Overall measures of functioning	25	0.64	10	7
Functioning in social interactions	5	0.13	1	3
Self-regulation	4	0.10	3	1
Self-esteem/self-efficacy	5	0.13	2	1
Cognition	5	0.13	2	1
Physical health	4	0.10	1	1

Notes: There are 39 interventions, 119 economic effect sizes and 196 mental health effect sizes. Outcome variable categories are not mutually exclusive (for example, interventions can measure employment and education outcomes), which is why percentages within categories can exceed 100%. Functioning at work measures are qualitative measures of functioning on the job. For example, the IDEAS scale is a rating from one of the interventions which evaluates a patient's disability in work on a 5 point scale. Self-regulation captures ability to set goals, control impulses and structure one's time. Self-esteem or self-efficacy is underlying beliefs about one's ability to carry out actions or achieve desired outcomes. Table A3 lists each unique measurement tool used for each group of outcomes.

of mental health conditions according to the World Health Organization International Classification of Disease (ICD-10) ([World Health Organization, 2016](#)): common mental disorders (CMDs, including anxiety and depression), severe mental disorders (SMDs, including schizophrenia and bipolar disorder), substance use disorders (SUDs) and post-traumatic stress disorder (PTSD). The categories are based on shared clinical presentation, functional disability, and treatment approaches.<sup>20</sup>

Treatments can be psychosocial (involving psychotherapy or training to provide education, guidance and support) or pharmacological (involving administration of medication), or combine both psychosocial and pharmacological treatments. We group different types of psychosocial treatments together because these have been found to have similar effects on mental health ([Cuijpers et al., 2008](#), [Cleary et al., 2008](#)). The most frequently observed elements of these psychosocial treatments are cognitive behavioral therapy, psychoeducation, problem-solving therapy and interpersonal therapy (Tables H and A2). Pharmacological treatments are usually somewhat specific to a condition. For example, anti-depressants are regularly prescribed for depression while anti-psychotics are prescribed for severe mental disorders or substance use disorders.

Studies use different types of control condition. If a treatment is widely available and known to improve recipient outcomes, it is considered unethical to deprive a control group of the standard of care they could receive outside the trial. In these cases trials test if an experimental treatment performs better than this standard treatment. However, as often there is no widely available treatment provided for mental health conditions in LMICs, no treatment controls are common. Enhanced usual care (EUC) controls involve limited treatment, such as receiving information pamphlets, general health home visits, or referrals to a doctor. Treatment as usual (TAU): pharmacological controls are used when the public health system offers drug treatments.

Two distinct types of interventions and study designs appear in our search with sufficient frequency to conduct a meta-analysis. The first type is studies of 16 interventions targeting common mental disorders (depression and anxiety), described in Column 3, Table 1. The second type is studies of 9 interventions targeting severe mental disorders, which include schizophrenia and bipolar disorder and have more severe impacts on functioning and a longer duration than CMDs, described in Column 3, Table 1. We follow the medical literature which studies the effects of mental health treatments and estimate, for each outcome category, an average effect for interventions targeting CMDs and for interventions targeting SMDs. This also has the advantage that studies of these two intervention types

---

<sup>20</sup>We retrieve only studies including an economic outcome so the disorders retrieved by the search may not capture all disorders examined in mental health trials in LMICs.



use similar control strategies. We do not report one average across interventions targeting CMDs and interventions targeting SMDs because the interventions and target populations are too different to make aggregation meaningful.

Of the 16 CMD interventions, 14 provide psychosocial treatment only. They are usually compared to limited treatment: 5 interventions are compared to no treatment controls, 8 to enhanced usual care, usually a patient leaflet or one consultation with a doctor, and 1 to anti-depressants (see Table H). Two interventions treat CMDs with a combination of a psychosocial intervention and anti-depressants and are compared to control groups where participants only receive anti-depressants. These two trials thus also identify the effect of psychosocial interventions, under the assumption that treatment effects of psychosocial interventions and anti-depressants are additive. Throughout the paper, we aggregate these two types of studies together as capturing the effects of psychosocial interventions for CMDs. We show findings are robust to accounting for our pooling of studies with different types of control groups in Section 6.1.

All of the 9 SMD interventions are combination treatments including both a psychosocial intervention and a pharmacological treatment (an anti-psychotic). Of these, 8 are compared to a TAU pharmacological control, an anti-psychotic, available as standard treatment in the setting. Again, studies of these interventions identify the effect of psychosocial interventions for SMD under the assumption that treatment effects of psychosocial interventions and anti-psychotics are additive. One is compared to enhanced usual care. We aggregate these studies as capturing the effects of psychosocial interventions for SMDs. Again, we show robustness to pooling studies with different types of control groups in Section 6.1.

We observe studies of interventions for other conditions: post-traumatic stress (5 interventions) and substance abuse (5 interventions).<sup>21</sup> We also observe 4 interventions where the study is the only one of its design in the sample.<sup>22</sup> Results for these three groupings are reported in Appendix Table A12. There are too few studies per category and too much heterogeneity within categories of studies (using measures discussed in Section 4.2) to conduct meaningful analysis.

### 3.2 Economic outcomes

We pre-specified groupings of outcomes: employment, education, assets, income, consumption, financial behavior, health costs, subjective indicators of poverty, and social net-

---

<sup>21</sup>This includes Blattman et al. (2017), where all studied individuals are diagnosed with substance abuse problems.

<sup>22</sup>This includes Angelucci and Bennett (2024), who study effects of antidepressants.

works.<sup>23</sup> Table A3 lists each measurement tool used in each group of outcomes.

Panel C of Table 1 reports the frequency with which outcomes are reported. Most relevant are columns 3 and 4, which show the frequency with which effect sizes are reported for the two main intervention-target condition pairs we focus on (psychosocial or combination interventions targeting CMDs, column 3, and combination interventions targeting SMDs, column 4).

Employment or work-related outcomes are the most commonly reported category, reported on in 14 of 16 interventions targeting CMDs and all 9 interventions targeting SMDs. We had sufficient employment outcomes to disaggregate these further. The first two measures capture the intensive and extensive margins of employment. “In employment” captures if someone is employed. “Time in work” is the amount of time worked in hours or months over different recall periods. Being “unable to work” is known in HIC studies as “work-related disability”, and indicates when a person is prevented from working by a health-related challenge. “Days unable to work” is similar to measures of disability days or sick leave in HIC studies, and measures the duration for which a person cannot work due to a health-related challenge.<sup>24</sup> “Functioning at work” measures are validated qualitative scales used in medical studies, where a clinician or participant rates the extent to which a participant is able to perform their normal role at work or whether their attendance or performance is impaired.<sup>25</sup> Table A6 provides wording for commonly used measures of functioning at work in our sample. Measures tend to relate to an individual’s participation in paid and unpaid work both inside and outside the home. “Job search” captures measures of a person’s engagement in, or intensity of, job search.

Relatively few studies of interventions capture non-work-related economic outcomes for our two main study types, so we present findings on these outcomes with caution.

### 3.3 Psychological and behavioral mechanisms

We also extracted all effects on psychological and behavioral pathways which might act as mechanisms for effects on economic outcomes and report on the frequency with which they appear in Panel C of Table 1. We coded any mental health outcome pre-specified as a primary outcome by the authors, as well as all outcomes which fell into one of 22

---

<sup>23</sup>We did not include broad measures of financial behavior, such as financial empowerment from Baranov et al. (2020), as these measures may not necessarily represent material economic outcomes. We instead included the sub-aggregate measures of impacts on our pre-specified outcomes where these were available.

<sup>24</sup>See Nieuwenhuijsen et al. (2020) and Salomonsson et al. (2018) for examples of HIC studies of these outcomes.

<sup>25</sup>For example, on the IDEAS scale, a clinician evaluates a patient’s disability in work on a 5-point scale from no (0) to profound disability (4). A ranking of moderate disability indicates “Declining work performance, frequent absences, lack of concern about all this. Financial difficulties foreseen.”



categories: suicide risk, re-hospitalisation, relapse, diagnosis with a mental health condition, psychiatric morbidity, depression, anxiety, CMD symptoms, alcohol misuse, drug misuse, schizophrenia, SMD symptoms, PTSD symptoms, disability, global functioning, executive functioning, cognitive functioning, social functioning, general health, general mental health, self-efficacy and self-esteem. The measures used to assess behavioral and psychological pathways are listed in Tables [A4](#) and [A5](#).

The bulk of outcome measures capture symptoms of mental ill health through psychological scales reported by the participant which measure the severity, frequency or duration of symptoms of personal distress. For example, for depression, these would include low mood, loss of interest or pleasure, sleep disturbance and difficulty concentrating. Some scales are used only for a particular disorder. Others, such as measures of depression and anxiety, are used across both conditions. Thirteen of 16 interventions targeting CMDs measure a scale of CMD symptoms; 4 of 9 interventions targeting SMDs measure a scale of SMD symptoms. Other studies measure whether a mental health condition is diagnosed or make a qualitative assessment of it. Some outcome measures are from hospital or clinician records, such as whether individuals made any suicide attempts or were at risk of suicide, or whether participants have relapsed, recovered, or been rehospitalized. We list the specific wording for commonly used scales in our sample in Tables [A6-A9](#).

Studies of most interventions – 12 of 16 interventions targeting CMD; 8 of 9 targeting SMDs – report effects on a measure of functioning or disability. Functional impairment occurs when an individual’s health condition reduces their capacity to fulfil their normal social and work roles ([Edlund et al., 2018](#)). Where only an overall functioning score is reported, we treat this effect as a psychological and behavioral mechanism. Some interventions capture functioning in specific domains of life, including performing daily tasks, personal care, family relationships, broader social interactions and work. Where these different domains are reported separately, we include effects for work-related functioning as economic outcomes, in the “functioning at work” category, and social interactions as psychological and behavioral mechanisms.

### **3.4 Other intervention characteristics**

Table [A2](#) shows other intervention-level characteristics. Most interventions for both CMD (11 of 16) and SMD (5 of 9) are restricted to adults above 17, with others target participants aged 14 and above. Within interventions targeting CMD, 11 target both genders and 5 target women. Within interventions targeting SMD, all target both genders.

There is a degree of spread over regions. For CMD interventions, 10 interventions are in South Asia, 3 in sub-Saharan Africa and the remainder in other regions. For SMD

interventions, 6 interventions are in East Asia and the Pacific, with the rest spread over regions. CMD interventions have been mostly in lower-middle income countries, while SMD interventions are mostly in upper-middle income countries.

We include effects measured at any point after the beginning of treatment and often include multiple measurement points per intervention. The average intervention in our sample has 1.5 follow-up rounds. Measurement occurs 15.2 months after treatment, on average. Interventions have various combinations of follow-up periods. For CMD interventions, 10 interventions have one follow-up: 5 of these follow-up before 7 months and 4 between 7 and 12 months. Three interventions have two follow-ups, all before 12 months. Three interventions have three follow-ups, with different durations between follow-ups. SMD interventions in our sample usually have much shorter follow-ups: 7 of 9 interventions have only one round of follow-up before 7 months, while only 2 interventions have more than one follow-up. We average over these outcomes but disaggregate results by length of follow-up in Section 6.1.

## 4 Empirical strategy

### 4.1 Aggregating from raw effect sizes to inference datasets

We begin with a dataset of effect sizes of a single intervention on one outcome in one survey round and its associated confidence interval. A study often reports multiple estimates of the effect size of an intervention on an outcome, such as in robustness checks or repeated survey rounds. As is standard in meta-analyses, we average across the multiple effect size estimates (Higgins et al., 2022), with details outlined in Appendix D. Averaging processes allow for dependence between multiple effect sizes reported within a given study (Gleser and Olkin, 2009) and do not give studies with more effect sizes reported more weight. We calculate the standard error of the average effect size following Borenstein et al. (2009).

As discussed in Section 3.1, we follow the medical literature, which studies the effects of mental health treatments, and estimate, for each outcome category, an average effect for interventions targeting CMDs and for interventions targeting SMDs. This also has the advantage that studies of these two intervention types use similar control strategies. As discussed, we observe a few studies of interventions for post-traumatic stress and substance abuse, as well as single studies of pharmacological interventions against no-treatment controls, so present these with caution. In Table A16, we show that results are similar if we do not average across the multiple effect size estimates and instead perform inference on the individual effects reported by studies, while explicitly accounting for correlation between effects estimated for the same intervention.

We also face a decision about how much to pool effect sizes for different economic outcomes. Here, there is a trade-off between statistical power and interpretability. In our preferred specifications, we generate two aggregate outcomes upon which we perform inference. The first aggregates across all work-related outcomes, and the second across all non-work-related economic outcomes. We focus on work-related outcomes, where we have a moderately large sample and substantial power to detect effects, although there is heterogeneity in our estimates. Second, we report average effect sizes for groups of similarly measured outcomes. For example, we include variables capturing “Self-reported employment status” and “Engaged in work in the last week” in an “In employment” aggregate. While tests conducted on treatment effects at this level of aggregation are poorly powered, coefficients are more easily interpreted. Finally, we present findings averaging over work- and non-work-related economic outcomes, but view these estimates with caution given high levels of heterogeneity in the outcomes being measured.

## 4.2 Model

We expect study-level treatment effect heterogeneity in our sample of effect sizes. Even within groupings of the same intervention type, treating the same condition, we aggregate across effects from interventions with subtly different features in diverse contexts. We therefore follow the random-effects meta-analysis literature ([DerSimonian and Laird, 1986](#)). For each study  $k$ , we model the observed average treatment effect,  $\{\hat{\tau}_{k=1}^K\}$  as the study-specific intervention effect  $\tau_k$  and a sampling error term  $\epsilon_k$ .

$$\hat{\tau}_k = \tau_k + \epsilon_k \tag{1}$$

This allows us to estimate the quantity of interest: the average latent treatment effect across studies and contexts,  $\tau = E[\tau_k]$ . We estimate Equation 1 using two approaches. First, we follow the frequentist meta-analysis literature, computing a weighted average  $\hat{\tau}_{RE} = \sum_{k=1}^K \hat{\tau}_k \hat{\phi}_k / \sum_{k=1}^K \hat{\phi}_k$  to aggregate point estimates of intervention effects across studies. The weight  $\hat{\phi}_k$  allocated to a study’s estimate is set as the inverse of its variance, which minimizes the variance of the pooled estimate. This approach gives higher weight to more precise estimates, which tend to come from larger studies.

Second, we take a hierarchical Bayesian approach to model treatment effect heterogeneity explicitly and to allow the model to discount information from the marginal study where there is significant heterogeneity in studied effects. We implement the simple [Rubin](#)

(1981) model:

$$\begin{aligned}\hat{\tau}_k | \hat{se}_k, \sigma &\sim N(\tau_k, \hat{se}_k^2) \quad \forall k \\ \tau_k | \tau, \sigma &\sim N(\tau, \sigma^2) \quad \forall k\end{aligned}$$

Where  $\{\hat{\tau}_{k=1}^K\}, \{\hat{se}_{k=1}^K\}$  are the observed estimated effects and sampling errors, and setting  $\sigma^2 = 0$  recovers the random-effects specification in Equation 1 (Gelman et al., 2009). We assume that the effect  $\tau_k$  is drawn from a normal distribution of effects across sites governed by  $(\tau, \sigma_\tau^2)$ . In our preferred specification, our priors on  $\tau$  and  $\sigma$  are only weakly informative:

$$\begin{aligned}\tau &\sim N(0, 1) \\ \sigma &\sim HC(10)\end{aligned}$$

Where  $N$  indicates the Normal distribution and  $HC$  the Half-Cauchy distribution. These choices allow us to concentrate our estimates of  $\tau$  in the reasonable space of standard deviation effect sizes without assuming a sign on effects, and to enforce positive  $\hat{\sigma}$ , while allowing it to vary widely. As our priors are only weakly informative, we have a moderate number of studies, and we observe substantial effect size heterogeneity, we expect less power under the Bayesian approach relative to the frequentist approach. In estimating both models, we winsorize the top 1% of effect sizes to limit the impact of large outliers.

### 4.3 Quantifying heterogeneity

The approach outlined above offers two means of understanding the extent of and impact of study-level effect heterogeneity on our findings. First, we analyse the difference in point estimates and standard errors under the frequentist and Bayesian approaches. The Bayesian approach directly accounts for study-level heterogeneity in standard errors, while the frequentist approach does not (Higgins et al., 2009). In a zero-heterogeneity environment, the Bayesian hierarchical model pools effect sizes from all studies equally, using information from each study to shrink the estimates  $\hat{\tau}_{k=1}^K$  towards the average  $\tau$ , and precisely estimate  $\tau$ . In contrast, in a high-heterogeneity environment, the hierarchical model will not pool information across sites, generating large credible intervals on  $\tau$ . If the Bayesian models present larger credible intervals relative to their frequentist analogues, and produce evidence of high heterogeneity, then we should be suspicious that the frequentist confidence intervals are too tight because they fail to account for this heterogeneity.

Second, we estimate three measures of heterogeneity to show whether our effect size

estimates are stable across studies, as well as across the pooling decisions we make about outcomes. First, our estimate of  $\sigma^2$  is an absolute measure of heterogeneity in the distribution of effect sizes. If the [Rubin \(1981\)](#) model returns  $\sigma^2 \approx 0$ , then there is no unexplained heterogeneity between studies. However, this metric is difficult to interpret for non-zero values: any positive value indicates some degree heterogeneity but it is difficult to identify what constitutes a large amount of heterogeneity ([Vivalt, 2020](#)). To account for this, secondly we report the average pooling metric, per [Meager \(2019\)](#):

$$\omega(\tau) = \frac{1}{K} \sum_{i=k}^K \frac{\hat{se}_k^2}{\hat{\sigma}^2 + \hat{se}_k^2}$$

This has a more obvious interpretation:  $\omega(\tau_k) > 0.5$  implies that  $\sigma^2$  is smaller than the sampling variation and that heterogeneity is “small” ([Gelman and Hill, 2006](#)). Third, we report the  $I^2$ , where  $I^2 \approx \frac{\hat{\sigma}^2}{\hat{\sigma}^2 + \hat{se}_k^2}$ , under both frequentist and Bayesian specifications. This measure of heterogeneity is closely related to the pooling factor, but has the opposite interpretation: a higher  $I^2$  indicates a greater degree of heterogeneity. We extend consideration of heterogeneity with additional analysis in [Section 6.1](#).

## 5 Results

In this section, we present our core meta-analysis findings on the impact of mental health interventions on economic outcomes. We report separate estimates of treatment effects within populations experiencing CMDs and SMDs under both frequentist and Bayesian estimation strategies, and at different levels of outcome pooling.

### 5.1 Work-related outcomes

Our core findings are summarized in [Figure 1](#), which reports estimates of the latent average treatment effect of psychosocial interventions,  $\hat{\tau}$ , on a range of work-related outcomes for interventions targeting CMDs ([Panel A](#)) and targeting SMDs ([Panel B](#)). These are recovered from repeated meta-analyses estimating [Equation 1](#) using both frequentist and Bayesian approaches. Within each panel, each boxplot summarizes the distribution of the estimate recovered from a meta-analysis on a different outcome grouping, arranged by row of the figure. For example, the “In employment” meta-analyses included effect sizes on all dummies that measure employment status. The “Work aggregate” represents the results of a meta-analysis pooling all of the effect sizes used to estimate the rows below. Box edges represent the bounds of a 50% confidence interval or credible intervals of the frequentist and Bayesian estimates, respectively, while whiskers represent their 95% analogues. In reporting findings, CI refers to 95% confidence or credible intervals unless otherwise spec-

ified. Details of each meta-analysis, including exact effect sizes and confidence intervals, sample sizes and heterogeneity measures, are reported in Table 2. Findings are reported in standard deviation (SD) units to allow for aggregation of different outcome measures across studies.<sup>26</sup>

### 5.1.1 Psychosocial interventions in populations experiencing CMDs

We find that psychosocial interventions significantly improve the “Work aggregate” among populations experiencing CMDs (Row 1 of Panel A of Figure 1 and of Table 2). Under the frequentist specification, we observe a moderately large effect of these interventions of 0.16 standard deviations (Column 1 of Table 2) with a 95% confidence interval of [0.05, 0.27] (Columns 2,3). This estimate is constructed from 36 observations of effect sizes (Column 4). These 36 observations are first aggregated to intervention-level average effect estimates of 14 interventions (Column 5) as described in Appendix G.2, before the final pooled estimate is constructed as a weighted average. There is evidence of some heterogeneity in reported effect sizes included in the weighted average, with a reported  $I^2$  of 0.68 (Column 8).

In the rows which follow, we show effects at a lower level of pooling of outcomes measured in different ways, on sub-aggregate measures. We find evidence of an effect on the most commonly measured sub-aggregate of similar outcomes, “Days unable to work”, for which there are 17 effect sizes recorded for 9 interventions. Psychosocial interventions targeting CMDs improve “Days unable to work” by 0.07 SD, CI: [0.01,0.13]. For three other sub-aggregates – time in work, functioning at work and job search – effects are positive but not significant at conventional levels, likely due to small effective sample sizes.<sup>27</sup>


Our main findings are robust to adjusting for effect heterogeneity using the Bayesian specification. Under the Bayesian specification, the effect on the work aggregate is 0.16 SD, CI: [0.03,0.31], an identical point estimate and significant at conventional levels. The effect on “Days unable to work” is similarly robust. The Bayesian estimate is 0.08 SD, CI: [0.01,0.17]. Standard errors are not markedly different for this outcome under frequentist and Bayesian methods due to little observed heterogeneity in effect sizes ( $I^2=0.31$  under the Bayesian framework).

---

<sup>26</sup>We do not adjust for multiple hypothesis testing. However, our main findings are on aggregate outcomes, limiting the number of tests performed.

<sup>27</sup>The reported frequentist  $I^2$  estimates for these treatment effect estimates are likely substantially downward-biased by small sample bias, complicating direct inference on heterogeneity (von Hippel, 2015).

Figure 1: Positively-coded work-related economic impacts of mental health interventions: summary



Notes: Each boxplot represents the distribution of estimates from meta-analyses across study effect sizes captured under the category of the row title. The Work aggregate meta-analysis includes effect sizes from each of the other outcome groupings. There are two meta-analyses per outcome row, performed under both frequentist (red) and Bayesian (yellow) specifications outlined in Section 4.2. The (marginal posterior) maximum likelihood estimator estimate,  $\hat{\tau}$ , is represented by the line within the box.  $\hat{\tau}$  is measured in standard deviations. Box edges represent the bounds of a 50% confidence interval or shortest credible intervals of the frequentist and Bayesian estimates respectively, while whiskers represent their 95% analogues. Panel A presents estimates of the standard deviation effects of psychosocial interventions targeting common mental disorders, Panel B the effects of combined interventions targeting severe mental disorders. ^ indicates variables that have been reverse-coded such that higher values are positive. To allow visual inspection of small effect sizes, whiskers are trimmed to  $[-1.5, 1.5]$  if  $\tau \notin [-1.5, 1.5]$ , while full untrimmed results are presented in Table 2. \* indicates variables that have at least one trimmed estimate. The average measurement in our sample happens 15.2 months after intervention start. The procedure for aggregating multiple effect sizes from a given intervention is described in subsection 4.1. All individual effect sizes are winsorized at the 99<sup>th</sup> percentile.



Table 2: Positively-coded work-related economic impacts of mental health interventions: details

	$\hat{\tau}$ (SD)	$\hat{\tau}$ CI		Sample size		Heterogeneity		
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
	Average	2.5 <sup>th</sup> <i>pctl.</i>	97.5 <sup>th</sup> <i>pctl.</i>	# obs.	# intrv.	$\sigma$	$\omega(\tau)$	$I^2$
<b>Panel A: Treatment effects of psychosocial interventions on <i>common</i> mental disorders</b>								
<i>Frequentist specification</i>								
<b>Work aggregate</b>	0.16***	0.05	0.27	36	14			0.68
In employment (dummy)	-0.00	-0.12	0.11	4	4			0.00
Time in work	0.17	-0.09	0.43	3	3			0.64
Days unable to work <sup>^</sup>	0.07**	0.01	0.13	17	9			0.13
Functioning at work	0.21	-0.10	0.52	8	5			0.86
Job search	0.09	-0.09	0.27	4	2			0.00
<b>Work-related effects in original units</b>								
Self-reported as employed (dummy)	0.00	-0.04	0.04	4	4			0.00
Days in last 30 days unable to work <sup>1</sup>	-1.42	-3.15	0.30	12	6			0.66
<i>Bayesian specification</i>								
<b>Work aggregate</b>	0.16**	0.03	0.31	36	14	0.21	0.32	0.8
In employment (dummy)	-0.02	-0.35	0.25	4	4	0.18	0.4	0.67
Time in work	0.16	-0.61	0.87	3	3	0.58	0.06	0.95
Days unable to work <sup>^</sup>	0.08**	0.01	0.17	17	9	0.06	0.72	0.31
Functioning at work	0.19	-0.3	0.67	8	5	0.48	0.08	0.93
Job search	0.05	-1.12	1.16	4	2	1.13	0.01	0.98
<b>Work-related effects in original units</b>								
Self-reported as employed (dummy)	-0.01	-0.15	0.1	4	4	0.08	0.38	0.71
Days in last 30 unable to work <sup>1</sup>	-0.67	-2.05	0.73	12	6	1.9	0.42	0.75
<b>Panel B: Treatment effects of psychosocial interventions on <i>severe</i> mental disorders</b>								
<i>Frequentist specification</i>								
<b>Work aggregate</b>	0.30**	0.06	0.54	20	9			0.76
In employment (dummy)	0.81**	0.16	1.45	1	1			1.00
Time in work	0.24**	0.05	0.44	4	2			0.07
Unable to work (dummy) <sup>^</sup>	0.18***	0.06	0.30	8	3			0.00
Days unable to work <sup>^</sup>	0.11**	0.00	0.22	1	1			1.00
Functioning at work	0.23	-0.41	0.87	6	4			0.89
<i>Bayesian specification</i>								
<b>Work aggregate</b>	0.30*	-0.05	0.67	20	9	0.45	0.21	0.88
In employment (dummy)	0.22	-1.66	1.85	1	1	5.37	0	NaN
Time in work	0.21	-1.09	1.32	4	2	1.28	0.02	0.98
Unable to work <sup>^</sup>	0.21	-0.41	0.8	8	3	0.4	0.13	0.9
Days unable to work (dummy) <sup>^</sup>	0.04	-1.69	1.71	1	1	4.92	0	NaN
Functioning at work	0.19	-0.86	1.17	6	4	1.12	0.07	0.97

Notes: The frequentist and Bayesian specifications are outlined in Section 4.2. In column (1),  $\hat{\tau}$  is the estimate of the latent treatment effect in standard deviations. \*, \*\* and \*\*\* represent significant at the 10, 5 and 1% levels respectively. In columns (2) and (3),  $\hat{\tau}$  CI presents estimates of 95% confidence or credible interval under the frequentist or Bayesian specification, respectively. The Work aggregate meta-analysis includes effect sizes from each of the other outcome groupings below. Panel A presents estimates of the standard deviation effects of psychosocial interventions targeting common mental disorders and Panel B the effects of psychosocial interventions targeting severe mental disorders. <sup>^</sup> indicates variables that have been reverse-coded such that higher values indicate improvements in outcomes. The average measurement in our sample happens 15.2 months after intervention start. The procedure for aggregating multiple effect sizes from a given intervention is described in subsection 4.1. All individual effect sizes are winsorized at the 99<sup>th</sup> percentile. <sup>1</sup> = based on the WHO Disability Assessment Schedule (WHODAS 2.0). The control mean for “self-reported as employed” in original units is 0.18 and for “days in last 30 days unable to work” in original units is 10.93.



We observe wider confidence intervals under the Bayesian specification relative to the frequentist specification across all other results. This is consistent with the frequentist approach failing to adequately account for study-level heterogeneity in effect sizes.<sup>28</sup>

How large are these effect sizes? Where possible, we report effects in “original units”. A subset of interventions for CMD measured work outcomes on identical scales, allowing us to generate aggregate estimates across studies without standardising effects. We report these aggregate effects where at least two studies reported in the same units, with the caveat that this is a selected sample of interventions. Six interventions targeting CMDs report the identical WHODAS measure “Days that participants are unable to work in the last 30 days”. These interventions reduced days unable to work by 1.42, CI: [-3.14,0.30] days, or an economically significant 13% reduction, under the frequentist specification, although this result has marginal statistical significance due to a small number of estimates.<sup>29</sup> We observe a null effect on an employment dummy.

### 5.1.2 Psychosocial interventions within populations experiencing SMDs

In Panel B of Figure 1, we show a large, positive average effect of psychosocial interventions targeting SMDs on the work aggregate under the frequentist specification of 0.30 SD, CI: [0.06,0.54], but are cautious in our interpretation of this effect. Relative to our estimate of the average treatment effects on CMDs, we observe substantially greater variance in our estimated treatment effect within populations experiencing SMDs, attributable to the substantially smaller effective sample size (9 interventions for SMDs compared to 14 for CMDs for which work outcomes are measured). Once we account for heterogeneity under the Bayesian specification, we find that the effect on the work aggregate is significant only at the 90% level (0.30 SD, CI: [-0.05,0.67]). This is consistent with evidence of substantial heterogeneity. The point estimate of the  $I^2$  ranges from 0.76 to 0.88 in the frequentist and Bayesian models, respectively, and aligns with other measures. The Bayesian model factors in the uncertainty associated with this effect heterogeneity into standard errors, generating substantially wider confidence intervals.

---

<sup>28</sup>Across outcomes, the relative width of each of the credible intervals under the Bayesian specification is consistent with the heterogeneity measures and sample sizes we observe in Table 2. We observe that outcome groupings with the highest estimates of heterogeneity (Columns 6, 7 and 8; note a higher value in Column 7 indicates lower heterogeneity), and smallest sample sizes (Column 5), have the widest credible intervals. We present the distributions of these estimates in Appendix F.2. Our choice of a mean zero prior shrinks the coefficients on estimates generated from small samples towards zero. For example, the coefficient on “Job search” is 0.09 under the frequentist specification, but only 0.05 under the Bayesian specification, and the confidence interval is substantially wider. This is consistent with estimates of high heterogeneity (e.g.  $\widehat{\omega(\tau)} = 0.01$ ).

<sup>29</sup>We report the frequentist, rather than Bayesian, point estimate because it provides a more representative indication of the magnitude of effects. Here, because there are so few intervention observations, the choice of standard normally distributed prior on effect sizes anchors the estimated effect size to be closer to zero.

Turning to the sub-aggregate measures, we find only limited evidence of specific treatment effects. Under the frequentist specification, we do observe positive and significant effects: treatment significantly improves “In employment” (0.81 SD, CI: [0.16,1.45]), “Time in work” (0.24 SD, CI: [0.05, 0.44]), “Unable to work (0.18 SD, CI: [0.06, 0.30]) and “Days unable to work” (0.11 SD, CI: [0.00,0.22]). However, these effects are non-significant under the Bayesian specification. First, the effective sample sizes are very small, ranging from 1-4 interventions. Our choice of mean zero normal priors shrinks the estimate of the latent mean generated from small samples toward zero. Second, there is evidence of very high heterogeneity in these subgroupings, so accounting for it substantially inflates standard errors. We view these effects as suggestive evidence that interventions targeting SMDs may show promise in improving work outcomes in LMICs, but more high-quality studies are needed before meaningful aggregated evidence can be produced.

### **5.1.3 Comparing effect sizes in populations experiencing CMDs and SMDs**

Treatment effects in populations experiencing SMDs are almost twice as large as those in populations experiencing CMDs. However, one should be careful to not over-interpret this finding. First, the trials treating SMDs with psychosocial interventions mainly compare a psychosocial intervention combined with a pharmacological treatment to a control group that received a pharmacological treatment only. This identifies the effect of psychosocial interventions only under the assumption that treatment effects of psychosocial and pharmacological interventions are additive, ruling out plausible synergies between psychosocial and pharmacological interventions. Larger treatment effects in populations experiencing SMDs might be partially explicable by such synergies. In contrast, the trials treating CMDs with psychosocial interventions mainly compare psychosocial interventions to no treatment or enhanced usual care. Second, treatment selection may be endogenously determined. For example, physicians may opt for higher treatment intensity in populations experiencing a higher burden of mental ill-health. We might expect larger treatment effects in populations experiencing SMDs, if the illness is successfully treated. Finally, the trials of interventions targeting SMDs mainly have fairly short-term follow-ups, with 7 of 9 trials following up participants after less than 7 months. In contrast, the trials of interventions targeting CMDs often include at least one round of longer-term follow-up, in which effect sizes may be smaller. Future work must unpack these differences.

## **5.2 Comparisons to high income country effects**

How do these results compare to those from meta-analyses in high-income countries (HIC)? In Table A1, we summarize effects from recent meta-analyses in HIC alongside findings from our study, referred to as “Lund et al., 2024” in the table. We report only HIC meta-

analyses that overlap with at least one target condition or intervention and note some caution as studies have different inclusion criteria. Generally, effects are similar in magnitude to our study, consistent with findings that effects of treatment on mental health are similar across contexts (Patel et al., 2018, Singla et al., 2017).

Our estimates of the effects of psychosocial interventions in populations experiencing CMDs are very close to those reported in the HIC literature. At the aggregate level, our estimate of the effect of psychosocial interventions targeting CMDs is the same as that of Timbie et al. (2006) (0.16 SD) on a similar aggregate. At the sub-aggregate level, we observe slightly smaller effects on measures of absence from work (analogous in our study to “Days unable to work”) relative to Nieuwenhuijsen et al. (2020), Salomonsson et al. (2018) and Finnes et al. (2019) (0.08 SD, compared to 0.15 SD,  $SD=\{0.12,0.17\}$  and 0.17 SD respectively). We observe a non-significant effect on “Functioning at work” of 0.19 SD, which falls squarely between that of Nieuwenhuijsen et al. (2020) (0.05 SD), and Kamenov et al. (2017) (0.43 SD).

Comparisons between HIC results and our own are more difficult for effects in populations experiencing SMDs: no study reports a “Work aggregate” result within these settings, and our estimates on sub-aggregate measures have large standard errors. However, our broad finding that effect sizes on work outcomes tend to be larger among populations experiencing severe mental disorders compared to those experiencing common mental disorders also holds in HICs.

### 5.3 Non-work economic outcomes

In Tables A10 and A11, we present findings on non-work-related economic outcomes, including education expenditure; assets; income, consumption and input expenditure; and subjective poverty measures. While individual studies may find effects on these outcomes, the small number of studies and the lack of homogeneity across studies prevent us from constructing meaningful aggregate effects. Under the frequentist specification (Table A10), we find that psychosocial interventions improve the aggregate of non-work-related economic outcomes, driven by a large effect on education outcomes (from only a single intervention) and a marginally significant result on subjective poverty measures (from two interventions). However, under the Bayesian specification (Table A11), we see only weak evidence for an effect on the non-work aggregate and no evidence of an effect on education or subjective poverty once we account for heterogeneity.

## 6 Robustness to heterogeneity and publication bias

This section examines robustness of our core findings to accounting for observed measures of study heterogeneity. We then summarize results of tests for publication bias, concluding there is minimal evidence of publication bias in our sample of studies.

### 6.1 Heterogeneity

We extend our frequentist meta-analysis framework to explore robustness of our core findings on the “Work aggregate” to heterogeneity. This offers some insight into potential drivers of heterogeneity captured by the Bayesian model. As part of our search, we captured study- and intervention-level data that proxies for heterogeneity in measurement, interventions and context. We perform repeated multi-variate meta-analyses that include these (de-meaned) proxies as controls. The model is detailed in Appendix F.1.

In Table A16, we report findings from these repeated meta-regressions. The first column represents a “base model” in which we regress (non-aggregated) study effects on only a constant and intervention-level fixed effects. Each column that follows includes a collection of specified study-level covariates. In Panel A, we consider psychological interventions targeting CMDs. We find that the intercept, which represents the mean treatment effect on the work-related outcomes aggregate at the mean of the included (de-meaned) covariates, is roughly stable across the models, falling in the range [0.15,0.25] and remaining significant at the 95% level. This provides evidence against the observed measures of heterogeneity “driving” our core findings.

A  $\chi^2$  test of modifier relevance indicates whether the covariates in a model predict differential treatment effects. We observe that both a measure of the time between the intervention and outcome measurement, and an indicator for whether interventions are provided by a specialist are statistically significant modifiers. Error term variance, a proxy for “small sample effects” associated with publication bias, is non-significant. Variation in the  $I^2$  statistic across these models is suggestive of how well the model, given its covariates, captures heterogeneity. While interventions costs are not a significant modifier, their inclusion reduces the  $I^2$  from 0.77 to 0.56. The Cochran  $Q$  test of residual (unexplained) heterogeneity indicates that none of the observed characteristics capture all of the remaining heterogeneity in effects.

In the severe mental disorders model (Panel B), none of the measures of heterogeneity are explanatory, though there is weak evidence that measurement timing may be relevant ( $p=0.13$ ). Standard errors on the estimate are large, consistent with the smaller sample size and with findings under the Bayesian model. As for the common mental disorder

model, the test for residual heterogeneity is significant across models.

## 6.2 Sub-group analyses

In Table A17, we present effects on the “Work aggregate” for subgroups of studies where the analysis just presented suggests results may differ from the average effect. We re-estimate the frequentist model of Equation 1, partitioning our dataset into subsamples using indicators of intervention and study characteristics.<sup>30</sup> We urge caution in interpreting differences between groups of studies causally. For example, if studies with different control conditions have different average effects on work outcomes, this could be because of characteristics of the groups of studies other than the control condition. We report on heterogeneity by intervention cost in Section 9.

### 6.2.1 Measurement timing

For interventions targeting CMD, treatment effects are largest in the six months following exit (0.31 SD, CI: [0.06, 0.55]), before falling in the six months that follow (0.12 SD, CI: [0.01, 0.23]) and becoming undetectable more than a year after exit. In the SMD group, it is more difficult to draw conclusions about effect decay. Treatment effects are large in the six months following exit (0.29 SD, CI: [0.04, 0.54]). Only a single intervention reports on work outcomes after more than a year after exit, although this finds effects may be large and persistent. We caveat these findings by acknowledging that this evidence might be subject to selective reporting: follow-up surveys may only be conducted for interventions initially found to be effective.

### 6.2.2 Delivery type

For interventions targeting CMD, treatment effects on the work aggregate are larger for interventions delivered by specialists (0.27 SD, CI: [0.03, 0.52]) than laypeople (0.06 SD, CI: [0.01, 0.12]), although both are positive and significant.<sup>31</sup> However, we are cautious in over-interpretation of these findings. A number of studies in South Asia (where delivery by laypeople is common) are with female populations in settings where women have low labor force participation. It may be the labor market context rather than the delivery agent causing differences in effect sizes on the work aggregate.

In the SMD group, there is no difference in coefficient magnitude (0.36 SD), although only effects for specialist delivery are significant (CI: [0.09, 0.63]) due to a small sample of 3 interventions for non-specialist delivery. Trials with treatment by laypeople may differ

---

<sup>30</sup>As for the results for outcomes in “original units”, discussed in footnote 29, we report the frequentist instead of the Bayesian specification results for this subsample analysis.

<sup>31</sup>Consistent with these findings, we also find that treatment effects on mental health and functioning outcomes are larger for interventions delivered by specialists than laypeople.

in multiple ways: interventions may be shorter, cheaper, or delivered at scale through government rather than research institutions. As the evidence base grows, research should unpack which dimensions are relevant for whether mental health treatments improve work outcomes.

### 6.2.3 Target population

Although we did not find that indicators of target population in general explained heterogeneity in the work aggregate, we do see one important difference by study context. In the right panel of Figure A2, we separate out studies targeting “standard” economically active populations from 1) populations of perinatal mothers and 2) female populations in contexts of low female labor force participation. Unsurprisingly, treatment of CMD among perinatal women induces smaller labor market effects than in the general population, consistent with women being engaged in child-rearing and potentially limiting labor market engagement. However, for this group, we observe effects on education investment (for the participants’ children). Interventions in contexts of low female labor force participation have smaller, sometimes negative and very noisily estimated effects than in the general population. This might reflect the lack of labor market attachment of the participants in these samples.

### 6.2.4 Measurement of work outcomes

In Table A18, we show that the choice to aggregate across the different elements of our work-related outcomes aggregate to a work-related outcome aggregate is broadly reasonable i.e. we can aggregate over some heterogeneity in outcome definitions within this aggregate.<sup>32</sup> Regressing the work-related outcome groupings on indicators of particular sub-aggregate outcomes indicates that no sub-aggregate outcome is systematically different to the reference class of the most commonly studied outcome, “Days unable to work”.

## 6.3 Publication bias

We summarize findings on publication bias in our entire study sample here and provide a detailed discussion in Appendix F.3. Conventional methods suggest little evidence of publication bias in reporting on economic outcomes. In Figure A3, we find little visual evidence of bunching of published results around the usual threshold significance level 5%, or asymmetry in the funnel plot. We formally assess funnel plot asymmetry via the Egger et al. (1997) regression test for small-study effects with standard errors clustered by study, with the Pustejovsky and Rodgers (2019) correction for false positives. We find no

---

<sup>32</sup>Conceptually, the findings here are identical to a column in Table A16, but here we additionally report coefficients on each of the included covariates.

evidence against the null hypothesis of no small-study effects,  $\hat{\beta} = 0.01(0.19)$  (Table A20). We also formally model the impact of publication bias in our study sample, following Andrews and Kasy (2019).<sup>33</sup> We find no evidence that statistically significant findings are reported more often than null findings (Table A21).

## 7 Mental health effects: a likely mechanism

In this section, we present evidence that improvements in mental health and functioning associated with treatments are an important mechanism through which mental health interventions affect economic outcomes. We first present meta-analyses to estimate the effects of mental health interventions on psychological and behavioral mechanisms, in the same sample of interventions for which we estimated effects on economic outcomes. We then show that the economic effect sizes from included studies are highly correlated with mental health effect sizes. We extend these findings with evidence from microdata in Section 8.

### 7.1 Treatment effects on psychological and behavioral mechanisms

We summarise our findings on the effects of treatments for mental ill-health on psychological and behavioral mechanisms in Figure 2. This figure reports the distributions of estimates of average treatment effects,  $\hat{\tau}$ , recovered from repeated meta-analyses estimating Equation 1 under both frequentist and Bayesian specifications. Detailed results from the frequentist and Bayesian specifications are reported in Table A13 and Table A14, respectively.


We organize our findings into three groupings: mental health disorder symptoms measures; functioning and disability measures; and other outcome measures. We report findings on two aggregates, one for mental health disorder symptoms, and a second for functioning and disability. Example wording of a representative sample of commonly reported mental health and functioning measures is provided in Tables A6-A9.

---

<sup>33</sup>This is valuable as the tests above are known to be underpowered with respect to some types of publication bias and in the presence of multiple reported effects within study (Rodgers and Pustejovsky, 2020).



Figure 2: Positively-coded psychological and behavioral impacts of mental health interventions: summary



Notes: Each boxplot represents the distribution of estimates from meta-analyses across study effect sizes captured under the category of the row title. The Mental health disorder symptoms aggregate is made up of effect sizes captured under each of the sub-aggregate headings between it and the Functioning and disability aggregate. The Functioning and disability aggregate is made up of “Overall measures of functioning”, “Social support” and “Functioning in social interactions”. There are two meta-analyses per outcome row, performed under both frequentist (red) and Bayesian (yellow) specifications outlined in Section 4.2. The (marginal posterior) maximum likelihood estimator estimate,  $\hat{\tau}$ , is represented by the line within the box.  $\hat{\tau}$  is measured in standard deviations. Box edges represent the bounds of a 50% confidence interval or shortest credible intervals of the frequentist and Bayesian estimates respectively, while whiskers represent their 95% analogues. Panel A presents estimates of the standard deviation effects of psychosocial interventions targeting common mental disorders, Panel B the effects of combined interventions targeting severe mental disorders. <sup>^</sup> indicates variables that have been reverse-coded such that higher values are positive. To allow visual inspection of small effect sizes, whiskers are trimmed to  $[-1.5, 1.5]$  if  $\tau \notin [-1.5, 1.5]$ , while full untrimmed results are presented in Table A13 and Table A14. \* indicates variables that have at least one trimmed estimate. The average measurement in our sample happens 15.2 months after intervention start. The procedure for aggregating multiple effect sizes from a given intervention is described in subsection 4.1. All individual effect sizes are winsorized at the 99<sup>th</sup> percentile.



Across both populations experiencing CMDs and SMDs, we consistently observe improvements in mental health disorder symptoms and functioning and disability. Treatments improve the aggregate of mental health disorder symptoms (made up of each of the measures in the rows below this symptoms aggregate). Under the Bayesian approach, there are large effects both for psychosocial interventions targeting CMDs (0.25 SD, CI: [0.12,0.41]) and SMDs (0.39 SD, CI: [0.16,0.65]) (Table A14). These interventions also substantially improve an aggregate of functioning and disability measures, made up of measures of overall functioning, social support and functioning in social interactions. Effects are broadly similar for psychosocial interventions targeting CMDs (0.32 SD, CI: [0.09,0.54]) and SMDs (0.41 SD, CI:[0.19,0.65]).

Turning to sub-aggregate indicators, we find treatment for CMDs reduces CMD symptoms (measured in 13 interventions, 0.31 SD, CI: [0.12,0.53]) and improves both overall measures of functioning and social support (0.28 and 0.25 SD, significant at the 10% level), even under the more conservative Bayesian specification. Treatment for SMDs marginally reduces relapse (measured in 4 of 9 interventions, 0.31 SD, CI: [0.12,0.53]) and improves overall measures of functioning (measured in 7 of 9 interventions, 0.36, CI: [0.12,0.62]).

For both CMD and SMD treatment, there are positive, significant effects on most other sub-aggregates in the frequentist specification (Table A13). But we observe substantial heterogeneity among the sub-aggregate indicators not mentioned above (Columns 6-8 of Tables A13-A14), often because only a subsample of studies collect each type of measure and/or there is heterogeneity in outcome measurement. This makes it difficult to draw conclusions on other sub-aggregate measures, as indicated by the large standard errors under the Bayesian specification compared to the frequentist approach in Figure 2. This highlights the importance of the Bayesian method.

### 7.1.1 Effect heterogeneity by measuring party

Figure A4 offers an insight into the impact of self-reporting biases on mental health effects. We disaggregate our mental health and functioning outcome findings by the party responsible for measurement, showing outcomes measured by clinicians vs. self-rated by patients. The results are quite similar for interventions targeting both CMD and SMD, with no evidence of a pattern of larger effects for self-reported outcomes. This suggests that findings are not driven by treatment-induced social desirability bias, such as by participants deducing from the content of therapy that an improvement in mental health is desirable to the experimenter and hence reporting improvements.

## 7.2 Correlation between psychological and behavioral mechanisms and economic outcomes

The sizes of effects of mental health interventions on economic outcomes and on potential psychological and behavioral mechanisms are strongly positively correlated. This indicates that psychological and behavioral factors may play an important role in mediating the effect of mental health interventions on labor market outcomes. Figure 3 reports the unconditional correlations between the aggregate treatment effects on behavioral and psychological pathways and the aggregate treatment effects on economic outcomes, measured at the intervention level.<sup>34</sup> The slope of the blue line corresponds to a  $\beta$  coefficient retrieved from a simple OLS regression, representing the “effect” of a 1 SD increase in behavioral and psychological pathways on economic outcomes. We include effects from all types of treatments we identify in our review, including treatments for substance use disorders and post-traumatic stress disorders, but results are even stronger when only treatments for CMD and SMD are considered.

In each case, there is a strong positive correlation between the effect size on a given economic outcome and the effect size for the potential mechanism. Mental health disorder treatment effects are highly correlated with work-related ( $\beta = 0.70$ ) and non-work-related outcome treatment effects ( $\beta=0.38$ ). This provides strong suggestive evidence that mental health is an important mechanism through which mental health interventions affect economic outcomes.

We observe similar correlations between functioning treatment effects and work-related ( $\beta = 0.63$ ) and non-work-related ( $\beta = 0.80$ ) outcomes. Mental ill-health and functioning tend to be highly correlated. Symptoms of mental ill-health, like depressed mood, often worsen functioning by reducing motivation or energy to conduct day-to-day activities or the desire to engage in social interactions. The consistency of correlations between economic outcomes and different measures of an individual’s psychological health suggests this pattern is robust.

## 8 New evidence from aggregating microdata



In this section, we present a new dataset and analysis, where the units of observation are individuals within studies, rather than treatment effect estimates aggregated on a study-level. We pool microdata from the largest subset of included studies that measure the im-

---



<sup>34</sup>Where a study reports functioning in different domains separately, we include effects for work-related functioning as economic outcomes and social interactions with psychological and behavioral mechanisms. We never include the overall functioning score including work-related functioning among mechanisms if we also include the work-related functioning score as an economic outcome.

Figure 3: Intervention-level correlations between economic outcomes and behavioral and psychological pathways at the individual level

(a) Work-related effects and mental health disorders (b) Work-related effects and disability + functioning



(c) Other economic effects and mental health disorders (d) Other economic effects and disability + functioning



These four scatterplots present average work outcome effect sizes (Hedges'  $g$ ) by intervention, for a total of 39 interventions. The horizontal axis displays the average mental health disorder effect size (panels a and c) or the average disability/functioning effect size (panels b and d). The vertical axis shows the average economic effect for work-related outcomes (panels a and b) or other economic outcomes (panels c and d). The size of the circles indicates the sample size of the respective intervention. The aggregation of individual effect sizes works as described in Section 4.1. Individual effect sizes are winsorized within outcome type (work-related, other economic, mental health disorders, disability/functioning) at the 99<sup>th</sup> percentile. The blue lines indicate the prediction of the economic effect size from a linear regression of the economic effect size on the behavioral/psychological effect size, along with the 95% confidence interval.

impact of psychosocial interventions in the same target group (populations suffering CMD), on the same economic outcome (days unable to work).<sup>35</sup> By only evaluating an outcome reported by each of the included studies that we can harmonize across studies, we avoid standardising the outcome measure (cf. [Vivalt, 2020](#), [Meager, 2019](#)). Our approach balances the competing goals of comparing very similar interventions and capturing sufficient studies to have power to explore the following questions. First, as a test for the impacts of heterogeneity in our meta-analysis sample, do we observe the same findings in this subset of interventions that are “more similar” in terms of intervention characteristics? Second,

<sup>35</sup>Similarly, [Tan and Kremer \(2020\)](#), [Meager \(2019\)](#) and [Banerjee et al. \(2018\)](#) show results from pooling microdata.

is there heterogeneity in treatment effects by participant characteristics? Third, what is the relationship between mental ill-health and work outcomes? To the authors' knowledge, this is the first time that multi-study microdata has been pooled from mental health interventions in low and middle-income countries.

Our sample is made up of all 6 RCTs in our meta-analysis which meet three criteria: i) they evaluate a psychosocial intervention for depression relative to no treatment or enhanced usual care ii) they measure a depression screening questionnaire iii) they measure an outcome that can be harmonized to represent how many days a study participant is able to work per month. These RCTs study 9 interventions, all cognitive behavioral therapy or behavioral activation.<sup>36</sup> We expect relatively little heterogeneity in study population or treatment in this sample relative to the total meta-analysis sample. Variable construction is outlined in Section G.2.

## 8.1 Average treatment effects

We find that treatment reduces depression by 0.22 standard deviations (standard error 0.06) (Column 1, Table A24) in a simple regression of the combined depression measure on psychosocial treatment and study fixed effects. This is consistent with our finding in the meta-analysis sample that psychosocial treatments for CMDs reduce symptoms of common mental disorders by 0.31 standard deviations. The included depression questionnaires are the PHQ-9, BDI, DSM-IV and Kessler Scale, which are aggregated into an index of depression severity.<sup>37</sup> Findings in Columns (4)-(7) indicate that there is some heterogeneity in the standard deviation effects of interventions across measures of depression, which could reflect differences in interventions or measures.

We find that treatment reduces days unable to work by a significant (at the 10% level) 1.57 days per month (SE 0.85, Column 1, Table A25). Broadly, our results are highly consistent with those under the meta-analysis specification. We find that psychosocial treatments for CMDs improve days unable to work by a statistically significant 0.08 standard deviations ([CI: 0.01,0.17]) in the 9 interventions which measure variants of this variable e.g. with different recall periods (Bayesian specification, Table A10). It is also consistent with our meta-analysis finding that psychosocial treatments for CMDs improve days unable to work by 1.42 days (frequentist specification, Table A10). By contrast, we find no

---

<sup>36</sup>The six studies are Fuhr et al. (2019), Sikander et al. (2019), Baranov et al. (2020), Barker et al. (2022), Weobong et al. (2017), Patel et al. (2011). Recall we have 16 interventions targeting CMDs in the meta-analysis. We exclude 5 studies of interventions targeting depression because they do not have the days unable to work outcome (see Table G). We also exclude 2 studies of interventions which target depression with a psychosocial intervention and a pharmacological intervention compared to a pharmacological intervention alone, to reduce heterogeneity.

<sup>37</sup>Details on the variable construction can be found in Appendix G.2.

evidence of an effect on “Healthy days”, reported by [Baranov et al. \(2020\)](#), though the effect is imprecisely estimated due to the small sample size ( $n=429$ , from a single study).

## 8.2 Sample characteristic heterogeneity

Two theoretically important recipient characteristics that could act as mediators of the impacts of treatments on mental ill-health and economic outcomes are reported at baseline by these studies. They are a categorical measure of depression severity, and age. We explore treatment effect heterogeneity by these characteristics by estimating an interacted regression model with median splits. Model details are provided in [Appendix G.3](#). Unfortunately, we cannot test for heterogeneity by participant gender because the majority of the included studies have a sample of single-gender participants.<sup>38</sup>

We find strong evidence of heterogeneous treatment effects of psychosocial interventions on depression severity at endline, by baseline depression severity. More severe baseline depression predicts larger treatment effects. Treatment reduces depression more among people experiencing moderate ( $-0.17$  SD,  $p < 0.01$ ) and severe ( $-0.23$  SD,  $p < 0.01$ ) depression at baseline compared to the group experiencing mild depression (which has a treatment effect of  $-0.12$  SD,  $p < 0.10$ ). The differences between treatment effects for people with mild vs moderate, and mild vs severe, depression are highly statistically significant (footer of [Table A24](#)).<sup>39</sup>

We also find suggestive evidence that treatment for depression leads to stronger reductions in days unable to work (i.e. improvements in work outcomes) for those with higher baseline depression. Coefficients on the interaction terms between having moderate or severe (vs mild) depression and treatment are negative, consistent with effects on work outcomes being larger among populations experiencing more severe mental ill-health at baseline (Column 3, [Table A25](#)). However, coefficients are noisily estimated, preventing strong conclusions. Having higher baseline depression is associated with working between 1.05 and 1.42 days per month less (for moderate and severe groups, respectively) relative to participants not diagnosed with depression at baseline (Column 3, [Table A25](#),  $p < 0.01$  in both cases).

We see few heterogeneous effects by age, although being above median age is associated with marginally significantly higher depression (Column 2, [Table A24](#)) and significantly fewer days worked (Column 2, [Table A25](#)).

---

<sup>38</sup>[Baranov et al. \(2020\)](#), [Fuhr et al. \(2019\)](#) and [Sikander et al. \(2019\)](#) only include female participants.

<sup>39</sup>As might be expected, depression is also highly persistent: relative to people diagnosed with mild depression, those diagnosed with more moderate depression or severe depression experience worse depression at endline ( $0.24$  SD and  $0.43$  SD, respectively, Column 3, [Table A24](#)).

### 8.3 Instrumenting depression with treatment assignment

Does mental ill-health worsen work outcomes in LMICs? We test this hypothesis by instrumenting changes in depression with random assignment of treatment to estimate the effect of a change in depression on days able to work via 2SLS. Psychosocial interventions used in this sample significantly improve mental health (Table A24). If these interventions have no further effects on economic outcomes that are not mediated by improvements in mental health, then we can estimate the impact that mental ill-health has on ability to work. Under this assumption, 2SLS identifies the “total effect” of mental health on work outcomes, across other potential mediators, such as functioning.

In our view, this is the *best feasible test* of the causal impact of mental ill-health on work outcomes. The (theoretical) first-best test would be to randomize mental health across individuals. This is impossible, but best approximated by random assignment to a treatment that is calibrated to improve mental health, and which has few effects on other potential mechanisms.

Our identifying assumption may be violated if either 1) treatments improve ability to work directly or 2) affect a non-mental health-based mechanism that is correlated with ability to work. To minimize the possibility of reverse causality – changes in economic outcomes causing changes in mental health, and not vice versa – we use data on mental health effects from midline surveys and data on economic effects from endline surveys where available, in four of the five trials.

We estimate the relationship between depression and ability to work via 2SLS, instrumenting depression with treatment.

$$MH_i = \gamma_0 + \gamma_1 T_{is} + S_s + \varepsilon_{is}, \quad (2)$$

where  $MH_i$  is participant  $i$ ’s depression outcome (measured at the earliest follow-up) and  $T_{is}$  is the indicator for whether  $i$  received the randomly allocated therapy treatment (as opposed to being in the control group) in study  $s$ . We then estimate the 2SLS equation:

$$y_i = \beta_0 + \beta_1 \widehat{MH}_i + S_s + \varepsilon_{is}, \quad (3)$$

where  $y_i$  is participant  $i$ ’s days able to work measure (measured at endline),  $\widehat{MH}_i$  is her depression outcome instrumented by therapy treatment, and  $\varepsilon_{is}$  is a participant-study specific error term. Further model details are provided in Appendix G.

Treatment is a relevant instrument, as indicated by the F-test labeled “Weak identification”:  $F > 10$  for each instrument (Table 3). This is consistent with our finding that

treatments significantly improve mental health in both the meta-analysis and microdata samples.

Table 3: Instrumenting the decrease in depression with random treatment allocation in the pooled sample

	Days unable to work		Healthy days	
	(1)	(2)	(3)	(4)
	OLS	IV	OLS	IV
Depression reduction	-3.282*** (0.239)	-7.615** (3.058)	0.0762 (0.363)	0.434 (1.041)
Constant	6.721*** (0.324)		26.27*** (0.362)	
Study FE	Yes	Yes	Yes	Yes
Control mean	6.43	6.43	26.16	26.16
Standard deviation	9.86	9.86	7.66	7.66
# of participants	10302	10302	429	429
Obs.	15088	15088	429	429
Studies	5	5	1	1
Underidentification		0.00		0.00
Weak identification		10.70		26.41

*Notes:* This table shows four different regression of the outcome variable on the depression scale, as well as study fixed effects, the endline round, and the number of months after treatment when the outcome was measured. The odd columns show the (endogenous) OLS regression of the outcome on the depression measure, while in the even columns the depression measure is instrumented by the treatment indicator. Columns 1-2 show the impact on days unable to work in the last month, columns 3-4 on healthy days per month. Outcome definitions and further details of the methodology are provided in Appendix G.2. Standard errors are in parentheses and clustered by the original clustering unit of each study. \*  $p < 0.10$ , \*\*  $p < 0.05$ , \*\*\*  $p < 0.01$ .

Our preferred model aggregates across the five studies that measure “Days unable to work”. We estimate that a one standard deviation improvement in depression symptoms is associated with a 7.62-day decrease in “Days unable to work” (Column 2, Table 3), relative to a control mean of 6.43. Our preferred interpretation is to instead consider the effect of the mean intervention, rather than a hypothetical intervention that generates a one standard deviation improvement. The average intervention in our sample improves depression symptoms by 0.22 standard deviations. A back-of-the-envelope calculation indicates that at the mean, the improvement in days unable to work would be 1.68 (26%) fewer days unable to work.<sup>40</sup> While we cannot rule out violations of the identifying assumption, these

<sup>40</sup>We do not observe a statistically significant effect of depression on healthy days alone, potentially due to the relatively small sample size ( $n=429$ ) from only a single study.



results indicate that treating depression in these contexts will cause an increase in work days. Moreover, they provide the strongest evidence to date that depression worsens work outcomes in LMICs by an economically meaningful magnitude.

## 9 Costs

Are the interventions considered by this paper sufficiently cheap to be a scalable or cost-effective method to improve work outcomes? We gained access to cost data on 20 of the 39 interventions covered by this paper either because it was publicly available, or by contacting authors. The studies for which cost data was, or was not, available are listed in section I. The sub-sample of studies for which we have cost data has roughly the same distribution of observable characteristics as the full study sample (Table A27).

Costs of treatments for mental ill-health are moderate on average, but highly heterogeneous. The median per-participant average cost of psychosocial interventions in populations experiencing CMDs and SMDs are reported in Table A26. The median cost of psychosocial interventions for CMDs was USD 105, while that for psychosocial interventions for SMDs was USD 180. However, the least and most costly interventions differ in cost by several orders of magnitude, even within intervention-condition combinations.<sup>41</sup>

Costs differ markedly across intervention regions. On average, interventions that took place in South Asia and East Asia & Pacific had substantially lower costs than those delivered in Europe & Central Asia and in Sub-Saharan Africa. This is consistent with interventions in Asia more commonly being administered by non-specialists.

In Table A17, we report effects on the work aggregate for the subsample of interventions costing less than 100 USD per participant compared to all interventions in our sample, and those costing more than this. For interventions targeting CMD, interventions costing less than 100 USD per participant display a non-significant average treatment effect of only 0.05 SD, while the whole sample average is 0.16 SD. This is consistent with earlier findings that delivery by specialists has larger effects on the work aggregate than delivery by non-specialists, although both are positive and statistically significant (see Section 6.2.2). However, we are cautious in over-interpretation of these findings, because many of the South Asian studies where delivery is by laypeople are with women in settings where women have low labor force participation. It may be the labor market context rather than the intervention cost causing differences in effect sizes.

In contrast, we do not find that more expensive interventions have larger treatment effects in populations experiencing severe mental disorders. If anything, the point estimate

---

<sup>41</sup>For example, the cheapest psychosocial treatment used among a population experiencing common mental disorders cost 1.43 USD per participant, while the most expensive cost 1226 USD per participant.



for the subsample of relatively “cheap” interventions is larger – 0.46 SD, relative to 0.30 SD – but based on only a single intervention.

These findings, suggest that on average, interventions may be cost-effective in improving economic outcomes. It may also be possible to reduce costs of interventions with only limited impacts on intervention effectiveness. Psychosocial interventions in clinical trials may require administration by doctors or psychiatrists, while this may not be necessary when treatments are scaled. Therapies were successfully administered by lay-counsellors in many of the considered interventions, with strong effects on work outcomes.

## 10 Conclusion

Our study presents findings from the first meta-analysis of the economic impacts of common treatments for mental ill-health in low- and middle-income countries. Psychosocial interventions generate substantial and economically meaningful improvements in work outcomes in populations experiencing CMDs, even after conservatively accounting for study-level heterogeneity using Bayesian methods. Our findings indicate that they likely have even larger effects in populations experiencing SMDs, though this finding is only significant at the 90% level under our most conservative approach. Impacts on mental health are highly correlated with impacts on economic outcomes.

We conduct an analysis of the economic impacts of mental health interventions in LMICs using microdata pooled from across trials that treat common mental disorders with psychosocial treatments, and measure days able to work. In this sample, we find that populations experiencing more severe mental ill-health at baseline benefit more from treatment in terms of improvements in mental health, and present suggestive evidence that effects on work outcomes are also larger. We instrument depression with random assignment of psychosocial treatment, and find that depression reduces “Days able to work”. This is the cleanest feasible test of whether mental ill-health causes poorer work outcomes.

Taken together, our results suggest that work outcomes might be an important channel through which mental ill-health causes or exacerbates poverty. However, further work is needed on the mechanisms through which mental ill-health affects work-related outcomes. Our paper motivates future trials of mental health treatments powered to detect economic effects (see e.g. [Angelucci and Bennett \(2024\)](#), [Barker et al. \(2022\)](#), [Blattman et al. \(2017\)](#)). These could productively measure more potential psychological and behavioral mechanisms through which mental health treatment improves ability to work, such as increasing future orientation in economic decision-making or enabling more realistic appraisals of financial options rather than attention to threat ([Haushofer and Fehr, 2014](#)). Future work should also capture measures of labor supply, earnings and wealth, to enable

further study of relationships between poor mental health and poverty. Multiple follow-up rounds would allow researchers to leverage the timing of changes in outcomes to explore causal pathways.

Further research could also develop and test multidimensional, integrated interventions targeting both poverty alleviation and mental health. This builds on findings that administering interventions targeting poverty and mental health alongside one another can be more effective than interventions on their own ([Angelucci and Bennett, 2024](#), [Blattman et al., 2017](#)) and that the mentorship and handholding components of intensive livelihood programs are important elements of their success ([Banerjee et al., 2018](#)).

Our findings provide strong support to other calls to invest in mental health care as an important component of poverty alleviation ([Patel et al., 2018](#)). Policy-makers and international agencies focused on economic development have tended to overlook the importance of mental health. Existing, cost-effective interventions targeting mental health conditions both alleviate symptoms and improve recipients' ability to generate a livelihood. Further investment in mental health interventions is an urgent global priority.

## References

- ALLOUSH, M. (2024): “Income, Psychological Well-being, and the Dynamics of Poverty,” *Economic Development and Cultural Change* (forthcoming).
- ANDREWS, I. AND M. KASY (2019): “Identification of and Correction for Publication Bias,” *American Economic Review*, 109, 2766–94.
- ANGELUCCI, M. AND D. BENNETT (2024): “The Economic Impact of Depression Treatment in India: Evidence from Community-based Provision of Pharmacotherapy,” *American Economic Review*, 114, 169–198.
- ANGRIST, N. AND R. MEAGER (2023): “Implementation Matters: Generalizing Treatment Effects in Education,” *University of Oxford: Blavatnik School of Government Working Paper*, 23-802.
- BANERJEE, A., D. KARLAN, D. OSEI, H. TRACHTMAN, AND C. UDRY (2018): “Unpacking a Multifaceted Program to Build Sustainable Income for the Very Poor,” *National Bureau of Economic Research Working Paper*, 24271.
- BARANOV, V., S. BHALOTRA, P. BIROLI, AND J. MASELKO (2020): “Maternal Depression, Women’s Empowerment, and Parental Investment: Evidence from a Randomized Controlled Trial,” *American Economic Review*, 110, 824–59.
- BARKER, N., G. BRYAN, D. KARLAN, A. OFORI-ATTA, AND C. UDRY (2022): “Cognitive Behavioral Therapy among Ghana’s Rural Poor Is Effective Regardless of Baseline Mental Distress,” *American Economic Review: Insights*, 4, 527–45.
- BHAT, B., J. DE QUIDT, J. HAUSHOFER, V. H. PATEL, G. RAO, F. SCHILBACH, AND P. L. P. VAUTREY (2022): “The Long-run Effects of Psychotherapy on Depression, Beliefs, and Economic Outcomes,” *National Bureau of Economic Research Working Paper*, 30011.
- BIASI, B., M. DAHL, AND P. MOSER (2021): “Career Effects of Mental Health,” *National Bureau of Economic Research Working Paper*, 29031.
- BLATTMAN, C., J. C. JAMISON, AND M. SHERIDAN (2017): “Reducing Crime and Violence: Experimental Evidence from Cognitive Behavioral Therapy in Liberia,” *American Economic Review*, 107, 1165–1206.
- BLOOM, D. E., E. CAFIERO, E. JANÉ-LLOPIS, S. ABRAHAMS-GESSEL, L. R. BLOOM, S. FATHIMA, A. B. FEIGL, T. GAZIANO, A. HAMANDI, M. MOWAFI, D. O’FARRELL, AND EMRE (2011): “The Global Economic Burden of Noncommunicable Diseases,” Tech. rep., World Economic Forum, Geneva.
- BORENSTEIN, M., H. COOPER, L. HEDGES, AND J. VALENTINE (2009): “Effect Sizes for Continuous Data,” *The Handbook of Research Synthesis and Meta-analysis*, 2, 221–235.
- BORENSTEIN, M., L. V. HEDGES, J. P. HIGGINS, AND H. R. ROTHSTEIN (2011): *Introduction to Meta-analysis*, John Wiley & Sons.
- BÜTIKOFER, A., C. J. CRONIN, AND M. M. SKIRA (2020): “Employment Effects of Healthcare Policy: Evidence from the 2007 FDA Black Box Warning on Antidepressants,” *Journal of Health Economics*, 73, 102348.
- CHAN, J. Y., H. W. HIRAI, AND K. K. TSOI (2015): “Computer-assisted Cognitive Remediation and Employment/Productivity Outcomes in Severe Mental Illness: A Meta-analysis of Prospective Controlled Trial,” *Journal of Psychiatric Research*, 68, 293–300.
- CHISHOLM, D., K. SWEENEY, P. SHEEHAN, B. RASMUSSEN, F. SMIT, P. CUIJPERS, AND S. SAXENA (2016): “Scaling-up Treatment of Depression and Anxiety: A Global Return on Investment Analysis,” *The Lancet Psychiatry*, 3, 415 – 424.
- CLEARY, M., G. E. HUNT, S. L. MATHESON, N. SIEGFRIED, AND G. WALTER (2008): “Psychosocial Interventions for People with Both Severe Mental Illness and Substance Misuse,” *Cochrane Database of Systematic Reviews*, 12.

- COHEN, J. (1988): *Statistical Power Analysis for the Behavioral Sciences*, 2nd edn, Erlbaum Associates, Hillsdale.
- CUIJPERS, P., E. KARYOTAKI, M. REIJNDERS, M. PURGATO, AND C. BARBUI (2018): "Psychotherapies for Depression in Low- and Middle-income Countries: A Meta-analysis," *World Psychiatry*, 17, 90–101.
- CUIJPERS, P., A. VAN STRATEN, G. ANDERSSON, AND P. VAN OPPEN (2008): "Psychotherapy for Depression in Adults: A Meta-analysis of Comparative Outcome Studies," *Journal of Consulting and Clinical Psychology*, 76, 909.
- DE SILVA, M. J., S. COOPER, H. L. LI, C. LUND, AND V. PATEL (2013): "Effect of Psychosocial Interventions on Social Functioning in Depression and Schizophrenia: Meta-analysis," *British Journal of Psychiatry*, 202, 253–260.
- DERSIMONIAN, R. AND N. LAIRD (1986): "Meta-analysis in Clinical Trials," *Controlled Clinical Trials*, 7, 177–188.
- EDLUND, M. J., J. WANG, K. G. BROWN, V. L. FORMAN-HOFFMAN, S. L. CALVIN, S. L. HEDDEN, AND J. BOSE (2018): "Which Mental Disorders Are Associated With the Greatest Impairment in Functioning?" *Social Psychiatry and Psychiatric Epidemiology*, 53, 1265–1276.
- EGGER, M., G. D. SMITH, M. SCHNEIDER, AND C. MINDER (1997): "Bias in Meta-analysis Detected by a Simple, Graphical Test," *British Medical Journal*, 315, 629–634.
- FINNES, A., P. ENEBRINK, A. GHADERI, J. DAHL, A. NAGER, AND L.-G. ÖST (2019): "Psychological Treatments for Return to Work in Individuals on Sickness Absence Due to Common Mental Disorders or Musculoskeletal Disorders: A Systematic Review and Meta-analysis of Randomized Controlled Trials," *International Archives of Occupational and Environmental Health*, 92, 273–293.
- FUHR, D. C., B. WEOBONG, A. LAZARUS, F. VANOBBERGHEN, H. A. WEISS, D. R. SINGLA, H. TABANA, E. AFONSO, A. DE SA, E. D'SOUZA, ET AL. (2019): "Delivering the Thinking Healthy Programme for Perinatal Depression Through Peers: An Individually Randomised Controlled Trial in India," *The Lancet Psychiatry*, 6, 115–127.
- GBD 2019 COLLABORATORS (2022): "Global, Regional, and National Burden of 12 Mental Disorders in 204 Countries and Territories, 1990–2019: A Systematic Analysis for the Global Burden of Disease Study 2019," *The Lancet Psychiatry*, 9, 137–150.
- GELMAN, A., J. B. CARLIN, H. S. STERN, AND D. B. RUBIN (2009): *Bayesian Data Analysis (3rd ed.)*, Abingdon: Taylor and Francis.
- GELMAN, A. AND J. HILL (2006): *Data Analysis Using Regression and Multilevel/Hierarchical Models*, Analytical Methods for Social Research, Cambridge University Press.
- GLESER, L. J. AND I. OLKIN (2009): "Stochastically Dependent Effect Sizes," in *The Handbook of Research Synthesis and Meta-analysis*, ed. by H. Cooper, L. B. Hedges, and J. Valentine, Russell Sage Foundation, 357–376.
- HAUSHOFER, J. AND E. FEHR (2014): "On the Psychology of Poverty," *Science*, 344, 862–867.
- HAUSHOFER, J., R. MUDIDA, AND J. P. SHAPIRO (2020): "The Comparative Impact of Cash Transfers and a Psychotherapy Program on Psychological and Economic Well-being," *National Bureau of Economic Research Working Paper*, 28106.
- HEDGES, L. V. (1981): "Distribution Theory for Glass's Estimator of Effect Size and Related Estimators," *Journal of Educational Statistics*, 6, 107–128.
- HIGGINS, J., S. THOMPSON, AND D. SPIEGELHALTER (2009): "A Re-evaluation of Random Effects Meta-analysis," *Journal of the Royal Statistical Society. Series A, (Statistics in Society)*, 172, 137–159.
- HIGGINS, J. P. T., J. THOMAS, J. CHANDLER, M. CUMPSTON, T. LI, M. PAGE, AND V. A. WELCH (2022): *Cochrane Handbook for Systematic Reviews of Interventions*, Wiley-Blackwell.

- JACKSON, D., R. RILEY, AND I. R. WHITE (2011): "Multivariate Meta-analysis: Potential and Promise," *Statistics in Medicine*, 30, 2481–2498.
- KAMENOV, K., C. TWOMEY, M. CABELLO, A. M. PRINA, AND J. L. AYUSO-MATEOS (2017): "The Efficacy of Psychotherapy, Pharmacotherapy, and their Combination on Functioning and Quality of Life in Depression: A Meta-analysis," *Psychological Medicine*, 47, 414–425.
- LEUCHT, S., A. CIPRIANI, L. SPINELLI, D. MAVRIDIS, D. ÖREY, F. RICHTER, M. SAMARA, C. BARBUI, R. R. ENGEL, J. R. GEDDES, ET AL. (2013): "Comparative Efficacy and Tolerability of 15 Antipsychotic Drugs in Schizophrenia: A Multiple-treatments Meta-analysis," *The Lancet*, 382, 951–962.
- MEAGER, R. (2019): "Understanding the Average Impact of Microcredit Expansions: A Bayesian Hierarchical Analysis of Seven Randomized Experiments," *American Economic Journal: Applied Economics*, 11, 57–91.
- NADKARNI, A., H. A. WEISS, B. WEOBONG, D. MCDAID, D. R. SINGLA, A.-L. PARK, B. BHAT, B. KATTI, J. MCCAMBRIDGE, P. MURTHY, M. KING, G. T. WILSON, B. KIRKWOOD, C. G. FAIRBURN, R. VELLEMAN, AND V. PATEL (2017a): "Sustained Effectiveness and Cost-effectiveness of Counselling for Alcohol Problems: A Brief Psychological Treatment for Harmful Drinking in Men, Delivered by Lay Counsellors in Primary Care - 12-month Follow-up of a Randomised Controlled Trial," *PLOS Medicine*, 14, 1–20.
- NADKARNI, A., B. WEOBONG, H. A. WEISS, J. MCCAMBRIDGE, B. BHAT, B. KATTI, P. MURTHY, M. KING, D. MCDAID, A.-L. PARK, G. T. WILSON, B. KIRKWOOD, C. G. FAIRBURN, R. VELLEMAN, AND V. PATEL (2017b): "Counselling for Alcohol Problems (CAP): A Lay Counsellor-delivered Brief Psychological Treatment for Harmful Drinking in Men, in Primary Care in India: A Randomised Controlled Trial," *The Lancet*, 389, 186–195.
- NIEUWENHUIJSEN, K., J. H. VERBEEK, A. NEUMEYER-GROMEN, A. C. VERHOEVEN, U. BÜLTMANN, AND B. FABER (2020): "Interventions to Improve Return to Work in Depressed People," *Cochrane Database of Systematic Reviews*, 1–160.
- NIGATU, Y. T., Y. LIU, M. UPPAL, S. MCKINNEY, S. RAO, K. GILLIS, AND J. WANG (2016): "Interventions for Enhancing Return to Work in Individuals with a Common Mental Illness: Systematic Review and Meta-analysis of Randomized Controlled Trials," *Psychological Medicine*, 46, 3263–3274.
- PATEL, V., S. SAXENA, C. LUND, G. THORNICROFT, F. BAINGANA, P. BOLTON, D. CHISHOLM, P. Y. COLLINS, J. L. COOPER, J. EATON, ET AL. (2018): "The Lancet Commission on Global Mental Health and Sustainable Development," *The Lancet*, 392, 1553–1598.
- PATEL, V., H. A. WEISS, N. CHOWDHARY, S. NAIK, S. PEDNEKAR, S. CHATTERJEE, B. BHAT, R. ARAYA, M. KING, G. SIMON, H. VERDELI, AND B. R. KIRKWOOD (2011): "Lay Health Worker-Led Intervention for Depressive and Anxiety Disorders in India: Impact on Clinical and Disability Outcomes Over 12 Months," *British Journal of Psychiatry*, 199, 459–466.
- PUSTEJOVSKY, J. E. AND M. A. RODGERS (2019): "Testing for Funnel Plot Asymmetry of Standardized Mean Differences," *Research Synthesis Methods*, 10, 57–71.
- RAN, M.-S., M.-Z. XIANG, C. L.-W. CHAN, J. LEFF, P. SIMPSON, M.-S. HUANG, Y.-H. SHAN, AND S.-G. LI (2003): "Effectiveness of Psychoeducational Intervention for Rural Chinese Families Experiencing Schizophrenia," *Social Psychiatry and Psychiatric Epidemiology*, 38, 69–75.
- RIDLEY, M., G. RAO, F. SCHILBACH, AND V. PATEL (2020): "Poverty, Depression, and Anxiety: Causal Evidence and Mechanisms," *Science*, 370, eaay0214.
- RODGERS, M. AND J. PUSTEJOVSKY (2020): "Evaluating Meta-analytic Methods to Detect Selective Reporting in the Presence of Dependent Effect Sizes," *Psychological Methods*, 26(2), 141–160.

- RUBIN, D. B. (1981): “Estimation in Parallel Randomized Experiments,” *Journal of Educational Statistics*, 6, 377–401.
- SALOMONSSON, S., E. HEDMAN-LAGERLÖF, AND L.-G. ÖST (2018): “Sickness Absence: A Systematic Review and Meta-Analysis of Psychological Treatments for Individuals on Sick Leave Due to Common Mental Disorders,” *Psychological Medicine*, 48, 1954–1965.
- SIKANDER, S., I. AHMAD, N. ATIF, A. ZAIDI, F. VANOBBERGHEN, H. A. WEISS, A. NISAR, H. TABANA, Q. U. AIN, A. BIBI, ET AL. (2019): “Delivering the Thinking Healthy Programme for Perinatal Depression Through Volunteer Peers: A Cluster Randomised Controlled Trial in Pakistan,” *The Lancet Psychiatry*, 6, 128–139.
- SINGLA, D. R., B. A. KOHRT, L. K. MURRAY, A. ANAND, B. F. CHORPITA, AND V. PATEL (2017): “Psychological Treatments for the World: Lessons from Low- and Middle-income Countries,” *Annual Review of Clinical Psychology*, 13, 149–181.
- STOOP, N., M. LEIBBRANDT, AND R. ZIZZAMIA (2019): “Exploring Psychological Well-being and Poverty Dynamics in South-Africa: Evidence from NIDS waves 1-5,” *Southern African Labour and Development Research Unit Working Paper*, 240.
- TAN, B. AND M. KREMER (2020): “Water Treatment and Child Survival: A Meta-analysis,” *National Bureau of Economic Research Working Paper*, 30835.
- TIMBIE, J., M. HORVITZ-LENNON, R. G. FRANK, AND S.-L. T. NORMAND (2006): “A Meta-analysis of Labor Supply Effects of Interventions for Major Depressive Disorder,” *Psychiatric Services*, 57, 212–218.
- VAN DUIN, D., L. DE WINTER, M. OUD, H. KROON, W. VELING, AND J. VAN WEEGHEL (2019): “The Effect of Rehabilitation Combined with Cognitive Remediation on Functioning in Persons with Severe Mental Illness: Systematic Review and Meta-analysis,” *Psychological Medicine*, 49, 1414–1425.
- VIVALT, E. (2020): “How Much Can We Generalize from Impact Evaluations?” *Journal of the European Economic Association*, 18, 3045–3089.
- VON HIPPEL, P. (2015): “The Heterogeneity Statistic I Can Be Biased in Small Meta-analyses,” *BioMed Central Medical Research Methodology*, 15, 35.
- WEOBONG, B., H. A. WEISS, D. MCDAID, D. R. SINGLA, S. D. HOLLON, A. NADKARNI, A.-L. PARK, B. BHAT, B. KATTI, A. ANAND, S. DIMIDJIAN, R. ARAYA, M. KING, L. VIJAYAKUMAR, G. T. WILSON, R. VELLEMAN, B. R. KIRKWOOD, C. G. FAIRBURN, AND V. PATEL (2017): “Sustained Effectiveness and Cost-effectiveness of the Healthy Activity Programme, a Brief Psychological Treatment for Depression Delivered by Lay Counsellors in Primary Care: 12-month Follow-up of a Randomised Controlled Trial,” *PLOS Medicine*, 14, e1002385.
- WORLD HEALTH ORGANIZATION (2016): “International Classification of Diseases (ICD),” <http://www.who.int/classifications/icd/en/>.
- (2021): “Mental Health Atlas 2020,” Tech. rep.

# Supplementary Appendix

## For Online Publication

### A Search and included studies

#### A.1 Search strategy

Searches of the databases and forward and backward reference tracking of citations of included papers yielded 15,031 potential studies. A sample set of search terms for PubMed can be found online under the following link: <http://tiny.cc/0duyvz>. Three reviewers independently screened abstracts against inclusion criteria using Covidence software. Disagreements were resolved by a third reviewer. After removing 90 duplicates, abstracts of 14,941 selected articles were screened by two reviewers, with disagreements again resolved by a third reviewer. 13,813 studies were removed as they did not meet inclusion criteria. We reviewed the full text of 1,128 articles. 1,089 were removed because they did not meet inclusion criteria, with reasons detailed in Figure A1, leaving 40 studies. Five studies combined psychosocial with economic interventions, which we exclude. We assessed inter-rater agreement with the Kappa statistic, which measures the probability of agreement between two raters who each classify  $N$  items into  $C$  mutually exclusive categories. Our Kappa agreement probability was 0.90, reflecting high agreement.


Information was then input into a piloted, pre-populated Excel spreadsheet by multiple members of the study team. A different author checked this information against papers. We coded all economic outcomes matching those in our search criteria, primary mental health outcomes, as defined by the authors, as well as all outcomes which fell into one of 22 categories of mental health or functioning outcome (see Section 3.3 for the list). We coded the definition of outcomes measured and statistical information on the effects, including the raw (reported) effect size, its type (continuous vs dichotomous) and standard error, the means and standard deviations in treatment and control groups, and sample sizes. We requested any missing information needed to compute effect sizes for a study from authors. In terms of study quality, we include only RCTs. We code measures of risk of bias, following the Cochrane Collaboration's recommendations. We observe relatively high study quality among included RCTs on these indicators and did not exclude any studies.

**List of databases searched:** Social Science Research Network (SSRN), Research Papers in Economics (RePEc), the Abdul Latif Jameel Poverty Action Lab (JPAL) Evaluation and Publication Database, the World Bank Poverty Impact Evaluations Database, Research for Development (R4D), ECONLIT, WHO regional databases that cover LMICs, Sociological Abstracts, Applied Social Sciences Index and Abstracts (ASSIA), Public Affairs Information Service (PAIS International), Pubmed (including Medline), Scopus (including Embase), Web of Science, Social Science Citation Index (SSCI), EbscoHost, Africa Wide, Cumulative Index to Nursing and Allied Health Literature (CINAHL), PsycInfo, PROQUEST, and Published International Literature on Traumatic Stress (PILOTS).



**List of trial registries searched:** Cochrane, ClinicalTrials.gov, the EU clinical trial registry, the Pan African Trials Registry, the ISRCTN Registry, the 3ie Registry for International Development Impact Evaluations (RIDIE), and the American Economic Association trial registry.

Figure A1: Flow of citations reviewed during systematic review



## A.2 Included studies

## References

- ANGELUCCI, M. AND D. BENNETT (2024): “The Economic Impact of Depression Treatment in India: Evidence from Community-based Provision of Pharmacotherapy,” *American Economic Review*, 114, 169–198.
- AYOUGHI, S., I. MISSMAHL, R. WEIERSTALL, AND T. ELBERT (2012): “Provision of Mental Health Services in Resource-poor Settings: A Randomised Trial Comparing Counselling with Routine Medical Treatment in North Afghanistan (Mazar-e-Sharif),” *BioMed Psychiatry*, 12, 14.
- BARANOV, V., S. BHALOTRA, P. BIROLI, AND J. MASELKO (2020): “Maternal Depression, Women’s Empowerment, and Parental Investment: Evidence from a Randomized Controlled Trial,” *American Economic Review*, 110, 824–59.
- BARKER, N., G. BRYAN, D. KARLAN, A. OFORI-ATTA, AND C. UDRY (2022): “Cognitive Behavioral Therapy among Ghana’s Rural Poor Is Effective Regardless of Baseline Mental Distress,” *American Economic Review: Insights*, 4, 527–45.
- BETANCOURT, T. S., R. MCBAIN, E. A. NEWNHAM, A. M. AKINSULURE-SMITH, R. T. BRENNAN, J. R. WEISZ, AND N. B. HANSEN (2014): “A Behavioral Intervention for War-affected Youth in Sierra Leone: A Randomized Controlled Trial,” *Journal of the American Academy of Child & Adolescent Psychiatry*, 53, 1288–1297.
- BHAT, B., J. DE QUIDT, J. HAUSHOFER, V. PATEL, G. RAO, F. SCHILBACH, AND P. VAUTREY (2022): “The Long-run Effects of Psychotherapy on Depression, Beliefs, and Economic Outcomes,” *National Bureau of Economic Research Working Paper*, 30011.
- BLATTMAN, C., J. C. JAMISON, AND M. SHERIDAN (2017): “Reducing Crime and Violence: Experimental Evidence from Cognitive Behavioral Therapy in Liberia,” *American Economic Review*, 107, 1165–1206.
- BOLTON, P., J. BASS, R. NEUGEBAUER, H. VERDELI, K. F. CLOUGHERTY, P. WICKRAMARATNE, L. SPEELMAN, L. NDOGONI, AND M. WEISSMAN (2003): “Group Interpersonal Psychotherapy for Depression in Rural Uganda: A Randomized Controlled Trial,” *Journal of the American Medical Association*, 289, 3117–3124.
- BUTTORFF, C., R. S. HOCK, H. A. WEISS, S. NAIK, R. ARAYA, B. R. KIRKWOOD, D. CHISHOLM, AND V. PATEL (2012): “Economic Evaluation of a Task-shifting Intervention for Common Mental Disorders in India,” *Bulletin of the World Health Organization*, 90, 813–821.
- CHATTERJEE, S., S. NAIK, S. JOHN, H. DABHOLKAR, M. BALAJI, M. KOSCHORKE, M. VARGHESE, R. THARA, H. A. WEISS, P. WILLIAMS, P. MCCRONE, V. PATEL, AND G. THORNICROFT (2014): “Effectiveness of a Community-based Intervention for People with Schizophrenia and Their Caregivers in India (COPSI): A Randomised Controlled Trial,” *The Lancet*, 383, 1385–1394.
- CHUAN-QIAN, Q., Z. ZHAO-XIANG, AND L. ZHI-CHENG (2005): “Influence of Family Intervention by Physician on the Social Function and Quality of Life in Community Schizophrenic Patients: A Follow-up for Half a Year,” *Chinese Journal of Clinical Rehabilitation*, 12, 75–77.
- CILLIERS, J., O. DUBE, AND B. SIDDIQI (2016): “Reconciling After Civil Conflict Increases Social Capital but Decreases Individual Well-being,” *Science*, 352, 787–794.
- DUARTE, P. S., M. C. MIYAZAKI, S. L. BLAY, AND R. SESSO (2009): “Cognitive-behavioral Group Therapy: An Effective Treatment for Major Depression in Hemodialysis Patients,” *Kidney International*, 76, 414–421.
- FUHR, D. C., B. WEOBONG, A. LAZARUS, F. VANOBERGHEN, H. A. WEISS, D. R. SINGLA, H. TABANA, E. AFONSO, A. DE SA, E. D’SOUZA, ET AL. (2019): “Delivering the Thinking Healthy Pro-

- gramme for Perinatal Depression Through Peers: An Individually Randomised Controlled Trial in India,” *The Lancet Psychiatry*, 6, 115–127.
- GUREJE, O., J. APPIAH-POKU, T. BELLO, L. KOLA, R. ARAYA, D. CHISHOLM, O. ESAN, B. HARRIS, V. MAKANJUOLA, C. OTHIENO, L. PRICE, AND S. SEEDAT (2020): “Effect of Collaborative Care Between Traditional and Faith Healers and Primary Health-care Workers on Psychosis Outcomes in Nigeria and Ghana (COSIMPO): A Cluster Randomised Controlled Trial,” *The Lancet*, 396, 612–622.
- HALL, B. J., P. A. BOLTON, J. ANNAN, D. KAYSEN, K. ROBINETTE, T. CETINOGLU, K. WACHTER, AND J. K. BASS (2014): “The Effect of Cognitive Therapy on Structural Social Capital: Results From a Randomized Controlled Trial Among Sexual Violence Survivors in the Democratic Republic of the Congo,” *American Journal of Public Health*, 104, 1680–1686.
- HAUSHOFER, J., R. MUDIDA, AND J. P. SHAPIRO (2020): “The Comparative Impact of Cash Transfers and a Psychotherapy Program on Psychological and Economic Well-being,” *National Bureau of Economic Research Working Paper*, 28106.
- HIRANI, S. S., R. KARMALIANI, J. MCFARLANE, N. ASAD, F. MADHANI, ET AL. (2010): “Testing a Community-derived Intervention to Promote Women’s Health: Preliminary Results of a 3-arm Randomized Controlled Trial in Karachi, Pakistan,” *Southern Online Journal of Nursing Research*, 10, 1.
- HU, T.-W., Y. HE, M. ZHANG, AND N. CHEN (2007): “Economic costs of depression in China,” *Social psychiatry and psychiatric epidemiology*, 42, 110–116.
- LUO, X., S. F. LAW, X. WANG, J. SHI, W. ZENG, X. MA, W. CHOW, S. LIU, W. ZHAO, X. LIU, S. YAO, AND M. R. PHILLIPS (2019): “Effectiveness of an Assertive Community Treatment Program for People with Severe Schizophrenia in Mainland China – A 12-month Randomized Controlled Trial,” *Psychological Medicine*, 49, 969–979.
- MEFFERT, S. M., T. C. NEYLAN, C. E. MCCULLOCH, K. BLUM, C. R. COHEN, E. A. BUKUSI, H. VERDELI, J. C. MARKOWITZ, J. G. KAHN, D. BUKUSI, H. THIRUMURTHY, G. ROTA, R. ROTA, G. OKETCH, E. OPIYO, AND L. ONGERI (2021): “Interpersonal Psychotherapy Delivered by Non-specialists for Depression and Posttraumatic Stress Disorder Among Kenyan HIV-positive Women Affected by Gender-based Violence: A Randomized Controlled Trial,” *PLOS Medicine*, 18, 1–22.
- MIN, Z., L. XU, H. CHEN, X. DING, Z. YI, AND Z. MINGYUANG (2011): “A Pilot Assessment of Relapse Prevention for Heroin Addicts in a Chinese Rehabilitation Center,” *American Journal of Drug and Alcohol Abuse*, 37, 141–147.
- NADKARNI, A., H. A. WEISS, R. VELLEMAN, J. MCCAMBRIDGE, D. MCDAID, A.-L. PARK, P. MURTHY, B. WEOBONG, B. BHAT, AND V. PATEL (2019): “Feasibility, Acceptability, and Cost-effectiveness of a Brief, Lay Counsellor-delivered Psychological Treatment for Men with Alcohol Dependence in Primary Care: An Exploratory Randomized Controlled Trial,” *Addiction*, 114, 1192–1203.
- NADKARNI, A., H. A. WEISS, B. WEOBONG, D. MCDAID, D. R. SINGLA, A.-L. PARK, B. BHAT, B. KATTI, J. MCCAMBRIDGE, P. MURTHY, M. KING, G. T. WILSON, B. KIRKWOOD, C. G. FAIRBURN, R. VELLEMAN, AND V. PATEL (2017a): “Sustained Effectiveness and Cost-effectiveness of Counselling for Alcohol Problems: A Brief Psychological Treatment for Harmful Drinking in Men, Delivered by Lay Counsellors in Primary Care: 12-month Follow-up of a Randomised Controlled Trial,” *PLOS Medicine*, 14, 1–20.
- NADKARNI, A., B. WEOBONG, H. A. WEISS, J. MCCAMBRIDGE, B. BHAT, B. KATTI, P. MURTHY, M. KING, D. MCDAID, A.-L. PARK, G. T. WILSON, B. KIRKWOOD, C. G. FAIRBURN, R. VELLEMAN, AND V. PATEL (2017b): “Counselling for Alcohol Problems (CAP), A Lay Counsellor-delivered Brief Psychological Treatment for Harmful Drinking in Men, in Primary Care in India: A Randomised Controlled Trial,” *The Lancet*, 389, 186–195.

- NAGARAJAIAH, G. JOTHIMANI, R. PARTHASARATHI, K. REDDEMMA, AND A. GIRI (2013): "Efficacy of Nursing Interventions in Reducing Social and Occupational Disabilities among Patients with Neurosis," *The Nursing journal of India*, 103, 256–60.
- PAN, S., H. JIANG, J. DU, H. CHEN, Z. LI, W. LING, AND M. ZHAO (2015): "Efficacy of Cognitive Behavioral Therapy on Opiate Use and Retention in Methadone Maintenance Treatment in China: A Randomised Trial," *PLOS ONE*, 10, e0127598.
- PATEL, V., H. A. WEISS, N. CHOWDHARY, S. NAIK, S. PEDNEKAR, S. CHATTERJEE, B. BHAT, R. ARAYA, M. KING, G. SIMON, H. VERDELI, AND B. R. KIRKWOOD (2011): "Lay Health Worker-led Intervention for Depressive and Anxiety Disorders in India: Impact on Clinical and Disability Outcomes Over 12 Months," *British Journal of Psychiatry*, 199, 459–466.
- PATEL, V., B. WEOBONG, H. A. WEISS, A. ANAND, B. BHAT, B. KATTI, S. DIMIDJIAN, R. ARAYA, S. D. HOLLON, M. KING, L. VIJAYAKUMAR, A.-L. PARK, D. MCDAID, T. WILSON, R. VELLEMAN, B. R. KIRKWOOD, AND C. G. FAIRBURN (2017): "The Healthy Activity Program (HAP), a Lay Counsellor-delivered Brief Psychological Treatment for Severe Depression, in Primary Care in India: A Randomised Controlled Trial," *The Lancet*, 389, 176–185.
- RAN, M.-S., C. L.-W. CHAN, S. M. NG, L.-T. GUO, AND M.-Z. XIANG (2015): "The Effectiveness of Psychoeducational Family Intervention for Patients with Schizophrenia in a 14-year Follow-up Study in a Chinese Rural Area," *Psychological Medicine*, 45, 2197–2204.
- RAN, M.-S., M.-Z. XIANG, C. L.-W. CHAN, J. LEFF, P. SIMPSON, M.-S. HUANG, Y.-H. SHAN, AND S.-G. LI (2003): "Effectiveness of Psychoeducational Intervention for Rural Chinese Families Experiencing Schizophrenia," *Social Psychiatry and Psychiatric Epidemiology*, 38, 69–75.
- SIKANDER, S., I. AHMAD, N. ATIF, A. ZAIDI, F. VANOBBERGHEN, H. A. WEISS, A. NISAR, H. TABANA, Q. U. AIN, A. BIBI, ET AL. (2019): "Delivering the Thinking Healthy Programme for Perinatal Depression Through Volunteer Peers: A Cluster Randomised Controlled Trial in Pakistan," *The Lancet Psychiatry*, 6, 128–139.
- VALENCIA, M., M. L. RASCON, F. JUAREZ, AND E. MUROW (2007): "A Psychosocial Skills Training Approach in Mexican Out-patients with Schizophrenia," *Psychological Medicine*, 37, 1393–1402.
- VIZZOTTO, A., D. CELESTINO, P. BUCHAIN, A. OLIVEIRA, G. OLIVEIRA, E. DI SARNO, I. NAPOLITANO, AND H. ELKIS (2021): "Occupational Goal Intervention Method for the Management of Executive Dysfunction in People With Treatment-resistant Schizophrenia: A Randomized Controlled Trial," *The American Journal of Occupational Therapy*, 75, 7503180050.
- WANG, S.-J., A. BYTYÇI, S. IZETI, M. KALLABA, F. RUSHITI, E. MONTGOMERY, AND J. MODVIG (2017): "A Novel Bio-psycho-social Approach for Rehabilitation of Traumatized Victims of Torture and War in the Post-conflict Context: A Pilot Randomized Controlled Trial in Kosovo," *Conflict and Health*, 10, 34.
- WEOBONG, B., H. A. WEISS, D. MCDAID, D. R. SINGLA, S. D. HOLLON, A. NADKARNI, A.-L. PARK, B. BHAT, B. KATTI, A. ANAND, S. DIMIDJIAN, R. ARAYA, M. KING, L. VIJAYAKUMAR, G. T. WILSON, R. VELLEMAN, B. R. KIRKWOOD, C. G. FAIRBURN, AND V. PATEL (2017): "Sustained Effectiveness and Cost-effectiveness of the Healthy Activity Programme, a Brief Psychological Treatment for Depression Delivered by Lay Counsellors in Primary Care: 12-month Follow-up of a Randomised Controlled Trial," *PLOS Medicine*, 14, e1002385.
- XIANG, M., M. RAN, AND S. LI (1994): "A Controlled Evaluation of Psychoeducational Family Intervention in a Rural Chinese Community," *British Journal of Psychiatry*, 165, 544–548.
- XIONG, H., W. YU-LING, AND F. HUI-PENG (2007): "Synthetical Family Treatment for Depression: A Randomized-controlled Single-blind Study Among 76 Cases," *Zhongguo Zuzhi Gongcheng Yanjiu Yu Linchuang Linchuang Kangfu*, 11, 7787.
- XIONG, W., M. R. PHILLIPS, X. HU, R. WANG, Q. DAI, J. KLEINMAN, AND A. KLEINMAN (1994):

“Family-Based Intervention for Schizophrenic Patients in China: A Randomised Controlled Trial,” *British Journal of Psychiatry*, 165, 239–247.

XU, X., S. CHEN, J. CHEN, Z. CHEN, L. FU, D. SONG, M. ZHAO, AND H. JIANG (2021): “Feasibility and Preliminary Efficacy of a Community-Based Addiction Rehabilitation Electronic System in Substance Use Disorder: Pilot Randomized Controlled Trial,” *JMIR Mhealth Uhealth*, 9, e21087.

ZHANG, M., Y. HE, M. GITTELMAN, Z. WONG, AND H. YAN (1998): “Group Psychoeducation of Relatives of Schizophrenic Patients: Two-year Experiences,” *Psychiatry and Clinical Neurosciences*, 52, S344–S347.

## B Comparison to high income country effect sizes

Table A1: Comparison to developed country effect sizes: work outcomes

Outcome	Study	Target Condition	Intervention	Effect Size	95% CI
<b>Aggregate work effects</b>					
Work aggregate	Lund et al. (2024)	Common Mental Disorders	Psychosocial	$g = 0.16$	[0.03, 0.31]
Work aggregate	Lund et al. (2024)	Severe Mental Disorders	Psychosocial	$g = 0.30$	[-0.05, 0.67]
Labour supply effects <sup>1</sup>	Timbie et al. (2006)	Depression	Pharmacological Psychosocial	$d = -0.39$ $d = 0.16$	[-1.01, 0.24] [0.02, 0.29]
<b>Absence from Work</b>					
Days unable to work	Lund et al. (2024)	Common Mental Disorders	Psychosocial	$g = 0.08$	[0.01, 0.17]
Sick leave <sup>2</sup>	Nieuwenhuijsen et al. (2020)	Depression	Psychosocial Psych. + pharm.	SMD = 0.15 SMD = 0.38	[0.03, 0.28] [-0.24, 0.99]
Sick leave <sup>a</sup>	Salomonsson et al. (2018)	Common Mental Disorders	Problem Solving Therapy Cognitive behavioural therapy	$g = 0.12$ $g = 0.17$	[0.02, 0.22] [0.02, 0.32]
Sickness absence	Finnes et al. (2019)	Common Mental Disorders + Musculoskeletal Disorders	Psychosocial (CBT, PST, PDT, MMCBT, MI)	$g = 0.17$	[-0.03, 0.36]
<b>Functioning at work</b>					
Functioning at work	Lund et al. (2024)	Common Mental Disorders	Psychosocial	$g = 0.01$	[-0.11, 0.13]
Functioning	Kamenov et al. (2017)	Depression	Psychosocial	$g = 0.43$	[0.33, 0.54]
Coping with work <sup>3</sup>	Nieuwenhuijsen et al. (2020)	Depression	Psychological	SMD = 0.05	[-0.46, 0.57]
<b>Employment Dummy</b>					
In employment	Lund et al. (2024)	Common Mental Disorders	Psychosocial	$g = -0.02$	[-0.35, 0.25]
In employment	Lund et al. (2024)	Severe Mental Disorders	Psychosocial	$g = 0.22$	[-1.66, 1.85]
Employment rate	van Duin et al. (2019)	Severe Mental Disorders	Psychiatric Rehab + Cognitive Rehab	SD = 0.41	[0.10, 0.72]
Employment rate	Chan et al. (2015)	Severe Mental Disorders	Computer Assisted Cognitive Remediation	SD = 0.15	[0.04, 0.25]
<b>Time in work</b>					
Time in work	Lund et al. (2024)	Common Mental Disorders	Psychosocial	$g = 0.16$	[-0.61, 0.87]
Time in work	Lund et al. (2024)	Severe Mental Disorders	Psychosocial	$g = 0.21$	[-1.09, 1.32]
Hours worked	van Duin et al. (2019)	Severe Mental Disorders	Psychiatric Rehab + Cognitive Rehab	SD = 0.31	[0.04, 0.58]
Employment frequency	Chan et al. (2015)	Severe Mental Disorders	Computer Assisted Cognitive Remediation	SD = 0.15	[0.02, 0.28]
Employment frequency	Chan et al. (2015)	Severe Mental Disorders	Computer Assisted Cognitive Remediation	19.5 more days / year	[2.50, 36.6]

Notes: Effect sizes are denoted:  $g$  = Hedges'  $g$ ;  $d$  = Cohen's  $d$ ; SD = Standard Deviation; SMD = Standardized Mean Difference and comparable, differing only in small sample corrections. <sup>1</sup> The aggregate of labor supply effects includes hours worked per week, odds of being unable to work, days of employment, percent employed, and aligns closely with our work aggregate. <sup>2</sup> Most studies reverse-coded effects such that a positive effect indicates an improvement in work outcomes as in our study. However, Nieuwenhuijsen et al. (2020) did not reverse code Sick Days, so we have given the absolute value of their effect size for comparison. <sup>3</sup> Each of the functioning at work scales are validated measures of functioning except "Coping with work", which measured people's capacity to copy with their work given their depression symptoms.

## C Outcome details and study characteristics

Table A2: Additional characteristics of interventions in included RCTs

	All		Target CMD	Target SMD
	(1) Number of interventions	(2) Share of interventions	(3) N	(4) N
<b>Age target groups:</b>	39	1	16	9
Adults (17+)	26	0.67	11	5
Youth <sup>1</sup>	3	0.08	0	0
Other ranges <sup>2</sup>	10	0.26	5	4
<b>Specific target groups:</b>	39	1	16	9
Males	3	0.08	0	0
Females	7	0.18	5	0
Both genders	29	0.74	11	9
<b>Publication period: (First publication)</b>	39	1	16	
Publication: 1990-2000	3	0.08	0	3
Publication: 2001-2010	8	0.21	4	3
Publication: 2011-2015	12	0.31	6	1
Publication: 2016-2020	11	0.28	4	1
Publication: 2021-present	6	0.15	2	1
<b>Country income (mutually exclusive)</b>	39	1	16	9
Upper middle income country	14	0.36	2	8
Lower middle income country	19	0.49	12	1
Low income country	6	0.15	2	0
<b>Regions (mutually exclusive)</b>	39	1	16	9
Sub-Saharan Africa	9	0.23	3	0
Europe and Central Asia	2	0.05	1	0
Latin America and the Caribbean	3	0.08	1	2
South Asia	14	0.36	10	1
East Asia and Pacific	11	0.28	1	6
<b>Follow-up timing:</b>	39	1	16	0
Follow-up: 1-6 months after start	25	0.64	9	3
Follow-up: >6-12 months after start	18	0.46	8	1
Follow-up: >1-2 years after start	6	0.15	1	1
Follow-up: >2 years after start	6	0.15	2	1
<b>Follow-up combinations (in months after start):</b>	39	1	16	9
1 round, < 7 months	16	0.41	5	7
1 round, 7 to 12 months	5	0.31	4	0
1 round, 13 to 24 months	1	0.20	1	0
2 rounds, < 7 months	2	2.00	1	0
2 rounds, <7 & 7-12 months	7	3.50	2	0
2 rounds, <7 & >12 months	3	0.43	0	1
2 rounds, 7-12 & >24 months	1	0.33	0	0
3 rounds, <7 & 7-12 & >12 months	3	3.00	2	1
3 rounds, 7-12 & 13-24 & >24 months	1	0.33	1	0
<b>Type of psychosocial intervention: (not mutually exclusive)</b>				
Cognitive-behavioral therapy (CBT)	9	0.23	3	0
Problem solving therapy	9	0.23	4	3
Interpersonal therapy	6	0.15	4	0
Psychoeducation (only)	7	0.18	2	5
Behavioural activation	4	0.1	4	0
Other	9	0.23	0	0
<b>Type of pharmacological intervention:</b>	18	0.46	2	9
Against psychotic disorders	10	0.26	0	9
Against mood disorders (depression)	7	0.18	2	0
Against substance abuse	1	0.02	0	0

Notes: There are 39 interventions. Psychosocial interventions often include more than one type of therapy. <sup>1</sup> 1 intervention with ages 15-24, 1 with 18-35, 1 with 25-35. <sup>2</sup> 1 intervention with 14+, 1 with 16+, 1 with 20+, 1 with 16-45, 3 with 18-65, 1 with 16-60, 1 with 16-50, 1 with 18-55.



Table A3: Economic outcomes

Outcome category	# of estimates	Detailed measures (throughout, “self” indicates a self-reported measure)
Assets	18	Durable goods index; Index of durable assets; Index of household assets: enumerator assessment. Uses data from 9 month endline in wave one. ; Index of household assets: enumerator assessment. Uses pooled endline data from both waves and rounds. ; Index of household assets: enumerator assessment. Uses data from 31 month endline in wave one.; Level of credit measured in rupees; Level of debt that the household owes to others, measured in rupees; Level of savings measured in rupees; Net worth = savings+credit-debt; Savings stock; Total value of assets owned (USD PPP)
Days unable to work	23	Days of sick leave in last 2 years: own assessment ; Days respondent was 'healthy' in the past 30 days at 7 year: own assessment ; WHODAS 2.0 Participation in Society: self-assessment of days unable to work or reduction in work; WHODAS 2.0: Number of days unable to work (12 months); WHODAS 2.0: Number of days unable to work (3 months); WHODAS 2.0: days unable to work + (0.5 x) days with reduced work; WHODAS 2.0: days unable to work and days with reduced work: self assessment ; WHODAS 2.0: days unable to work: self assessment ; WHODAS 2.0: self-reported days unable to work at 3 month endline; WHODAS 2.0: self-reported days unable to work at 6 month endline ; WHODAS 2.0: self-reported days unable to work at 6 month endline ; a self report of work days missed last month due to poor health
Education	17	Academic Performance Scale: Clinician (teacher) assessed; Binary enrollment: Clinician (teacher) assessed; Child investment index; Does index child attend private school: own assessment; Home Observation for Measurement of the Environment (HOME) Inventory: Own assessment of Learning Materials sub-scale; Home Observation for Measurement of the Environment (HOME) Inventory: Own assessment of Physical Environment sub-scale; Likert Scale: Clinician (teacher) assessed; Log of the family's educational expenditures in the past month: own assessment ; Mother's expected grade attainment for the index child: own assessment ; School quality (class size, number of teachers, number of rooms & classroom amenities): clinician assessment; homework time; school attendance; school enrollment
Employment (dummy)	11	Likelihood of re-employment over the 12 month follow up period. ; Mother is employed at 7 years: own assessment; Self reported 'employed' at 3 month endline ; Self reported 'employed' at 6 month endline ; Self reported 'unemployed' at 3 month endline ; Self reported 'unemployed' at 6 month endline ; Self reported employment status ; Self: Engaged in work in the last week; WHODAS 2.0: individual was able to work every day: self assessment
Functioning at work	20	ASI index: clinician employment status; ASI index: clinician employment status for respondents receiving relapse prevention treatment ; ASI: Indication of ideal employment status; Clinician: Bracelets made in ten minutes; IDEAS scale: Clinician employment, housework and educational performance; 12 months; IDEAS scale: Clinician employment, housework and educational performance; 6 months; Independent Living Skills Survey: job maintenance. Clinician assessment. ; KDQOL-SF: work status; Life Chart Schedule: Performance at Work; MRSS: activity/inactivity: clinician rating of functioning in employment and leisure ; Overall occupational disabilities (GSDS-II - Groningen Social Disability Scale); Own assessment of capacity to do farming; Own assessment of capacity to do manual labour; Own assessment of capacity to grow food; PSFS Occupational Functioning: Own satisfaction with functioning in occupation ; WHO QoL work item: own satisfaction with capacity for work; WHODAS 2.0: Life activities domain 5
Income, consumption and input expenditure	27	Earnings are from primary and secondary jobs measured in Rupees; Earnings in the past 4 weeks; Food and non-food consumption in past 2 weeks; Investment in the past 2 weeks; Monthly household revenue (USD PPP); Monthly per-capita non-durable consumption (USD PPP); Mother's monthly earnings: own assessment ; Per capita consumption; Self reported monthly income at 3 month endline ; Self reported monthly income at 6 month endline ; Self: Durable goods expenditure; Self: Food expenditure; Self: Medical expenditure; Self: Other expenditures; Self: Total monthly expenditure; Self: earnings in the past month; Value of business assets
Job search	6	Self: available to take a job opportunity; Self: job search hours per week; job search hours
Other	5	PSFS Occupational Functioning: Own satisfaction with functioning in money-management ; Self: Applied for ability-based contract; Self: Reservation wage
Social networks	7	Frequency of borrowing and lending: Self-reported. Uses pooled endline data from both waves and rounds. ; Integrated Questionnaire for the Measurement of SocialCapital: Own assessment of Financial Social Network Size ; Integrated Questionnaire for the Measurement of SocialCapital: Own assessment of Instrumental Support Network Size; Monetary value of borrowing and lending: Own assessment. Uses pooled endline data from both waves and rounds. ; Respondent belongs to an osusu (savings group): Self-reported. Uses pooled endline data from both waves and rounds.
Subjective poverty measures	11	Clinician-rated measure of poverty; Composed of self-reported economic status and projected economic status in five years time; Projected economic status in 5 years time using Cantril's ladder; Satisfaction that household needs are met: Self-reported. Uses pooled endline data from both waves and rounds. ; Satisfaction that household needs are met: Self-reported. Uses data from 31 month endline in wave one.; Satisfaction that household needs are met: Self-reported. Uses data from 9 month endline in wave one.; Satisfaction with household's economic situation relative to 1 year ago: Self-reported. Uses pooled endline data from both waves and rounds. ; Satisfaction with household's economic situation relative to 1 year ago: Self-reported. Uses data from 31 month endline in wave one.; Satisfaction with household's economic situation relative to 1 year ago: Self-reported. Uses data from 9 month endline in wave one.; Self-reported economic status today using Cantril's ladder. ; WHO QoL work item: own satisfaction with financial resources and condition
Time in work	17	Hours per week of work in the last 2 months; Months engaged in normal occupation: family assessment at 12 month endline; Months engaged in normal occupation: family assessment at 18 month endline; Months engaged in normal occupation: family assessment at 6 month endline; Percent of time at work: own assessment ; SDSS: Ability to Work (full time); Self: Work hours in the last week; Time per 24h in productive activities (converted to weekly value); child care work hours; domestic work hours; primary and secondary jobs and agricultural work hours
Unable to work	18	Percent of time on sick leave: own assessment ; SDSS: own assessment of ability to work (full time); SDSS: own assessment of ability to work (part time); SDSS: own assessment of ability to work (part-time); SDSS: own assessment of ability to work (unable to work); SDSS: own assessment of ability to work (unable to work in farm or house work (full time and part-time); WHODAS 2.0: days unable to work - None (12 months); WHODAS 2.0: days unable to work - None (3 months); WHODAS 2.0: days unable to work - at least one (12 months); WHODAS 2.0: days unable to work - at least one (3 months)

Table A4: Mental health outcomes

Outcome category	# of estimates	Detailed measures (throughout, “self” indicates a self-reported measure)
Antisocial Behaviour	2	Antisocial behaviour index: self
Anxiety	6	Adapted Zung Anxiety Index: self; Generalised Anxiety Disorder Assessment (GAD-7): self; Hopkins Symptom Checklist - anxiety: self; Self Rating Anxiety Scale (SAS): self
Cognition	11	Cognition index; Cognition index: clinician; Digit Span: backwards; Digit span: forwards; Executive function index: self; Kidney Disease and Quality of Life-Short Form - cognitive function: self; Raven's Progressive Matrices; World Health Organization Quality of Life (WHOQOL) subscale - Cognitive function: Clinician
Depression	33	Adapted Zung Depression Index: self; Beck Depression Inventory (BDI): self; Beck Depression Inventory II- Depression score: self; Beck Depression Inventory Version II (BDI-II): self; Culturally Grounded Screening for Depression: self; Depression Remission on Patient Health Questionnaire (PHQ-9): self; Depression score on Patient Health Questionnaire (PHQ-9): self; Depression status: Clinician; Hamilton Depression Rating Scale (HDRS): clinician; Hopkins Symptom Checklist - depression: self; Hopkins Symptom Checklist 25 (HSCL-25) - depression: self; Index of locally-relevant depression features: self; Locally adapted Hopkins Symptom Checklist (HSCL) - depression subscale: Clinician; Mini International Neuropsychiatric Interview - depression: clinician; Patient Health Questionnaire (PHQ-9): self; Patient Health Questionnaire 9 (PHQ-9): self
Diagnosed with mental disorder	14	Depression Remission on Patient Health Questionnaire (PHQ-9): self; Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) - Adapted Depression Index: Clinician; Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV) - Adapted Depression Index: clinician; Hopkins Symptom Checklist: self; Mini International Neuropsychiatric Interview - depression: clinician; Mini International Neuropsychiatric Interview: self; No depression on Patient Health Questionnaire (PHQ-9): self; No moderate/severe depression on Patient Health Questionnaire (PHQ-9): self
Functioning	56	Activities of daily living: self; Addiction Severity Index (ASI): clinician; Brief Disability Questionnaire (BDQ): self; Direct Assessment of Functional Status; Direct assessment of functional status: dealing with finances. Clinician assessment. ; Global Assessment of Functioning (GAF)scale: clinician; Groningen Social Disability Schedule (GSDS-II): clinician; IDEAS scale - self-care : Clinician; Independent Living Skills Survey; Independent Living Skills Survey: money management. Clinician assessment. ; Indian Disability Evaluation and Assessment Scale (IDEAS) - overall: Clinician; Locally adapted gender specific functional impairment: Clinician; Morningside Rehabilitation Status Scale (MRSS) subscale - Current symptoms and deviant behavior: Clinician; Personal and Social Performance Scale; Short Inventory of Problems (SIP) mean score: self; Social Disability Screening Schedule (SDSS) - social dysfunction subscale: self ; WHO Disability Assessment Schedule- Functional impairment: self; WHOQOL subscale - Independence: Clinician; World Health Organization Disability Assessment Schedule 2.0 - 12 item for ICD-10 diagnosis at baseline subgroup: self; World Health Organization Disability Assessment Schedule 2.0 - 12 item for depression diagnosis at baseline subgroup: self; World Health Organization Disability Assessment Schedule 2.0 - 12 item for positive screen at baseline subgroup: self; World Health Organization Disability Assessment Schedule 2.0 - 12 item for subthreshold at baseline subgroup: self; World Health Organization Disability Assessment Schedule 2.0 - 12 item: self; World Health Organization Disability Assessment Schedule 2.0 - 36 item: self; local functioning tool; study-specific Psychosocial Functioning Scale (PSFS): self
Functioning in social interactions	9	IDEAS scale - Interpersonal activities: clinician; IDEAS scale - communication and understanding: Clinician; Oxford Measure of Psychosocial Adjustment adapted subscale- prosocial behaviour: self; Revised Social Disability Screening Schedule (SDSS-R) ; Social Disability Screening Schedule (SDSS) ; Social Disability Screening Schedule (SDSS) - social dysfunction subscale: self
General mental health	18	30 minus days in last month with poor mental health; Addiction Severity Index (ASI) - psychiatric status: clinician; Addiction Severity Index (ASI) - legal problems: clinician; Behavioural Risk Factor Surveillance Survey: Self-rating of mental health; Clinical Global Impression Subscale for Severity of Illness (CGIS): clinician; Kessler Psychological Distress Scale; Mean effect index of psychological health: self; Mental health index; Mood score; Quality Adjusted Life Years; Subjective well-being index; Subjective wellbeing: self; World Health Organization Quality of Life (WHOQOL) subscale - Mental health: Clinician
Mental health disorders	4	Proportion currently treated with antipsychotics: self; Proportion never treated with antipsychotic medication: self
Non-specific CMD	21	Clinical Interview Schedule - Revised (CIS-R) for positive screen at baseline subgroup: clinician; Clinical Interview Schedule - Revised (CIS-R) morbidity score for ICD-10 diagnosis at baseline subgroup: clinician; Clinical Interview Schedule - Revised (CIS-R) morbidity score for depression diagnosis at baseline subgroup: clinician; Clinical Interview Schedule - Revised (CIS-R) score for subthreshold at baseline subgroup: clinician; Hopkins Symptom Checklist 25 (HSCL-25) - anxiety: self; Hopkins Symptom Checklist: self; Oxford Measure of Psychosocial Adjustment adapted subscale- psychological distress: self; Proportion with common mental disorder diagnosis (ICD-10) for positive screen at baseline subgroup on CIS-R: clinician; Proportion with common mental disorder diagnosis (ICD-10) for subthreshold at baseline subgroup on CIS-R: clinician; Proportion with common mental disorder diagnosis (ICD-10) on CIS-R for ICD-10 diagnosis at baseline subgroup: clinician; Proportion with common mental disorder diagnosis (ICD-10) on CIS-R for depression diagnosis at baseline subgroup: clinician
Overall assessment of mental disorder	10	Addiction Severity Index (ASI) - mental health: clinician; Clinical Global Impression Subscale for Severity of Illness (CGIS): clinician; Clinical Interview Schedule - Revised (CIS-R) - total score: clinician; General mental health; Kidney Disease and Quality of Life-Short Form - Overall mental health: self; PANSS Scale: General psychopathological health ; state of illness: clinician

Table A5: Mental health outcomes

Outcome category	# of estimates	Detailed measures (throughout, “self” indicates a self-reported measure)
PTSD	13	Adapted PTSD Symptom Scale: self; Harvard Trauma Questionnaire (HTQ): self; Index of locally-relevant posttraumatic stress features: self; Mini International Neuropsychiatric Interview - PTSD: clinician; Post-Traumatic Stress Disorder Reaction Index (PTSD-RI): self; Posttraumatic Stress Disorder Checklist-Civilian
Physical health	10	Addiction Severity Index (ASI) - medical: clinician; Addiction Severity Index (ASI) - physical health: clinician; Kidney Disease and Quality of Life-Short Form - overall health: self; Kidney Disease and Quality of Life-Short Form - sexual function: self; Kidney Disease and Quality of Life-Short Form - sleep: self; World Health Organization Quality of Life (WHOQOL) subscale - general physical health: Clinician
Recovery (dummy)	4	Depression Recovery on Patient Health Questionnaire (PHQ-9): self; Full Recovery: Social Disability Screening Schedule (SDSS) ; Full recovery from recorded mental health disorder: clinician
Rehospitalisation	6	Days of re-admission: clinician; Days of rehospitalisation: clinician; Rehospitalization rate: clinician
Relapse (dummy)	14	Depression Remission on Patient Health Questionnaire (PHQ-9): self; Proportion relapse: clinician; Relapse rate: clinician; Schizophrenia relapse rate: clinician; Schizophrenia relapse: clinician
SMD symptoms	8	PANSS Scale: General psychopathological health ; PANSS Scale: clinician; Positive and Negative Syndrome Scale (PANSS): clinician; Serious Mental Disability: Social Disability Screening Schedule (SDSS)
Self-esteem/self-efficacy	7	General Self-Efficacy Scale: self; Modified Rosenberg Self-Esteem Scale (SES): self; Self-Efficacy Scale (SE): self; Self-esteem index: self; World Health Organization Quality of Life (WHOQOL) subscale - self-esteem: Clinician
Self-regulation	7	Behavioural Assessment of the Dysexecutive Syndrome scale; Executive function; Patience Anderson index; Self-control scale; Short Grit Scale
Social support	27	Addiction Severity Index (ASI) - family support: clinician; Addiction Severity Index (ASI) - family/social: clinician; Contact with nonkin social network; Emotional support seeking: self; Inventory of Socially Supportive Behaviors (ISSB); KDQOL-SF: social interactions; KDQOL-SF: social support; Kidney Disease and Quality of Life-Short Form - quality of social interaction: self; Kidney Disease and Quality of Life-Short Form - social support: self; Perceived social support: self; Social network quality index: self; World Health Organization Quality of Life (WHOQOL) subscale - social support: Clinician
Stress	2	Perceived Stress Scale (PSS): self
Substance use	35	Addiction Severity Index (ASI) - alcohol use: clinician; Addiction Severity Index (ASI) - alcohol: clinician; Addiction Severity Index (ASI) - drug: clinician; Any ethanol consumed: self; Average proportion of negative urine test results: clinician; Daily drinking: self; Drug positive; Ethanol consumed: self; Heroin abstinence: clinician; Longest period of abstinence; Non-drinker; Percentage of days abstinent; Percentage of days of heavy drinking; Proportion of days abstinent: self; Proportion of days heavy drinking: self; Remission on Alcohol Use Disorders Identification Test (AUDIT): clinician; Remission on Alcohol Use Disorders Identification Test (AUDIT): self; Short Inventory of Problems (SIP) mean score: self; Substance abuse index: self
Suicide attempts or at risk of suicide	18	Any suicide attempt or suicidal ideation: self; Any suicide attempt: self; Mini International Neuropsychiatric Interview - suicide risk: clinician; Proportion suicidal behavior for common mental disorder diagnosis (ICD-10) group on CIS-R: clinician; Proportion suicidal behavior for depression diagnosis (ICD-10) group on CIS-R: clinician; Proportion suicidal behavior for positive screen group on CIS-R: clinician; Proportion suicidal behavior for subthreshold group on CIS-R: clinician; Proportion that take their own lives: clinician; Suicidal behaviour; Suicidal thoughts or attempts

Table A6: Scales used to measure mental health and functioning outcomes

Scale name	Survey question example wording (abridged)	Recall Period
<b>Functioning at work</b>		
Revised Social Disability Screening Schedule (SDSS)	I want to know about the functioning of the subject (you) at home and at work, whether or not he/she (you) is able to do what he/she (you) should be able to do. I will ask questions about different types of functioning; please let me know if he/she (you) has had any problems or difficulties in each type of functioning over the last three months: (1) Work (study)(a) None or very mild problems/difficulties; (b) Significant reduction in ability resulting in decreased functioning or complaints; (c) Unable to work/study or risks formal punishment or reprimand at work/school for poor functioning due to psychological problems.	3 months
World Health Organization Disability Assessment Schedule 2.0 (WHODAS)	In the past 30 days, for how many days were you totally unable to carry out your usual activities or work because of any health condition? Not counting the days that you were totally unable, for how many days did you reduce your usual activities or work because of any health condition?	Past 30 days
World Health Organisation Quality of Life (WHOQoL)	How satisfied are you with your capacity for work?	Not provided
Indian Disability Evaluation and Assessment Scale (IDEAS)	Employment, housework and educational performance. Guiding questions: a. Is he employed/unemployed? b. If employed, does he go to work regularly? c. Does he like his job and coping well with it? d. Can you rely on him financially? e. If unemployed does he make any efforts to find a job?	Not provided
Groningen Social Disability Scale	Dimensions: a. daily routine; b. work performance; c. contacts with others; d. (other) daily activities	4 weeks
World Health Organization Disability Assessment Schedule 2.0	In the past 30 days, for how many days were you totally unable to carry out your usual activities or work because of any health condition?	Past 30 days
Kidney Disease Quality of Life Short Form: work status	2 items: q20: during the past 4 weeks, did you work at a paying job? q21: does your health keep you from working at a paying job?	Past 30 days
Global Assessment of Functioning (GAF): occupational	The GAF rating doesn't have explicit wording, but draws on an interview or questionnaire; medical records; information from the person's doctor, care givers, or close relatives; police or court records about violent or illegal behavior.	Simultaneous
Morningside Rehabilitation Status Scale	Inactivity (occupational and leisure) scale: How well the patient has initiated and sustained activity and performed effectively in: 1. Work; 2. Training programme; 3. Method of looking for work; 4. Daily routine; 5. Leisure time routine, indoor/outdoor (weekdays and weekends); 6. Reading habits and interests, TV, radio, etc.	Not provided
<b>Social functioning</b>		
Kidney Disease Quality of Life Short Form (KDQOL-SF): Social Functioning	How much during the past 4 weeks did you: Act irritable toward those around you; Isolate yourself from people around you; Get along well with other people.	4 weeks
Short-Form 36 Health Survey Questionnaire (SF-36)	Have emotional problems interfered with your normal social activities with family, friends, neighbors, or groups?	Not provided
Multidimensional Scale of Perceived Social Support	1. There is a special person who is around when I am in need. 2. There is a special person with whom I can share my joys and sorrows. 3. My family really tries to help me. 4. I get the emotional help and support I need from my family. 5. I have a special person who is a real source of comfort to me. 6. My friends really try to help me. 7. I can count on my friends when things go wrong. 8. I can talk about my problems with my family. 9. I have friends with whom I can share my joys and sorrows. 10. There is a special person in my life who cares about my feelings. 11. My family is willing to help me make decisions. 12. I can talk about my problems with my friends.	Not provided
Indian Disability Evaluation and Assessment Scale (IDEAS): Social Functioning Subscale	Behaviours with others; responsiveness to questions; regulating verbal and physical aggression; acting independently in social interactions; behaviour with strangers; maintaining friendships. Understanding spoken and written/non-verbal messages and ability to reduce messages in order to communicate with others. Avoiding talking to people; when people come home what do they do; do they ever visit others; can they start, maintain and end a conversation? Do they understand body language?	Not provided
Groningen Social Disability Schedule (GSDS-II)	The GSDS-11 assesses 1. Role of self-care; 2. Family role; 3. Kinship role; relationships with parents and siblings; 4. Partner role; relationship with partner in marriage or cohabitation; 5. Parental role; relationship with children; 6. Citizen role; interest and participation in social life.; 7. Social role; relationships with friends and acquaintances.; 8. Occupational role; regular daily activities.	Four weeks



Table A7: Scales used to measure mental health and functioning outcomes

Scale name	Survey question example wording (abridged)	Recall Period
<b>Global Functioning</b>		
Brief Disability Questionnaire (BDQ)	1. Have your health problems limited you in daily activities? 2. Have you had to cut down or stop any activity you used to do, such as a hobby, because of your illness? 3. Have you been unable to do something that your family (or household) expected from you as part of your daily routine? 4. Have your personal problems decreased your motivation to work? 5. Have your personal problems decreased your personal efficiency at home, school or work? 6. Has there been a deterioration in your social relations with friends, workmates, or other people? 7. During the past week how many days in total were you unable to carry out your usual daily activities fully? 8. During the past week how many days in total did you stay in bed all or most of the day because of your illness?	1 week
World Health Organization Disability Assessment Schedule 2.0 (WHODAS)	The 36 item questionnaire asks about difficulty experienced in the domains: Understanding and communicating; Getting around; Self-care; Life activities; Work; and Participation in Society	3-4 days ("several")
Patient Health Questionnaire-9 (PHQ-9)	How often have they been bothered by the following over the past 2 weeks? 1. Little interest or pleasure in doing things? 2. Feeling down, depressed, or hopeless? 3. Trouble falling or staying asleep, or sleeping too much? 4. Feeling tired or having little energy? 5. Poor appetite or overeating? 6. Feeling bad about yourself or that you are a failure or have let yourself or your family down? 7. Trouble concentrating on things, such as reading the newspaper or watching television? 8. Moving or speaking so slowly that other people could have noticed? Or so fidgety or restless that you have been moving a lot more than usual? 9. Thoughts that you would be better off dead, or thoughts of hurting yourself in some way?	2 weeks
Global Assessment of Functioning (GAF) scale	Measures global functioning in two domains: (1) symptom severity, and (2) any serious impairment in psychological, social and occupational functioning on a mental health-illness continuum level of functioning).	Not provided
Personal and Social Performance Scale	Please rate the patient on his/her level of functioning during the reference period (e.g., past month or last 7 days). Consider what the person is doing, taking into account if she needs help or prompting by others. The four main domains of functioning considered in this scale are (a) personal and social relationships; (b) socially useful activities, including work and study; (c) self-care; and (d) aggressive behaviors.	7 days or one month
Revised Social Disability Screening Schedule	The SDSS assesses social functioning at home and at work, dealing with functioning the domains of work, marital functioning, parental function, loneliness, group activities, physical activities, family function, self care, concern for the outside world, and responsibility and plans for the future. Against each domain, respondents report the number of months among the last 3 in which they experienced a level of difficulty performing a function relative to what they should be able to do.	3 months
<b>Substance abuse</b>		
Alcohol Use Disorders Identification Test (AUDIT)	1. How often do you have a drink containing alcohol? 2. How many drinks containing alcohol do you have on a typical day when you are drinking? 3. How often do you have six or more drinks on one occasion? 4. How often during the last year have you found that you were not able to stop drinking once you had started? 5. How often during the last year have you failed to do what was normally expected from you because of drinking? 6. How often during the last year have you needed a first drink in the morning to get yourself going after a heavy drinking session? 7. How often during the last year have you had a feeling of guilt or remorse after drinking? 8. How often during the last year have you been unable to remember what happened the night before because you had been drinking? 9. Have you or someone else been injured as a result of your drinking? 10. Has a relative, friend, doctor or another health worker been concerned about your drinking or suggested you cut down?	Not provided
Addiction Severity Index (ASI)	The ASI is a semi-structured interview designed to address seven potential problem areas in substance-abusing patients: medical status, employment and support, drug use, alcohol use, legal status, family/social status, and psychiatric status. The ASI provides an overview of problems related to substance, rather than focusing on any single area.	30 days

Table A8: Scales used to measure mental health and functioning outcomes

Scale name	Survey question example wording (abridged)	Recall Period
<b>Mental Health - Common mental disorders</b>		
Kessler Psychological Distress Scale	During the last 30 days: 1. how often did you feel tired out for no good reason? 2. how often did you feel nervous? 3. How often did you feel so nervous that nothing could calm you down? How often did you feel hopeless? How often did you feel restless or fidgety? How often did you feel so restless you could not sit still? How often did you feel depressed? How often did you feel that everything was an effort? How often did you feel so sad that nothing could cheer you up? How often did you feel worthless?	30 days
Perceived Stress Scale (PSS)	In the last month, how often have you: 1. Been upset because of something that happened unexpectedly? 2. Felt that you were unable to control the important things in your life? 3. Nervous and stressed? 4. Felt confident about your ability to handle your personal problems? 5. Felt that things were going your way? 6. Found that you could not cope with all the things that you had to do? 7. Been able to control irritations in your life? 8. Felt that you were on top of things? 9. Been angered because of things that happened that were outside of your control? 10. Felt difficulties were piling up so high that you could not overcome them?	1 month
Adapted Zung Anxiety Index	In the last month: how much did you feel nervous or anxious or worried? Did you feel fear without cause? Did you often feel upset or feel sudden panic? How often have you felt that everything is alright and nothing bad will happen in the future? How much did your legs and arms shake and tremble? How much did you have headaches or pain in your neck and back? How often have you felt tired even if you not doing nothing? How much did you feel restless? Has your heart been pounding fast? How much were you bothered by pain in your stomach?	4 weeks
Beck Depression Inventory (BDI)	1. Experiencing sadness; 2. Discouraged about the future; 3. Feel like a failure; 4. Feelings of satisfaction from doing things I used to do; 5. Feeling guilty; 6. Feel I am being punished; 7. Feel disappointed in myself; 8. Blame myself for my faults; 9. Suicidal ideation; 10. Cry more than usual; 11. Feeling irritated; 12. Losing interest in other people; 13. Make good decisions; 14. I look worse than I used to; 15. Less effective at work; 16. Poor sleep quality; 17. Easily tired; 18. Worse appetite; 19. Weight gain; 20. Worried about health; 21. Changed in interest in sex	Not provided
Clinical Interview Schedule - Revised (CIS-R)	The CIS-R is a standardised, structured interview for the measurement and diagnosis of common mental disorders in community and general healthcare settings.	Not provided
Hopkins Symptom Checklist (HSCL-25)	A symptom inventory measuring symptoms of anxiety and depression, with 10 items for anxiety and 15 for depression.	4 weeks
Hamilton Depression Rating Scale	1. Depressed Mood; 2. Feelings of guilty; 3. Suicidal ideation; 4. Insomnia; 5. Work and activities; 6. Slowness of thought; 7. Agitation; 8; Anxiety; 9 Somatic symptoms; 10 Libido; 11. Hypochondriasis; 12. Insight/self-awareness.	Not provided
Patient Health Questionnaire-9 (PHQ-9)	How often have they been bothered by the following over the past 2 weeks? 1. Little interest or pleasure in doing things? 2. Feeling down, depressed, or hopeless? 3. Trouble falling or staying asleep, or sleeping too much? 4. Feeling tired or having little energy? 5. Poor appetite or overeating? 6. Feeling bad about yourself or that you are a failure or have let yourself or your family down? 7. Trouble concentrating on things, such as reading the newspaper or watching television? 8. Moving or speaking so slowly that other people could have noticed? Or so fidgety or restless that you have been moving a lot more than usual? 9. Thoughts that you would be better off dead, or thoughts of hurting yourself in some way?	2 weeks
Self Rating Anxiety Scale (SAS)	In the last month: 1. How much did you feel nervous or anxious or worried? 2. Did you feel fear without cause? 3. Did you often feel upset or feel sudden panic? 4. How often have you felt that everything is alright and nothing bad will happen in the future? 5. How much did your legs and arms shake and tremble? 6. How much did you have headaches or pain in your neck and back? 7. How often have you felt tired even if you not doing nothing? 8. How much did you feel restless? 9. Has your heart been pounding fast? 10. How much were you bothered by pain in your stomach?	1 month
South Asian Tension Scale	"Over the past 2 weeks, how often have you been bothered by any of these problems:" 1. Feeling sad, feeling like crying, lonely. 2. Feeling a loss of appetite, nausea, stomach pain. 3. Trouble concentrating, loss of memory. 4. Feeling angry or frustrated. 5. Insomnia. 6. Feeling cold in the body (not due to weather). 7. Feeling you would like to run away or escape. 8. Headaches or pain in your eyes. 9. Feeling anxious or afraid. 10. Feeling tired or a lack of energy. 11. Feeling helpless and unsupported. 12. Feelings of shakiness. 13. Sexual problems. 14. Feeling you want to be alone. 15. Problems with your periods. 16. Pains in your arms, legs, or other parts of your body. 17. Feeling homesick or missing family. 18. Feeling hot in parts of your body (not due to weather). 19. Vaginal discharge. 20. Feeling dizzy. 21. Pain or heaviness in your chest, heart palpitations. 22. Feeling a loss of control of your hands or feet. 23. Breathlessness. 24. Your hair turning white or falling out.	2 weeks



Table A9: Scales used to measure mental health and functioning outcomes

Scale name	Survey question example wording (abridged)	Recall Period
<b>Mental Health - Severe mental disorders, PTSD, substance abuse disorders and other mental health scales</b>		
Posttraumatic Stress Disorder Checklist-Civilian	1. Repeated, disturbing memories, thoughts, or images of a stressful experience from the past? 2. Repeated, disturbing dreams of a stressful experience from the past? 3. Suddenly acting or feeling as if a stressful experience were happening again (as if you were reliving it)? 4. Feeling very upset when something reminded you of a stressful experience from the past? 5. Having physical reactions (e.g., heart pounding, trouble breathing, or sweating) when something reminded you of a stressful experience from the past? 6. Avoid thinking about or talking about a stressful experience from the past or avoid having feelings related to it? 7. Avoid activities or situations because they remind you of a stressful experience from the past? 8. Trouble remembering important parts of a stressful experience from the past? 9. Loss of interest in things that you used to enjoy? 10. Feeling distant or cut off from other people? 11. Feeling emotionally numb or being unable to have loving feelings for those close to you? 12. Feeling as if your future will somehow be cut short? 13. Trouble falling or staying asleep? 14. Feeling irritable or having angry outbursts? 15. Having difficulty concentrating? 16. Being "super alert" or watchful on guard? 17. Feeling jumpy or easily startled?	Not provided
Positive and Negative Syndrome Scale (PANSS)	The positive and negative syndrome scale is made up of three subscales: one positive symptom, one negative symptom and one general psychopathology scale. The positive symptoms measured are: delusions, conceptual disorganization, hallucinations, excitement, grandiosity, suspiciousness and hostility. The negative symptoms measured are: blunted affect, emotional withdrawal, poor rapport, passive apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity & flow of conversation, stereotyped thinking. The general psychopathology scale measures somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgement & insight, disturbance of volition, poor impulse control, preoccupation, active social avoidance.	Not provided
Mini International Neuropsychiatric Interview (MINI)	Therapeutic areas: Behaviour and behaviour mechanisms; Mental Disorders; Chemically-induced Disorders. Therapeutic indications: suicidal ideation; psychotic disorders; anxiety disorders; depressive disorder; panic disorder; obsessive-compulsive disorder; alcoholism; bulimia nervosa; anorexia nervosa; antisocial personality disorder; bipolar disorder; substance-related disorders; binge-eating disorder; generic for mental disorders; stress disorders, post-traumatic stress disorders.	2 weeks
Present State Examination (PSE-9)	The PSE is semi-structured interview, intended to provide an objective evaluation of symptoms associated with mental disorders. It contains 140 items, each scored on a 3-point or 4-point scale, and it is designed for use by experienced clinicians.	Simultaneous
Harvard Trauma Questionnaire (HTQ)	The HTQ enquires about a variety of trauma events, as well as the emotional symptoms considered to be uniquely associated with trauma.	4 weeks



## D Approach to inference on effect sizes

The true effect size ( $\theta$ ) is the mean difference between the treatment ( $\mu_t$ ) and control groups ( $\mu_c$ ) as a proportion of the standard deviation of the outcome variables ( $\sigma$ ):

$$\theta = \frac{\mu_t - \mu_c}{\sigma}$$

An intuitive estimator for  $\theta$  is Cohen's  $d$  (Cohen, 1988) defined by

$$d = \frac{\bar{Y}_t - \bar{Y}_c}{S_p} = \frac{D}{S_p}$$

where  $\bar{Y}_t$  is the mean outcome of the treatment group and  $\bar{Y}_c$  that of the control group. The numerator of  $d$  captures the unstandardized treatment effect and is often reported as a treatment effect parameter estimate, such as an ATT, ITT, or LATE, rather than as differences in means; thus we use  $D$  to denote an unstandardized treatment effect estimate. The denominator of  $d$  is the pooled standard deviation from the standard deviations of the treatment and control groups and is equivalent to

$$S_p = \sqrt{\frac{(n_t - 1) * S_t^2 + (n_c - 1) * S_c^2}{n_t + n_c - 2}}$$

where  $n_c$  and  $n_t$  are the sample sizes of the control and treatment groups, respectively, and  $S_c$  and  $S_t$  are the sample standard deviations of the control and treatment groups, respectively. It has been shown that  $d$  has a bias and overestimates the absolute value of the effect in small samples (Hedges, 1981). For this reason, we use a small sample size adjusted estimator referred to as Hedges'  $g$ , which is given by

$$g = d \left( 1 - \frac{3}{4(n_t + n_c) - 9} \right)$$

The standard error of Hedges'  $g$  is given by

$$SE_g = \sqrt{\frac{n_t + n_c}{n_t * n_c} + \frac{g^2}{2 * (n_t + n_c)}}$$

A challenge encountered in the data extraction was the limited information available to compute the standardized mean difference (SD). Standard deviations for the treatment, control, and total sample groups were missing in 3 studies, even after attempting to correspond with authors to acquire this information. In such cases, the standard deviation of

the outcome variable was approximated using the formula from [Borenstein et al. \(2011\)](#):

$$S_p = SE * \sqrt{\frac{n_t * n_c}{n_t + n_c}} \quad (4)$$

where  $SE$  is the Standard Error of a comparison of means (e.g. standard error of the regression coefficient estimate). In the case of two studies, we were not even able to compute the standard deviation with the help of the above formula due to a lack of reported standard errors, so we used the standard deviations of the control group instead.

### Creating one effect size estimate per intervention

Some studies provided more than one impact estimate for a given outcome type. To arrive at summary effect sizes per intervention and aggregated effect sizes, we combine them to arrive at a single effect size estimate per outcome for each intervention. Estimating summary effect sizes (for example on intervention level, outcome level, target group level, and other types of aggregates) requires a careful procedure to avoid permitting a single group of evaluation survey respondents to influence the aggregate disproportionately. The median number of treatment effect estimates per study was three, with some studies providing more than 20 estimates. In such instances, there can be a multitude of treatment effects reported for the same group where there is no *a priori* reason to give preference to one measure over another.

Where studies reported both pooled effect sizes and effect sizes for subgroups, we dropped those effect sizes that were redundant for the desired level of aggregation. The desired level was always the pooled estimate, except when looking at subgroup effects by gender.

Once redundant effect sizes were removed in some cases we still had multiple effect sizes for one independent group, without clear justification for dropping some over others – for example if an intervention measured one outcome in multiple ways. In order to arrive at one single effect size per intervention, we applied the method for combining effect sizes from the same independent population suggested by [Borenstein et al. \(2009\)](#). The approach is as follows: let  $g_{ij}$  and  $SE_{g_j}$  be the  $i^{th}$  effect size, where  $i = 1, \dots, m$  and its standard error, respectively, for the sample population (e.g. intervention) identified by  $j$ . To arrive at a single combined effect size for intervention we take a simple average:

$$g_j = \frac{1}{m} \sum_{i=1}^m g_{ij} \quad (5)$$

and calculate the standard error of  $g_j$  by

$$SE_{g,j} = \sqrt{\left(\frac{1}{m}\right)^2 \left( \sum_{i=1}^m SE_{g,i}^2 + \sum_{i \neq k} \rho_{i,k} SE_{g,ij} SE_{g,kj} \right)}, \quad (6)$$

where  $\rho_{i,k}$  is the correlation coefficient between  $g_{ij}$  and  $g_{kj}$ . Ideally we would estimate  $\rho_{i,k}$  from the data. However, due to the lack sufficient number of observations an assumption on  $\rho_{i,k}$  was required. The assumption of  $\rho_{i,k} = 0$  would likely overestimate precision, while the assumption of  $\rho_{i,k} = 1$  would likely underestimate precision. We take the more conservative assumption that  $\rho_{i,k} = 1 \forall (i, j)$  where  $i \neq k$ . In other words, we assume perfect correlation across effect sizes for the same sample population.

### Creating aggregate effect sizes for groups of interventions

With one effect size per intervention, we can create aggregate effect sizes for different categories of interventions (such as interventions conducted in high-income countries) as well as an aggregate effect size for the whole sample. Given the range of different interventions included in our sample, it is likely that each intervention's true effect size ( $\theta_i$ ) deviates from the true aggregate effect size for the overall group it belongs to. Furthermore, each observed effect size, estimated by Hedges'  $g$ , contains a sampling error. Therefore,  $g$  will either be less than or greater than  $\theta_i$ . This can be expressed as

$$g_i = \mu + \zeta_i + \varepsilon_i = \theta_i + \varepsilon_i, \quad (7)$$

where  $\mu$  is the true aggregate effect size for the group as a whole,  $\zeta_i$  is the deviation of the true effect size of intervention  $i$  from the group's aggregate effect, and  $\varepsilon_i$  the sampling error. We estimate the true aggregate effect size for the group as a whole ( $\mu$ ) using a random-effects regression, following equation 7. Moreover, to obtain the most accurate estimate of  $\mu$ , we estimate a weighted random-effects model in which the weights are each study's inverse variance. Note that the study's variance corresponds to the term in equation D squared.

## E Additional results

### E.1 Economic outcomes

Table A10: Effects of mental health interventions on all economic outcomes: Frequentist approach

	(1) Aggregate Hedges' $g$	(2) 95% lower CI	(3) 95% upper CI	(4) # of obs.	(5) # of intrv.	(6) $I^2$
<b>Panel A: Psychosocial interventions targeting common mental disorders</b>						
<b>All economic outcomes aggregate</b>	0.16***	0.06	0.26	66	16	0.62
<b>Work aggregate</b>	0.16***	0.05	0.27	36	14	0.68
In employment (dummy)	-0.00	-0.12	0.11	4	4	0.00
Time in work	0.17	-0.09	0.43	3	3	0.64
Days unable to work <sup>^</sup>	0.07**	0.01	0.13	17	9	0.13
Functioning at work	0.21	-0.10	0.52	8	5	0.86
Job search	0.09	-0.09	0.27	4	2	0.00
<b>Non-work aggregate</b>	0.09**	0.01	0.17	30	6	0.00
Education	0.21**	0.04	0.38	6	1	1.00
Assets	0.04	-0.08	0.16	1	1	1.00
Income, consumption and input expenditure	0.04	-0.05	0.13	15	4	0.00
Subjective poverty measures	0.16*	-0.01	0.33	4	2	0.00
Other	0.05	-0.11	0.21	4	2	0.00
<b>Panel B: Psychosocial interventions targeting severe mental disorders</b>						
<b>All economic outcomes aggregate</b>	0.27**	0.06	0.49	22	9	0.70
<b>Work aggregate</b>	0.30**	0.06	0.54	20	9	0.76
In employment (dummy)	0.81**	0.16	1.45	1	1	1.00
Time in work	0.24**	0.05	0.44	4	2	0.07
Unable to work (dummy) <sup>^</sup>	0.18***	0.06	0.30	8	3	0.00
Days unable to work <sup>^</sup>	0.11**	0.00	0.22	1	1	1.00
Functioning at work	0.23	-0.41	0.87	6	4	0.89
<b>Non-work aggregate</b>	0.49	-0.30	1.28	2	2	0.76
Subjective poverty measures	0.15	-0.12	0.43	1	1	1.00
Other	0.97**	0.23	1.72	1	1	1.00

Notes: Table A10 reports estimates of the effect of mental health interventions on all studied economic outcomes under the frequentist specification outlined in Section 4.2. In Column (1), Hedges'  $g$  is the small-sample-bias-corrected standardized mean difference in the economic outcome between treatment and control. The aggregation of individual effect sizes is described in Section 4.1. Panel A presents estimates of the standard deviation effects of interventions targeting common mental disorders, Panel B interventions targeting severe mental disorders. \*, \*\* and \*\*\* denote statistical significance at 10 percent, 5 percent and 1 percent level of significance respectively. The average measurement in our sample happens 15.2 months after intervention start. <sup>^</sup> indicates variables that have been reverse-coded such that higher values indicate improvements in outcomes. Aggregate Hedges'  $g$  represents an estimate from random-effects inverse variance weighted meta-analysis. The aggregation of individual effect sizes works as described in subsection 4.1. All individual effect sizes are winsorized at the 99<sup>th</sup> percentile.

Table A11: Effects of mental health interventions on economic outcomes: Bayesian approach

	$\tau$ estimate	$\tau$ posterior quantiles				Heterogeneity		
	(1) mean	(2) 2.5 <sup>th</sup>	(3) 25 <sup>th</sup>	(4) 75 <sup>th</sup>	(5) 97.5 <sup>th</sup>	(6) $\sigma$	(7) $\omega(\tau)$	(8) $I^2$
<b>Panel A: Psychosocial interventions targeting <i>common</i> mental disorders</b>								
<b>All economic outcomes aggregate</b>	0.04	-0.02	0.02	0.06	0.13	0.06	0.74	0.33
<b>Work aggregate</b>	0.16**	0.03	0.12	0.21	0.31	0.21	0.32	0.8
In employment (dummy)	-0.02	-0.35	-0.08	0.05	0.25	0.18	0.4	0.67
Time in work	0.16	-0.61	0.03	0.3	0.87	0.58	0.06	0.95
Days unable to work <sup>^</sup>	0.08**	0.01	0.05	0.1	0.17	0.06	0.72	0.31
Functioning at work	0.19	-0.3	0.07	0.32	0.67	0.48	0.08	0.93
Job search	0.05	-1.12	-0.13	0.25	1.16	1.13	0.01	0.98
<b>Non-work aggregate</b>	0.08	-0.05	0.05	0.12	0.21	0.09	0.59	0.44
Education	0.07	-1.68	-0.42	0.55	1.73	4.95	0	1
Assets	0.01	-1.69	-0.46	0.49	1.7	4.92	0	1
Income, consumption, input expenditure	0.03	-0.18	-0.01	0.08	0.22	0.12	0.42	0.6
Subjective poverty measures <sup>^</sup>	0.09	-1.13	-0.11	0.3	1.2	1.18	0.02	0.97
Other	0.03	-1.09	-0.14	0.2	1.11	1.05	0.01	0.99
<b>Panel B: Psychosocial interventions targeting <i>severe</i> mental disorders</b>								
<b>All economic outcomes aggregate</b>	0.28*	-0.03	0.18	0.37	0.61	0.39	0.25	0.85
<b>Work aggregate</b>	0.30*	-0.05	0.2	0.41	0.67	0.45	0.21	0.88
In employment (dummy)	0.22	-1.66	-0.35	0.82	1.85	5.37	0	NaN
Time in work	0.21	-1.09	0.01	0.46	1.32	1.28	0.02	0.98
Unable to work (dummy) <sup>^</sup>	0.21	-0.41	0.11	0.31	0.8	0.4	0.13	0.9
Days unable to work <sup>^</sup>	0.04	-1.69	-0.44	0.51	1.71	4.92	0	NaN
Functioning at work	0.19	-0.86	-0.09	0.47	1.17	1.12	0.07	0.97
<b>Non-work aggregate</b>	0.27	-1.27	-0.07	0.66	1.58	1.95	0.02	0.98
Subjective poverty measures <sup>^</sup>	0.05	-1.68	-0.44	0.53	1.72	4.94	0	1
Other	0.24	-1.66	-0.34	0.87	1.89	5.55	0	NaN

Notes: Table A11 reports estimates of the effect of mental health interventions on all studied economic outcomes under the Bayesian specification outlined in Section 4.2. In column (1),  $\hat{\tau}$  is the estimate of the latent treatment effect in standard deviations. \*, \*\* and \*\*\* represent significant at the 10, 5 and 1% levels respectively. Columns (2) through (5) present posterior quantile estimates, summarising the distribution of  $\hat{\tau}$ . Columns (6) through (8) present summary indicators of heterogeneity. The Work aggregate and Non-work aggregate meta-analyses include effect sizes from each of the other outcome groupings below. Panel A presents estimates of the standard deviation effects of psychosocial interventions targeting common mental disorders and Panel B the effects of psychosocial interventions targeting severe mental disorders. <sup>^</sup> indicates variables that have been reverse-coded such that higher values indicate improvements in outcomes. The average measurement in our sample happens 15.2 months after intervention start. The procedure for aggregating multiple effect sizes from a given intervention is described in subsection 4.1. All individual effect sizes are winsorized at the 99<sup>th</sup> percentile. We take  $\tau \sim N(0, 1)$  and  $\sigma \sim HC(1)$  as our priors. The estimate of  $\sigma$  is bounded by zero below by the choice of Half-Cauchy prior. The number of observations and interventions for each of the meta-analyses is identical to that in Table A10.

Table A12: Effects of mental health interventions on economic outcomes: Frequentist approach, additional intervention type - target condition groupings

	(1) Aggregate Hedges' $g$	(2) 95% lower CI	(3) 95% upper CI	(4) # of obs.	(5) # of intrv.	(6) $I^2$
<b>Panel A: Psychosocial interventions targeting post-traumatic stress disorder</b>						
<b>All economic outcomes aggregate</b>	0.05	-0.08	0.17	26	5	0.12
<b>Work aggregate</b>	0.12	-0.22	0.46	5	2	0.61
In employment (dummy)	-0.05	-0.33	0.24	4	1	1.00
Days unable to work <sup>^</sup>	0.30*	-0.01	0.61	1	1	1.00
<b>Non-work aggregate</b>	-0.00	-0.08	0.08	21	4	0.00
Education	0.27	-0.26	0.80	3	1	1.00
Assets	0.09**	0.01	0.16	3	1	1.00
Income, consumption and input expenditure	-0.12	-1.03	0.80	2	1	1.00
Subjective poverty measures	-0.07	-0.16	0.02	6	1	1.00
Social networks	0.02	-0.05	0.08	7	2	0.00
<b>Panel B: Psychosocial interventions targeting substance use disorders</b>						
<b>All economic outcomes aggregate</b>	0.10	-0.10	0.29	24	5	0.58
<b>Work aggregate</b>	0.09	-0.11	0.28	14	5	0.59
In employment (dummy)	0.15	-0.21	0.50	2	1	1.00
Time in work	0.04	-0.15	0.23	2	1	1.00
Unable to work (dummy) <sup>1</sup>	0.05	-0.40	0.50	4	1	1.00
Days unable to work <sup>^</sup>	-0.08	-0.38	0.21	4	2	0.00
Functioning at work	0.16	-0.33	0.65	2	2	0.89
<b>Non-work aggregate</b>	0.08	-0.11	0.27	10	1	1.00
Assets	0.08	-0.09	0.26	4	1	1.00
Income, consumption and input expenditure	0.08	-0.12	0.28	6	1	1.00
<b>Panel C: Other intervention type-target condition groupings</b>						
<b>All economic outcomes aggregate</b>	0.11*	-0.02	0.25	42	4	0.24
<b>Work aggregate</b>	0.11	-0.06	0.28	20	4	0.54
Time in work	-0.07	-0.22	0.08	8	1	1.00
Unable to work (dummy) <sup>^</sup>	0.15	-0.08	0.39	6	1	1.00
Functioning at work	0.24**	0.03	0.44	4	2	0.00
Job search	-0.01	-0.14	0.11	2	1	1.00
<b>Non-work aggregate</b>	0.03	-0.13	0.18	22	1	1.00
Education	0.10	-0.09	0.28	8	1	1.00
Assets	0.01	-0.13	0.15	10	1	1.00
Income, consumption and input expenditure	-0.07	-0.20	0.07	4	1	1.00

Notes: Table A12 reports estimates of the effect of mental health interventions on economic outcomes for additional intervention type-target condition groupings under the frequentist specification outlined in Section 4.2. In Column (1), Hedges'  $g$  is the small-sample-bias-corrected standardized mean difference in the economic outcome between treatment and control. The aggregation of individual effect sizes is described in subsection 4.1. The Work aggregate and Non-work aggregate meta-analyses include effect sizes from each of the other outcome groupings below. Panel A presents estimates of the standard deviation effects of interventions targeting common mental disorders, Panel B interventions targeting severe mental disorders. \*, \*\* and \*\*\* denote statistical significance at 10 percent, 5 percent and 1 percent level of significance respectively. The average measurement in our sample happens 15.2 months after intervention start. <sup>^</sup> indicates variables that have been reverse-coded such that higher values indicate improvements in outcomes. All individual effect sizes are winsorized at the 99<sup>th</sup> percentile.

## E.2 Behavioral and psychological pathway outcomes

Table A13: Frequentist estimates of effects of mental health interventions on behavioral and psychological pathways (positively-coded)

	(1) Aggregate Hedges' $g$	(2) 95% lower CI	(3) 95% upper CI	(4) # of obs.	(5) # of intrv.	(6) $I^2$
<b>Panel A: Psychosocial interventions targeting common mental disorders</b>						
<b>All mental health disorder symptoms<sup>^</sup></b>	0.23***	0.13	0.33	76	14	0.53
Suicide attempts or at risk of suicide	0.16*	-0.00	0.31	12	6	0.34
Relapse (dummy)	0.24***	0.08	0.41	7	3	0.58
Recovery (dummy)	0.23**	0.02	0.45	1	1	1.00
Rehospitalisation (dummy)	0.31***	0.08	0.54	1	1	1.00
Diagnosed with mental disorder (dummy)	0.31**	0.04	0.58	7	4	0.51
CMD symptoms	0.29***	0.14	0.43	38	13	0.73
Overall assessment of mental disorder	0.53***	0.27	0.79	4	3	0.00
<b>All disability and functioning<sup>^</sup></b>	0.32***	0.15	0.49	37	12	0.86
Overall measures of functioning	0.16***	0.09	0.23	21	10	0.91
Social support	0.25***	0.09	0.41	15	4	0.54
Functioning in social interactions	0.60***	0.15	1.04	1	1	1.00
<b>Other outcomes<sup>^</sup></b>						
Self-regulation	0.15***	0.05	0.24	5	3	0.00
Self-esteem/self-efficacy	0.14	-0.42	0.70	2	2	0.39
Cognition	0.07*	-0.00	0.14	6	2	0.00
Physical health	0.29	-0.18	0.77	6	1	1.00
<b>Panel B: Psychosocial interventions targeting severe mental disorders</b>						
<b>All mental health disorder symptoms<sup>^</sup></b>	0.39***	0.20	0.59	23	8	0.64
Suicide attempts or at risk of suicide	-0.01	-0.27	0.26	1	1	1.00
Relapse (dummy)	0.33***	0.16	0.50	6	4	0.00
Recovery (dummy)	0.47***	0.17	0.78	2	2	0.00
Rehospitalisation (dummy)	0.13	-0.08	0.34	5	3	0.36
SMD symptoms	0.36	-0.08	0.80	5	4	0.68
Overall assessment of mental disorder	0.10	-0.16	0.37	3	2	0.27
<b>All disability and functioning<sup>^</sup></b>	0.41***	0.25	0.57	27	8	0.17
Overall measures of functioning	0.36***	0.20	0.51	20	7	0.18
Social support	0.82***	0.53	1.10	1	1	1.00
Functioning in social interactions	0.59***	0.33	0.85	6	3	0.01
<b>Other outcomes<sup>^</sup></b>						
Self-regulation	0.16**	0.00	0.32	2	1	1.00
Self-esteem/self-efficacy	1.00***	0.74	1.26	1	1	0.00
Cognition	0.69***	0.45	0.92	1	1	1.00
Physical health	0.65***	0.36	0.94	1	1	1.00

Notes: Table A13 reports estimates of the effect of mental health interventions on behavioral and psychological pathway outcomes under the frequentist specification outlined in Section 4.2. In Column (1), Hedges'  $g$  is the small-sample-bias-corrected standardized mean difference in the economic outcome between treatment and control. Panel A presents estimates of the standard deviation effects of interventions targeting common mental disorders, Panel B interventions targeting severe mental disorders. The "Mental health disorder symptoms" aggregate and "Functioning and disability" aggregate include effect sizes from each of the other outcome groupings below. \*, \*\* and \*\*\* denote statistical significance at 10 percent, 5 percent and 1 percent level of significance respectively. The average measurement in our sample happens 15.2 months after intervention start. <sup>^</sup> indicates variables that have been reverse-coded such that higher values indicate improvements in outcomes. Aggregate Hedges'  $g$  represents an estimate from random-effects inverse variance weighted meta-analysis. The aggregation of individual effect sizes works as described in subsection 4.1.



Table A14: Effects of mental health interventions on psychological and behavioral pathways: Bayesian approach (positively-coded)

	$\tau$ estimate	$\tau$ posterior quantiles				Heterogeneity		
	(1) mean	(2) 2.5 <sup>th</sup>	(3) 25 <sup>th</sup>	(4) 75 <sup>th</sup>	(5) 97.5 <sup>th</sup>	(6) $\sigma$	(7) $\omega(\tau)$	(8) $I^2$
<b>Panel A: Treatment effects of psychosocial interventions on <i>common</i> mental disorders</b>								
<b>Mental health disorder symptoms<sup>1</sup></b>	0.25**	0.12	0.2	0.3	0.41	0.16	0.55	0.72
Suicide attempts or at risk of suicide	0.16	-0.07	0.09	0.23	0.42	0.19	0.47	0.61
Relapse (dummy)	0.23	-0.4	0.14	0.33	0.78	0.41	0.06	0.95
Recovery (dummy)	0.08	-1.68	-0.41	0.56	1.73	4.96	0	1
Rehospitalisation (dummy)	0.1	-1.67	-0.4	0.59	1.74	4.98	0	NaN
Diagnosed with mental disorder (dummy)	0.33	-0.28	0.19	0.46	0.97	0.48	0.22	0.87
CMD symptoms	0.31**	0.12	0.24	0.37	0.53	0.26	0.43	0.85
Overall assessment of mental disorder	0.48	-0.3	0.36	0.64	1.04	0.45	0.21	0.79
<b>Functioning and disability<sup>1</sup></b>	0.32**	0.09	0.25	0.39	0.54	0.35	0.19	0.92
Overall measures of functioning	0.28*	-0.01	0.19	0.37	0.57	0.42	0.12	1
Social support	0.25*	-0.09	0.17	0.32	0.6	0.25	0.21	0.84
Functioning in social interactions	0.18	-1.66	-0.36	0.73	1.8	5.17	0	NaN
<b>Other outcomes<sup>1</sup></b>								
Self-regulation	0.16	-0.28	0.1	0.23	0.58	0.27	0.14	0.88
Self-esteem/self-efficacy	0.05	-1.34	-0.28	0.39	1.34	1.67	0.04	0.95
Cognition	0.09	-1.09	-0.08	0.28	1.2	1.14	0.02	0.98
Physical health	0.09	-1.68	-0.41	0.6	1.74	5	0	1
<b>Panel B: Treatment effects of psychosocial interventions on <i>severe</i> mental disorders</b>								
<b>Mental health disorder symptoms<sup>1</sup></b>	0.39**	0.16	0.31	0.46	0.65	0.25	0.4	0.73
Suicide attempts or at risk of suicide	0	-1.7	-0.48	0.48	1.7	4.93	0	1
Relapse (dummy)	0.36*	-0.06	0.26	0.45	0.83	0.29	0.41	0.66
Recovery (dummy)	0.34	-1.05	0.13	0.62	1.38	1.26	0.03	0.97
Rehospitalisation (dummy)	0.15	-0.58	0.03	0.29	0.88	0.54	0.11	0.91
SMD symptoms	0.34	-0.52	0.14	0.56	1.18	0.79	0.14	0.92
Overall assessment of mental disorder	0.02	-1.24	-0.23	0.27	1.23	1.38	0.02	0.98
<b>Functioning and disability<sup>1</sup></b>	0.41**	0.19	0.35	0.48	0.65	0.19	0.61	0.45
Overall measures of functioning	0.36**	0.12	0.29	0.43	0.62	0.2	0.56	0.51
Social support	0.23	-1.66	-0.33	0.83	1.84	5.35	0	NaN
Functioning in social interactions	0.46	-0.52	0.32	0.67	1.14	0.62	0.15	0.87
<b>Other outcomes<sup>1</sup></b>								
Self-regulation	0.05	-1.68	-0.43	0.53	1.72	4.93	0	NaN
Self-esteem/self-efficacy	0.27	-1.66	-0.33	0.92	1.89	5.56	0	NaN
Cognition	0.2	-1.66	-0.34	0.77	1.81	5.23	0	1
Physical health	0.19	-1.66	-0.35	0.75	1.8	5.19	0	NaN

Notes: Table A14 reports estimates of the effects of mental health interventions on psychological and behavioral pathways under the Bayesian specification outlined in Section 4.2. In column (1),  $\hat{\tau}$  is the estimate of the latent treatment effect in standard deviations. \*, \*\* and \*\*\* represent significant at the 10, 5 and 1% levels respectively. Columns (2) through (5) present posterior quantile estimates, summarising the distribution of  $\hat{\tau}$ . Columns (6) through (8) present summary indicators of heterogeneity. The Work aggregate and Non-work aggregate meta-analyses includes effect sizes from each of the other outcome groupings below. Panel A presents estimates of the standard deviation effects of psychosocial interventions targeting common mental disorders and Panel B the effects of psychosocial interventions targeting severe mental disorders. The “Mental health disorder symptoms” aggregate and “Functioning and disability” aggregate include effect sizes from each of the other outcome groupings below. Panel A presents estimates of the standard deviation effects of psychosocial interventions targeting common mental disorders, Panel B the effects of combined interventions targeting common mental disorders and Panel C combined interventions targeting severe mental disorders. ^ indicates variables that have been reverse-coded such that higher values indicate improvements in outcomes. The procedure for aggregating multiple effect sizes from a given intervention is described in subsection 4.1. All individual effect sizes are winsorized at the 99<sup>th</sup> percentile. We take  $\tau \sim N(0, 1)$  and  $\sigma \sim HC(1)$  as our priors. The estimate of  $\sigma$  is bounded by zero below by the choice of Half-Cauchy prior. The average measurement in our sample happens 15.2 months after intervention start.

Table A15: Effects of mental health interventions on behavioral and psychological pathways: Frequentist approach, additional categories (positively-coded)

	(1) Aggregate Hedges' $g$	(2) 95% lower CI	(3) 95% upper CI	(4) # of obs.	(5) # of intrv.	(6) $I^2$
<b>Panel A: Psychosocial interventions targeting post-traumatic stress disorder</b>						
<b>All mental health disorder symptoms</b>	0.13	-0.20	0.46	22	5	0.86
Diagnosed with mental disorder (dummy)	0.48***	0.27	0.69	3	2	0.00
CMD symptoms	0.18	-0.17	0.53	11	5	0.84
PTSD symptoms	0.10	-0.20	0.40	11	5	0.86
<b>All disability and functioning</b>	0.21**	0.01	0.40	14	3	0.00
Overall measures of functioning	0.23***	0.10	0.35	6	3	0.00
Social support	0.22*	-0.02	0.46	6	2	0.00
Functioning in social interactions	0.19**	0.01	0.38	2	1	1.00
<b>Panel B: Psychosocial interventions targeting substance use disorders</b>						
<b>All mental health disorder symptoms</b>	0.14**	0.03	0.26	45	5	0.00
Suicide attempts or at risk of suicide	0.09	-0.14	0.31	4	2	0.00
Substance use	0.20***	0.08	0.31	31	5	0.00
CMD symptoms	0.13	-0.09	0.35	7	4	0.65
PTSD symptoms	0.05	-0.14	0.24	2	1	1.00
<b>All disability and functioning</b>	0.16	-0.03	0.36	8	4	0.34
Overall measures of functioning	0.32	-0.31	0.96	5	2	0.78
Social support	0.15	-0.04	0.33	3	2	0.00
<b>Other outcomes<sup>1</sup></b>						
Self-esteem/self-efficacy	0.49	-0.31	1.28	4	2	0.93
Cognition	0.03	-0.14	0.21	2	1	1.00
Physical health	-0.13	-0.59	0.33	1	1	1.00
<b>Panel C: Other intervention-type target condition groupings</b>						
<b>All mental health disorder symptoms</b>	0.19	-0.08	0.47	21	4	0.75
Suicide attempts or at risk of suicide	-0.27*	-0.54	0.01	1	1	1.00
Relapse (dummy)	0.49**	0.00	0.97	1	1	1.00
Recovery (dummy)	0.31**	0.00	0.62	1	1	1.00
Diagnosed with mental disorder (dummy)	0.08	-0.07	0.23	4	1	1.00
Substance use	0.11	-0.07	0.29	4	1	1.00
CMD symptoms	0.08	-0.08	0.24	4	1	1.00
SMD symptoms	0.37	-0.28	1.02	3	2	0.83
Overall assessment of mental disorder	-0.10	-0.43	0.24	3	2	0.00
<b>All disability and functioning</b>	0.06	-0.17	0.30	6	4	0.83
Overall measures of functioning	0.14	-0.24	0.52	4	3	0.87
Social support	-0.10	-0.21	0.02	2	1	1.00
<b>Other outcomes<sup>1</sup></b>						
Cognition	-0.12	-0.26	0.02	2	1	1.00
Physical health	0.10	-0.06	0.26	2	1	1.00

Notes: Table A15 reports estimates of the effect of mental health interventions on behavioral and psychological pathway outcomes for additional intervention type-target condition groupings under the frequentist specification outlined in Section 4.2. In Column (1), Hedges'  $g$  is the small-sample-bias-corrected standardized mean difference in the economic outcome between treatment and control. The aggregation of individual effect sizes is described in Section 4.1. Panel A presents estimates of the standard deviation effects of interventions targeting common mental disorders, Panel B interventions targeting severe mental disorders. The "Mental health disorder symptoms" aggregate and "Functioning and disability" aggregate include effect sizes from each of the other outcome groupings below. \*, \*\* and \*\*\* denote statistical significance at 10 percent, 5 percent and 1 percent level of significance respectively. The average measurement in our sample happens 15.2 months after intervention start. ^ indicates variables that have been reverse-coded such that higher values indicate improvements in outcomes. All individual effect sizes are winsorized at the 99<sup>th</sup> percentile.

## F Robustness checks

### F.1 Meta-regression and sub-group analyses

We leverage a meta-regression framework to test robustness of our results to study-level heterogeneity and explore determinants of heterogeneity. We extend Equation 1 by allowing for a vector of de-meaned covariates  $\tilde{X}_{es}$ :

$$\begin{aligned}\hat{\tau}_{es} &= \tilde{\tau}_{es} + \tilde{X}_{es}\beta + \epsilon_{es} \\ \tilde{X}_{es} &= X_{es} - \bar{X}_{es} \quad \forall X_{es}\end{aligned}\tag{8}$$

Where  $\hat{\tau}_{es}$  is the observed average treatment effect for effect size  $e$  taken from study  $s$ .

Relative to estimation of Equation 1, we do not aggregate effect sizes within intervention to retain higher variation with respect to study-level covariates. The increase in sample size comes at a cost: we expect dependence between multiple effects from a given intervention, and need to account for overweighting of studies that report many effect sizes. We therefore implement a multivariate random-effects meta-regression procedure, controlling for intervention-level fixed effects. We estimate parameters via restricted maximum likelihood following [Jackson et al. \(2011\)](#).

Table A16: Meta-regression: robustness to study-level covariates

	Dep. var.: work-related outcomes (Hedges' $g$ )							
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
<b>Panel A: Psychosocial interventions targeting common mental disorders</b>								
Constant ( $\tilde{\tau}$ estimate)	0.176	0.247	0.170	0.165	0.186	0.162	0.118	0.236
Standard error of $\tilde{\tau}$	(0.058)	(0.082)	(0.064)	(0.057)	(0.068)	(0.072)	(0.052)	(0.110)
$I^2$	0.771	0.820	0.776	0.754	0.793	0.828	0.562	0.934
Cochran $Q$	128	128	127	123	117	97	83	128
Residual heterogeneity (p-value)	0.000	0.000	0.000	0.000	0.000	0.000	0.000	0.000
Modifier relevance (p-value)	0.003	0.161	0.712	0.048	0.732	0.761	0.294	0.000
Degrees of freedom (#obs-k)	35	34	34	34	31	29	25	34
Number of interventions	14	14	14	14	14	14	8	14
<b>Panel B: Psychosocial interventions targeting severe mental disorders</b>								
Constant ( $\tilde{\tau}$ estimate)	0.325	0.245	0.302	0.338	0.360	0.337	0.173	0.339
Standard error of $\tilde{\tau}$	(0.153)	(0.187)	(0.185)	(0.156)	(0.144)	(0.169)	(0.177)	(0.157)
$I^2$	0.913	0.917	0.925	0.915	0.902	0.926	0.793	0.917
Cochran $Q$	99	93	98	99	86	96	17	90
Residual heterogeneity (p-value)	0.000	0.000	0.000	0.000	0.000	0.000	0.044	0.000
Modifier relevance (p-value)	0.033	0.442	0.746	0.131	0.281	0.275	0.841	0.384
Degrees of freedom	19	18	18	18	17	17	9	18
Number of interventions	9	9	9	9	9	9	3	9
<b>Included covariates</b>								
<i>Measurement heterogeneity</i>								
Error term variance	No	Yes	No	No	No	No	No	No
Control conditions	No	No	Yes	No	No	No	No	No
Measurement timing	No	No	No	Yes	No	No	No	No
<i>Intervention and context heterogeneity</i>								
Region and income level	No	No	No	No	Yes	No	No	No
Sample characteristics	No	No	No	No	No	Yes	No	No
Intervention costs (USD 2011)	No	No	No	No	No	No	Yes	No
Delivery type	No	No	No	No	No	No	No	Yes
<i>Fixed effects</i>								
Intervention-level	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes

*Notes:* Table A16 presents the estimated latent treatment effect (Hedges'  $g$ ) at the mean of the included covariates for a given model ( $\tilde{\tau}$ ), and its standard error from the meta-regression model described in Section F.1. Each column represents a separate meta-regression with the included covariates indicated by "Yes". The error term variance captures the unexplained variation in the included study estimate, and is a commonly used proxy for small sample biases. Control conditions are described in Section 3.1. Measurement timing captures the number of months from the intervention to measurement. "Region and income level" indicates World Bank income groupings and regional classifications. Sample characteristics capture participant age range, gender, a proxy for female labor force participation, and rural status, where available. Intervention costs are average costs measured in 2011 USD. Delivery type is a dummy for whether the intervention was administered by a specialist, or not. " $I^2$ " is the percentage of variation across studies arising due to heterogeneity rather than sampling variance. Residual heterogeneity presents the p-value from the Cochran  $Q$   $\chi^2$  test of residual heterogeneity. Modifier relevance presents the p-value from a  $\chi^2$  test of joint significance of included moderators (excluding the intercept), or the p-value on the intercept in the univariate model. Degrees of freedom is the degrees of freedom from the test of modifier relevance, and is equal to the number of observed effect sizes, minus the number of included moderators,  $k$ . All individual effect sizes are winsorized at the 99<sup>th</sup> percentile.

Table A17: Work effects by other theoretically important dimensions of heterogeneity

	(1) Aggregate Hedges' $g$	(2) 95% lower CI	(3) 95% upper CI	(4) # of observations	(5) # of interventions
<b>Panel A: Psychosocial interventions targeting common mental disorders</b>					
<b>All interventions</b>	0.16***	0.05	0.27	36	14
<i>Measurement timing</i>					
<6 months after exit	0.31**	0.06	0.55	8	6
6-12 months after exit	0.12**	0.01	0.23	11	6
>1 year after exit	0.04	-0.08	0.16	12	3
<i>Delivery type</i>					
Specialist delivery	0.27**	0.03	0.52	12	7
Non-specialist delivery	0.06**	0.01	0.12	32	11
<i>Costs</i>					
Costs $\geq 100$ USD	0.12*	-0.02	0.25	11	5
Costs $< 100$ USD	0.05	-0.06	0.17	16	3
<b>Panel B: Psychosocial interventions targeting severe mental disorders</b>					
<b>All interventions</b>	0.30**	0.06	0.54	20	9
<i>Measurement timing</i>					
<6 months after exit	0.29**	0.04	0.54	13	8
>1 year after exit	0.31**	0.04	0.57	3	1
<i>Delivery type</i>					
Specialist delivery	0.36***	0.09	0.63	18	8
Non-specialist delivery	0.36	-0.14	0.85	4	3
<i>Costs</i>					
Costs $\geq 100$ USD	0.09	-0.14	0.31	8	2
Costs $< 100$ USD	0.46**	0.01	0.91	3	1

Notes: Table A17 reports estimates of effect of mental health interventions on the “Work aggregate” within various subsamples. Hedges'  $g$  is the small-sample-bias-corrected standardized mean difference in the economic outcome between treatment and control. Panel A presents estimates of the standard deviation effects of interventions targeting common mental disorders, Panel B interventions targeting severe mental disorders. \*, \*\* and \*\*\* denote statistical significance at 10 percent, 5 percent and 1 percent level of significance respectively. The average measurement in our sample happens 15.2 months after intervention start. The aggregation of individual effect sizes works as described in subsection 4.1. All individual effect sizes are winsorized at the 99<sup>th</sup> percentile.

Figure A2: Effects of psychosocial interventions by targeted sample




Figure A2 shows aggregate meta-effect sizes (Hedges'  $g$ ) for various economic outcomes. Colors represent findings from the subsample of interventions implemented in a given target population, namely "standard" populations, those suffering from perinatal depression or "difficult context", where there is very low labor force participation. The horizontal axis displays the average economic effect size in standard deviations. The aggregation of individual effect sizes works as described in subsection 4.1. Individual effect sizes are winsorized within outcome type at the 99<sup>th</sup> percentile. In the left panel, the first number next to the effect size marker represents the number of individual effects going into the aggregate meta-effect, the second number represents the number of different interventions from which these individual effect sizes come.

Table A18: Meta-regression: differential effects by measured labor market outcome

	Dep. var.: work-related outcomes (Hedges' $g$ )		
	Intercept ( $\tilde{\tau}$ , SD)	Standard error	# of obs.
<b>Panel A: Psychosocial interventions targeting common mental disorders</b>			
<i>Regression 1, omitted category: "Days unable to work"</i>			
Intercept	0.176	(0.061)	17
In employment	-0.097	(0.061)	4
Time in work	-0.018	(0.090)	3
Functioning at work	-0.054	(0.077)	8
Job search	0.005	(0.078)	4
Residual heterogeneity (p-value)	0.000		
Modifier relevance (p-value)	0.685		
Degrees of freedom (# obs-k)	31		
Number of interventions	14		
<b>Panel B: Psychosocial interventions targeting severe mental disorders</b>			
<i>Regression 2, omitted category: "Days unable to work"</i>			
Intercept	0.312	(0.176)	1
In employment	0.565	(0.616)	1
Time in work	0.091	(0.113)	4
Unable to work	0.036	(0.091)	8
Functioning at work	0.030	(0.361)	2
Residual heterogeneity (p-value)	0.000		
Modifier relevance (p-value)	0.832		
Degrees of freedom (# obs-k)	15		
Number of interventions	9		

Table A18 presents coefficients from two meta-regressions of work-related outcomes on indicators for sub-aggregate work-related outcomes. Each panel represents a separate meta-regression. The intercept term represents the estimated latent treatment effect (Hedges'  $g$ ) for the omitted category, "Days unable to work". Coefficients on the remaining terms represent differential effects with respect to other sub-aggregate outcomes.

## F.2 Heterogeneity in economic effects

We report the distribution of each of the heterogeneity parameters under the Bayesian specification for our core work-related results in Table A19.<sup>42</sup> In Panel A, we present evidence of low-to-moderate heterogeneity in the effect sizes used to estimate the latent effect of psychosocial interventions targeting CMDs on the work aggregate. Heterogeneity is small ( $\sigma = 0.05$ ) and precisely estimated (50% CI: [0.02, 0.06]) and heterogeneity relative to sample variance is low ( $\omega(\tau) = 0.81$ ,  $I^2 = 0.20$ ).

In contrast, we observe moderate-to-high heterogeneity in the interventions targeting SMDs grouping ( $\sigma = 0.40$ ) that is moderately precisely estimated (50% CI: [0.28, 0.48]). Again, this is substantial relative to sample variance ( $\omega(\tau) = 0.24$ ,  $I^2 = 0.85$ ).

Table A19: Summary statistics of Bayesian posteriors of heterogeneity measures from meta-analyses of the effects of mental health interventions on work-related outcomes

	$\sigma$ Distribution			$\omega(\tau)$ Distribution			$I^2$ Distribution		
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
	mean	25% CI	75% CI	mean	25 pctl. $\sigma$	75 pctl. $\sigma$	mean	25 pctl. $\sigma$	75 pctl. $\sigma$
<b>Panel A: Psychosocial interventions targeting common mental disorders</b>									
<b>Work aggregate</b>	0.21	0.16	0.25	0.32	0.26	0.42	0.8	0.7	0.85
In employment (dummy)	0.18	0.05	0.22	0.4	0.35	0.87	0.67	0.12	0.75
Time in work	0.58	0.18	0.65	0.06	0.04	0.36	0.95	0.65	0.96
Days unable to work <sup>^</sup>	0.06	0.02	0.08	0.72	0.59	0.94	0.31	0.05	0.47
Functioning at work	0.48	0.29	0.57	0.08	0.06	0.19	0.93	0.84	0.95
Job search	1.13	0.17	1.21	0.01	0.01	0.38	0.98	0.6	0.99
<b>Panel B: Psychosocial interventions targeting severe mental disorders</b>									
<b>Work aggregate</b>	0.45	0.32	0.55	0.21	0.17	0.33	0.88	0.79	0.92
In employment (dummy)	5.37	1.02	5.87	0	0	0.09	NaN	NaN	NaN
Time in work	1.28	0.22	1.4	0.02	0.02	0.34	0.98	0.61	0.98
Unable to work (dummy) <sup>^</sup>	0.4	0.09	0.44	0.13	0.11	0.67	0.9	0.29	0.92
Days unable to work <sup>^</sup>	4.92	0.83	5.32	0	0	0	NaN	NaN	NaN
Functioning at work	1.12	0.62	1.34	0.07	0.05	0.18	0.97	0.9	0.98

Notes: The Frequentist and Bayesian specifications are outlined in Section 4.2.  $\hat{\tau}$  is the MLE estimator under the Frequentist specification, or posterior mean (most likely value) under the Bayesian specification of the treatment effects and is measured in standard deviations. The Work aggregate meta-analysis includes effect sizes from each of the other outcome groupings below. Panel A presents estimates of the standard deviation effects of psychosocial interventions targeting common mental disorders, Panel B the effects of interventions targeting severe mental disorders. Details of scale wording is provided in Table A6. <sup>^</sup> indicates variables that have been reverse-coded such that higher values indicate improvements in outcomes. NaN represents the estimated  $I^2$  value “Not a number” as reported by  $\mathcal{R}$ . It can be taken as  $\approx 1$ .

<sup>42</sup>In small samples, the  $I^2$  statistic is biased and tends to have wide confidence intervals, complicating inference on heterogeneity (von Hippel, 2015).



### F.3 Publication bias

In this section, we present results from tests for publication bias on the full sample of 40 studies captured by our systematic review. This best reflects the extent of publication bias in the literature defined by our pre-specified search criteria.


#### F.3.1 Funnel plot asymmetry

Table A20: Egger’s test

(1) Egger’s test H0: no small-study effects	
Beta	0.01
S.E.	0.19
<i>p</i> -value	0.97

Notes: Table A20 displays the results of the Egger’s test. We cannot reject the null hypothesis of no small-study effects. The sample size are  $N = 95$  effect sizes of mental health treatment impacts on work-related outcomes.

Figure A3: Histogram and funnel plot of reported effect sizes



Notes: Figure A3 displays a binned density plot (histogram) for the  $Z$ -statistics recovered from our study sample,  $X/\Sigma$ , while the right panel shows a funnel plot, which plots effect sizes,  $X$ , against their standard errors,  $\Sigma$ . To enable us to visually distinguish reported data, we trim “extremely small sample” observations for which  $\Sigma > 8$ . We show robustness to their inclusion or exclusion in the formal analysis that follows. The grey lines indicate  $X/\Sigma = 1.96$ , which is the threshold for 95% significance. Substantial bunching around those thresholds would provide tentative evidence for publication bias. Moreover, asymmetry in the funnel plot for higher values of  $\Sigma$  might indicate small sample effects and publication bias.

### F.3.2 Conditional publication probability model

We follow the maximum likelihood approach of [Andrews and Kasy \(2019\)](#) to formally model the effect of publication bias in our setting. Under the standard independence assumption and under no selectivity, we can write the distribution of estimates for high variance studies as the distribution for low variance studies plus a noise term. Deviations from this prediction identify differential publication probabilities conditional on Z-scores. In particular, if we assume  $P(pub|Z > 1.96) = 1$ , and that the error term follows a t-distribution, which allows for differential publication probabilities whether the result is positive or negative, we can fit the following model using maximum likelihood estimation.

$$\Theta^* \sim \bar{\theta} + t(\tilde{\nu}) \cdot \tilde{\eta}, \quad p(Z) \propto \begin{cases} \beta_{p,1} & \text{if } Z < -1.96 \\ \beta_{p,2} & \text{if } Z \in [-1.96, 0) \\ \beta_{p,3} & \text{if } Z \in [0, 1.96) \\ 1 & \text{if } Z \geq 1.96 \end{cases} \quad (9)$$

Where  $\theta^*$  is the distribution of latent study effects, modeled as a t-distribution with degrees of freedom  $\tilde{\nu}$  location parameter  $\bar{\theta}$  and scale parameter  $\tilde{\eta}$ . We cluster standard errors by study to account for non-independence of within study-reported outcomes. We report findings for the whole sample in [Table A21](#).

Table A21: Differential publication probability estimates

$\bar{\theta}$	$\tilde{\tau}$	$\tilde{\nu}$	$\beta_{p,1}$	$\beta_{p,2}$	$\beta_{p,3}$
0.195	-0.800	5.017	1.074	1.833	1.912
(0.052)	(0.181)	(4.440)	(0.473)	(0.577)	(0.449)

*Notes:* [Table A21](#) displays the results of the MLE model for publication bias implemented on the whole sample.  $\bar{\theta}$  represents the estimated average effect size for large studies. Publication probability  $\beta_p$  is measured relative to the omitted category of studies which are positive and significant at the 5 percent level.  $\beta_{p,1}$  represents the probability of publication given  $Z < -1.96$ ,  $\beta_{p,2}$ ,  $Z \in [-1.96, 0]$  and  $\beta_{p,3}$ ,  $Z \in [0, 1.96]$ . Standard errors clustered by study are reported in parentheses.

Taken literally, our point estimates indicate that relative to the reference category for which  $Z > 1.96$ , the probability of publication of other effect sizes being published is higher. However, these probabilities are imprecisely estimated, and we interpret them as indicating that we have little evidence of differential publication probabilities conditional on Z-scores in our study sample. That is, we find no evidence of publication bias. We then replicate the model in the sub-sample for which standard errors are less than 10 (we have one observation for which  $SE = 8$ ). Our findings are broadly similar, but substantially

more precisely estimated.

Table A22: Differential publication probability estimates for  $SE \leq 8$  subsample

$\bar{\theta}$	$\tilde{\tau}$	$\tilde{\nu}$	$\beta_{p,1}$	$\beta_{p,2}$	$\beta_{p,3}$
0.185	0.320	5.035	0.954	1.421	1.379
(0.040)	(0.070)	(0.390)	(0.247)	(0.385)	(0.294)

Notes: Table A21 displays the results of the MLE model for publication bias implemented on the subsample for which  $SE \leq 8$ .  $\bar{\theta}$  represents the estimated average effect size for large studies. Publication probability  $\beta_p$  is measured relative to the omitted category of studies which are positive and significant at the 5 percent level.  $\beta_{p,1}$  represents the probability of publication given  $Z < -1.96$ ,  $\beta_{p,2}$ ,  $Z \in [-1.96, 0]$  and  $\beta_{p,3}$ ,  $Z \in [0, 1.96]$ . Standard errors clustered by study are reported in parentheses.

## F.4 Heterogeneity in mental health effects

### F.4.1 Heterogeneity by measuring party

Figure A4: Robustness to disaggregation by party responsible for measurement




Figure A4 shows aggregate mental health meta-effect sizes (Hedges'  $g$ ) on various psychological and behavioral pathways outcomes and aggregates. The two panels present 95% confidence intervals for effects of each intervention-target condition combination. The horizontal axis displays the average effect size in standard deviations. Colors represent findings from the subsample of interventions that were measured by a given party, namely the trial participant (self-rated) or a clinician (clinician-rated). The aggregation of individual effect sizes works as described in subsection 4.1. Individual effect sizes are winsorized within outcome type at the 99<sup>th</sup> percentile.

## G Pooled microdata analysis details

### G.1 Data availability

Table A23: Data inclusion attempts for interventions in microdata sample

Study name	Contact with authors	Data available	Depression?	Work days?	In pooled analysis
<b>Study did not have all relevant variables</b>					
<a href="#">Ayoughi et al. (2012)</a>	No	Unknown	Yes	No	No
<a href="#">Bolton et al. (2003)</a>	No	Unknown	Yes	No	No
<a href="#">Haushofer et al. (2020)</a>	No	Unknown	No	No	No
<a href="#">Hirani et al. (2010)</a>	Unsuccessful attempt	Unknown	Yes	No	No
<a href="#">Duarte et al. (2009)</a>	Yes	Do not want to share	Yes	No	No
<b>Included in sample of microdata studies</b>					
<a href="#">Baranov et al. (2020)</a>	Yes	Yes	Yes	Yes	Yes
<a href="#">Barker et al. (2022)</a>	Yes	Yes	Yes	Yes	Yes
<a href="#">Fuhr et al. (2019) / Bhat et al. (2022)</a>	Yes	Yes	Yes	Yes	Yes
<a href="#">Patel et al. (2017) / Weobong et al. (2017)</a>	Yes	Yes	Yes	Yes	Yes
<a href="#">Patel et al. (2011) / Buttorff et al. (2012)</a>	Yes	Yes	Yes	Yes	Yes
<a href="#">Sikander et al. (2019) / Bhat et al. (2022)</a>	Yes	Yes	Yes	Yes	Yes

## G.2 Variable construction details

In our microdata analysis, reported on in Table 3 and Table A25, we make use of the following directly comparable measures of “Days unable to work” from across included studies:

- Fuhr et al. (2019): ‘Number of days unable to work in the previous month’
- Sikander et al. (2019): ‘Number of days unable to work in the previous month’
- Barker et al. (2022): ‘Number of days unable to work in the previous month’
- Weobong et al. (2017): ‘Number of days unable to work in the previous month’
- Patel et al. (2011): ‘Number of days unable to work in the previous month’
- Baranov et al. (2020): This study reports on ‘Number of healthy days in past 30 days’. While this is a close proxy for number of days able to work, to ensure comparability, we report findings against this outcome separately.

In Table 3, we report findings from a regression of “Days unable to work” on a combined measure of depression, instrumented by treatment status. Our combined depression measure is constructed from the main/preferred depression measure captured by a given study as determined by the study’s authors. We standardise each of these measures within each study sample, then aggregate them across studies. The main depression measure from each of the included studies is as follows:

- Patient Health Questionnaire-9 (PHQ-9): Fuhr et al. (2019); Sikander et al. (2019); Weobong et al. (2017)
- Beck Depression Index (BDI): Baranov et al. (2020)
- Diagnostic and Statistical Manual of Mental Disorders - IV (DSM-IV): Patel et al. (2011)
- Kessler Psychological Distress K10 Scale (Kessler): Barker et al. (2022)

In Table A24, we report findings from a first stage regression of measures of depression on treatment status. In Columns (1) to (3), the combined measure is encoded as described above. In Column (4) we report effects on the Patient Health Questionnaire-9 (PHQ-9) which are aggregated from across three studies: Fuhr et al. (2019); Sikander et al. (2019); Weobong et al. (2017). In Columns (5) to (7) we report effects of treatment on

the BDI scale from [Weobong et al. \(2017\)](#), the DSM-IV scale from [Patel et al. \(2011\)](#) and the Kessler Psychological Distress K10 Scale from [Barker et al. \(2022\)](#).

In Table A24 and Table A25, we report interaction effects between treatment and categorical measures of depression. The cutoff used in each of the continuous depression measures to construct the categories of mild, moderate and severe depression is taken directly from the assessment criteria for each of the measures.

### G.3 Details of the median split model

For continuous dimension of heterogeneity  $X_i$  we estimate:

$$Y_{is} = \beta_0 + \beta_1 T_i + \beta_2 I[X_i > \mathbf{M}(X_i)] + \beta_3 T_{is} * I[X_i > \mathbf{M}(X_i)] + S_i + \epsilon_{is}, \quad (10)$$

for  $\mathbf{M}(X) = \text{Median}(X)$

where  $Y_{is}$  the outcome for participant  $i$  from study  $s$ ,  $T_i$  is an indicator for whether  $i$  was randomly allocated to CBT (as opposed to being in the control group) and  $X_i$  is a continuous measure of a dimension of heterogeneity.  $S_s$  is a study fixed effect. The median of each of the dimensions of heterogeneity is calculated *across* (not within) studies.

## G.4 Results from analysis of microdata

Table A24: First stage: effect of psychosocial treatments on depression

	Combined measure			PHQ-9	BDI	DSM-IV	Kessler
	(1)	(2)	(3)	(4)	(5)	(6)	(7)
Treatment	-0.222*** (0.061)	-0.236*** (0.058)	-0.124* (0.069)	-0.194** (0.096)	-0.309*** (0.098)	-0.662*** (0.129)	-0.186*** (0.037)
Above median age		0.059* (0.032)					
Treatment=1 × Above median age		0.033 (0.053)					
Moderate depr.			0.235*** (0.043)				
Severe depr.			0.428*** (0.056)				
Treatment=1 × Moderate depr.			-0.173*** (0.052)				
Treatment=1 × Severe depr.			-0.230*** (0.076)				
Constant	-0.002 (0.043)	-0.031 (0.041)	-0.138*** (0.048)	-0.000 (0.084)	-0.000 (0.066)	0.000 (0.116)	-0.000 (0.029)
Study FE	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Control mean	-0.00	-0.00	-0.00	0.00	-0.00	-0.00	-0.00
p(T × Mild=T × Mod)			0.00				
p(T × Mild=T × Sev)			0.00				
p(T × Mod=T × Sev)			0.40				
# of participants	10731	10731	10731	3138	447	429	6717
Obs.	15517	15517	15517	7924	447	429	6717
Studies	6	6	6	3	1	1	1

Notes: This table shows five different OLS regression of the outcome variable on the treatment indicator as well as study fixed effects, the endline round, and the number of months after treatment when the outcome was measured. Column 1 shows the impact on a combined depression outcome, columns 2-5 show the impact on depression measured by DSM-IV, PHQ-9, BDI, or Kessler, respectively (all standardized). Variable construction is further detailed in Appendix G.2. Standard errors are in parentheses and clustered by original study cluster variable. \*  $p < 0.10$ , \*\*  $p < 0.05$ , \*\*\*  $p < 0.01$ .



Table A25: Heterogeneous treatment effects of psychosocial treatments on days able to work measures

	Days unable to work			Healthy days
	(1)	(2)	(3)	(4)
Treatment	-1.571*	-2.133***	-1.296	0.288
	(0.855)	(0.783)	(0.843)	(0.661)
Above median age		1.555***		
		(0.464)		
Treatment=1 × Above median age		1.195		
		(0.859)		
Moderate depr.			1.046***	
			(0.343)	
Severe depr.			1.421***	
			(0.398)	
Treatment=1 × Moderate depr.			-0.656	
			(0.468)	
Treatment=1 × Severe depr.			-0.182	
			(0.648)	
Constant	7.027***	6.234***	6.507***	26.155***
	(0.588)	(0.617)	(0.569)	(0.476)
Study FE	Yes	Yes	Yes	Yes
Control mean	6.43	6.43	6.43	26.16
Standard deviation	9.86	9.86	9.86	7.66
p(T × Mild=T × Mod)			0.16	
p(T × Mild=T × Sev)			0.78	
p(T × Mod=T × Sev)			0.48	
# of participants	10302	10302	10302	429
Obs.	15088	15088	15088	429
Studies	5	5	5	1

Notes: This table shows four different OLS regressions of the outcome variable on the treatment indicator as well as study fixed effects, the baseline round, and the number of months after treatment when the outcome was measured. Columns (1-3) show the impacts on days unable to work in the last month, column (4) shows the impact on healthy days per month. Columns (2) and (3) show heterogeneous impacts by age median splits and depression status. Variable construction is further detailed in Appendix G.2. Standard errors are in parentheses and clustered by original study cluster variable. \*  $p < 0.10$ , \*\*  $p < 0.05$ , \*\*\*  $p < 0.01$ .

## H Details of included studies

Author, year	Country	Sample & age	Intervention category	Therapeutic type	Control group category	Description of intervention	Follow-up time points*	Target mental disorder	Economic outcomes**	Costs (per cap.)
<b>Psychosocial – Common Mental Disorders (CMD)</b>										
Ayoughi et al. 2012	Afghanistan	61 women, 14+	Psychosocial	Problem Solving Therapy	TAU Pharm: Antidepressants	5-8 sessions over 2 months	0.5 months	Depression	Subjective poverty measures	-
Baranov et al. 2020 (Rahman et al. 2008)	Pakistan	903 women, 16-45	Psychosocial	Cognitive Behavioural Therapy	EUC: Monthly home visits by Lady Health Workers	16 sessions over 11 months	8, 14 and 86 months	Depression	Financial, Education, Employment	10 USD, 2005/2006
Barker et al. 2022	Ghana	7227 adults 18+	Psychosocial	Cognitive Behavioural Therapy	No treatment	1 session weekly for 12 weeks (3 months)	1-3 months after intervention	Common mental disorders	Subjective poverty measures, Days unable to work	-
Bolton et al. 2003	Uganda	216 adults, 18+	Psychosocial	Interpersonal Therapy	No treatment	1 session weekly for 16 weeks (4 months)	0 and 6 months	Depression	Education, Social networks	-
Duarte et al. 2009	Brazil	90 adults, 18+	Psychosocial	Cognitive Behavioural Therapy	No treatment	1 session weekly for 12 weeks (3 months)	0 and 6 months	Depression	Social Networks, Employment	-
Fuhr et al. 2019; Bhat et al. 2022	India	250 women, 18+	Psychosocial	Behavioural Activation	EUC: Patient information leaflet	6-14 sessions over 7-12 months	3.5; 6.5; 38.5 months	Depression	Income, Consumption & input expenditure, Days unable to work, Employment, Functioning at work, Job search, Time in work	1.36 USD, 2016
Haushofer et al. 2020	Kenya	2122 adults 18+	Psychosocial	Problem Solving Therapy, Behavioural Activation	No treatment	1 session weekly for 5 weeks	13 months	Common mental disorders	Assets, Income, consumption & input expenditure	1189 USD, 2017
Hirani et al. 2010	Pakistan	24 women, 25-35	Psychosocial	Problem Solving Therapy, Stress & Anger Management, Communication skills	No treatment	1 session weekly for 8 weeks (2 months)	0.5 months	Depression	Employment	-
Patel et al. 2017; Weobong et al. 2017; Bhat et al. 2022	India	495 adults, 18-65	Psychosocial	Behavioural Activation	EUC: Consultation with PHC physician	6-8 sessions over 3-4 months	1; 10; 58 months	Depression	Income, Consumption & input expenditure, Days unable to work, Functioning at work, Employment, Job search, Time in work	66 USD, 2015
Patel et al. 2011; Buttorff et al. 2012	India	213 adults 17+	Psychosocial (Public facility)	Interpersonal Therapy, Psychoeducation	EUC: Facility in patients' community received their screening results	6 sessions over 12 months	9 months	Common mental disorders	Days unable to work	89 USD, 2009
	India	341 adults 17+	Psychosocial (Private facility)	Interpersonal Therapy, Psychoeducation		6 sessions over 12 months	9 months	Common mental disorders	Days unable to work	89 USD, 2009
	India	1648 adults, 17+	Psychosocial (Public facility)	Psychoeducation		6 sessions over 12 months	9 months	Common mental disorders	Days unable to work	89 USD, 2009
	India	1148 adults, 17+	Psychosocial (Private facility)	Psychoeducation		6 sessions over 12 months	9 months	Common mental disorders	Days unable to work	89 USD, 2009

Author, year	Country	Sample & age	Intervention category	Therapeutic type	Control group category	Description of intervention	Follow-up time points*	Target mental disorder	Economic outcomes**	Costs (per cap.)
<b>Psychosocial – Common Mental Disorders (CMD) (cont.)</b>										
Sikander et al. 2019; Bhat et al. 2022	Pakistan	570 women, 18+	Psychosocial	Behavioural Activation	EUC: Patient information leaflet	14 sessions over 9 months	3 and 6 months	Depression	Days unable to work	133.55 USD, 2016
<b>Combination – Common Mental Disorders (CMD)</b>										
Hu et al. 2007	China	76 adults, 18+	Psychosocial	Motivational Interviewing, Family Therapy, Social Support, & Medication: Antidepressants	TAU Pharm: Antidepressants	Unstated number of sessions for 24 months	0 months	Depression	Time in work	-
Nagarajaiah et al. 2013	India	60 adults, 18-65	Psychosocial	Interpersonal therapy, Problem Solving Therapy, Family Therapy, Social Support & Medication: Antidepressants	TAU Pharm: Antidepressants	10 sessions over 3 months	0 months	Anxiety	Functioning at work	-
<b>Combination – Severe Mental Disorders (SMD)</b>										
Chatterjee et al. 2014	India	282 adults, 16-60	Psychosocial & Pharmacological	Psychoeducation & Medication: Antipsychotics	TAU Pharm: Antipsychotics	22 sessions over 12 months	6 months after start, 0 after end	Schizophrenia	Functioning at work	6825 INR, 2009/2010
ChuanQuian et al. 2005	China	112 adults, 18+	Psychosocial & Pharmacological	Psychoeducation & Medication: Antipsychotics	TAU Pharm: Antipsychotics	1 session monthly for 6 months	0 months	Schizophrenia	Subjective poverty measures, Functioning at work	-
Luo et al. 2019	China	58 adults, 16+	Psychosocial & Pharmacological	Problem Solving Therapy, Psychoeducation, Family Therapy, & Medication: Antipsychotics	TAU Pharm: Antipsychotics	2 sessions weekly & 1 family session monthly for 12 months	0 months	Schizophrenia	Employment	-
Ran et al. 2003; 2015	China	326 adults, 18+	Psychosocial & Pharmacological	Psychoeducation & Medication: Antipsychotics	EUC	1 session monthly & 3 family workshops for 9 months	0 and 159 months	Schizophrenia	Unable to work	3100 RMB, 1994
Valencia et al. 2007	Mexico	82 adults, 16-50	Psychosocial & Pharmacological	Problem Solving Therapy, Psychoeducation, Family Therapy, & Medication: Antipsychotics	TAU Pharm: Antipsychotics	1 session weekly for 12 months (48 sessions)	0 months	Schizophrenia	Subjective poverty measures, Functioning at work	-
Vizzotto et al. 2021	Brazil	48 adults, 18-55	Psychosocial & Pharmacological	Occupational Goal Intervention (OGI) & Medication: Antipsychotics	TAU Pharm: Antipsychotics	30 sessions for 15 weeks	6 months	Schizophrenia	Functioning at work	-
Xiang et al. 1994	China	77 adults, 18+	Psychosocial & Pharmacological	Psychoeducation & Medication: Antipsychotics	TAU Pharm: Antipsychotics	1 session monthly for 4 months	0 months	Schizophrenia	Employment	-

Author, year	Country	Sample & age	Intervention category	Therapeutic type	Control group category	Description of intervention	Follow-up time points*	Target mental disorder	Economic outcomes**	Costs (per cap.)
<b>Combination – Severe Mental Disorders (SMD) (cont)</b>										
Xiong et al. 1994	China	63 adults, 18+	Psychosocial & Pharmacological	Problem Solving Therapy, Psychoeducation & Medication: Antipsychotics	TAU Pharm: Antipsychotics	1 session monthly for 12-24 months	6, 12 and 18 months after start	Schizophrenia	Employment	31.5 USD, 1990-1992
Zhang et al. 1998	China	1048 adults, 18+	Psychosocial & Pharmacological	Psychoeducation & Medication: Antipsychotics	TAU Pharm: Antipsychotics	14 lectures & 5 discussions over 24 months	0 months	Schizophrenia	Employment	-
<b>Psychosocial – Substance Use Disorders (SUD)</b>										
Blattman et al. 2017	Liberia	999 men, 18-35	Psychosocial	Cognitive Behavioural Therapy	No treatment	3 sessions every week for 2 months (24 sessions)	1 month after start, 10.5 after end	Antisocial behaviour	Assets, Income, Consumption & input expenditure, Time in work	314 USD, 2009-2012
Nadkarni et al. 2017a; 2017b	India	377 men, 18+	Psychosocial	Counselling for Alcohol Problems (CAP)	EUC: Consultation with PHC physician	Up to 4 sessions weekly or fortnightly	2 and 11 months	Substance dependence (Alcohol)	Days unable to work	33 USD, 2015
Nadkarni et al. 2019	India	135 men, 18+	Psychosocial	Counselling for Alcohol Problems (CAP)	EUC: Consultation with PHC physician	Up to 4 sessions weekly or fortnightly	-1 and 8 months	Substance dependence (Alcohol)	Days unable to work, Employment	39.93 USD, 2015
Xu et al. 2021	China	40 adults, 20+	Psychosocial	Community-based Addiction Rehabilitation Electronic system (CAREs) using a smartphone app	TAU: Community based care	1 session weekly for 6 months	0 months	Substance dependence (Methamphetamine & Heroin)	Functioning at work	-
Min et al. 2011	China	100 adults, 18+	Psychosocial	Cognitive Behavioural Therapy	EUC: Inpatient drug rehab. centre	20 sessions over 2 months	1 month	Substance dependence (Heroin)	Employment	-
<b>Psychosocial – Post Traumatic Stress Disorder (PTSD)</b>										
Betancourt et al. 2014	Sierra Leone	436 youth, 15-24	Psychosocial	Cognitive Behavioural Therapy & Interpersonal therapy	No treatment	1 session weekly for 10 weeks (2.5 months)	0, 6 and 8 months	PTSD	Education	-
Cilliers et al. 2016	Sierra Leone	2383 adults, 18+	Psychosocial	Community Reconciliation	No treatment	2 day-long workshops	9 and 31 months	PTSD	Assets, Employment, Financial, Consumption	-
Hall et al. 2014	DRC	405 women, 18+	Psychosocial	Cognitive Behavioural Therapy based	EUC: Invitation to access existing services	1 sessions weekly for 11 weeks (3 months)	2 and 7 months	PTSD	Assets, Social networks, Subjective poverty measures	1530.03 USD, 2011
Meffert et al. 2021	Kenya	206 women, 18+	Psychosocial	Interpersonal Therapy	TAU plus Waitlist	12 sessions weekly for 12 weeks (3 months)	0 months	PTSD	Social networks	-

Wang 2017	Kosovo	34 adults, 18+	Psychosocial	Cognitive Behavioural Therapy & Prolonged Exposure Therapy	No treatment	1 session weekly for 10 weeks (2.5 months)	0 and 3 months	PTSD	Income, Consumption & input expenditure, Employment	1019 EUR, 2012
Author, year	Country	Sample & age	Intervention category	Therapeutic type	Control group category	Description of intervention	Follow-up time points*	Target mental disorder	Economic outcomes**	Costs (per cap.)
Other										
Angelucci et al. 2024	India	602 adults 18+	Pharmacological	Medication: Antidepressants	No treatment	8 sessions monthly	-2, 13 months post intervention	Depression	Assets, Education, Income, Consumption & input expenditure, Job search, Time in work	221 USD, 2017
Gureje et al. 2020	Ghana and Nigeria	286 adults, 18+	Psychosocial & Pharmacological	Collaborative shared care: Traditional & Faith Healers & PHC; & Medication: Antipsychotics	No treatment	At least 1 visit weekly over 3-6 months	0 months	Schizophrenia	Functioning at work	444 USD, 2017/2018
Pan et al. 2015	China	195 adults, 18-65	Psychosocial & Pharmacological	Cognitive Behavioural Therapy & Methadone Maintenance Therapy (MMT)	TAU Pharm: MMT only	1 session weekly for 26 weeks (5 months)	3 & 6.5 months after start, 0.5 after end	Substance dependence (Heroin)	Employment	-
Ran et al. 2003; 2015	China	326 adults, 18+	Pharmacological	Medication: Antipsychotics	EUC	Medication for 9 months	0 and 159 months	Schizophrenia	Unable to work	1300 RMB, 1994

\* Assessment time point in months after intervention ends (not after intervention start/baseline)

\*\* See Table A4 for full explanation of economic outcomes

# I Costs

Cost data was available for the following studies: Blattman et al. (2017), Nadkarni et al. (2017b,a), Ran et al. (2003, 2015), Patel et al. (2017), Weobong et al. (2017), Buttorff et al. (2012), Hall et al. (2014), Xiong et al. (1994), Wang et al. (2017), Baranov et al. (2020), Fuhr et al. (2019), Sikander et al. (2019), Angelucci and Bennett (2024), Nadkarni et al. (2019), Bhat et al. (2022), Haushofer et al. (2020), Chatterjee et al. (2014), Luo et al. (2019), Gureje et al. (2020), Patel et al. (2011).

For the remaining papers, cost data was not available: Valencia et al. (2007), Xiang et al. (1994), Betancourt et al. (2014), Bolton et al. (2003), Duarte et al. (2009), Ayoughi et al. (2012), Hirani et al. (2010), Min et al. (2011), Nagarajaiah et al. (2013), Pan et al. (2015), Cilliers et al. (2016), Zhang et al. (1998), Xiong et al. (2007), Chuan-qian et al. (2005), Barker et al. (2022), Meffert et al. (2021), Vizzotto et al. (2021), Xu et al. (2021).

Table A26: Cost overview

	Median	(10 <sup>th</sup> pct)	(90 <sup>th</sup> pct)
<i>By intervention-condition combination</i>			
Psych. + CMD	104.98	1.43	1226.41
Combination + SMD	180.09	55.69	570.96
Psych. + PTSD	1599.49	1456.28	1742.69
Psych. + SUD	42.52	35.14	370.37
Other interventions	239.43	227.95	457.97
<i>By region</i>			
East Asia & Pacific	239.43	55.69	570.96
Europe & Central Asia	1456.28	1456.28	1456.28
Latin America & Caribbean			
South Asia	104.98	12.79	180.09
Sub-Saharan Africa	842.19	370.37	1742.69

*Notes:* This table shows intervention costs per participant in 2011 US-Dollars. Column 1 shows the median, columns 2 and 3 show the 10th and 90th percentile. No cost data is available for studies in Latin America.

Table A27: Study characteristics by whether cost data is available

	(1) Share (with cost data)	(2) (SD)	(3) Share (without cost data)	(4) (SD)	(5) Cost data difference	(6) (SE)
<b>Panel A: All interventions</b>						
<b>Intervention-condition combination</b> ( <i>mutually exclusive</i> )						
Psychosocial + common mental disorders (CMD)	0.45	(0.50)	0.37	(0.50)	0.08	(0.16)
Psychosocial + severe mental disorders (SMD)	0.15	(0.37)	0.32	(0.48)	-0.17	(0.14)
Psychosocial + post-traumatic stress disorders (PTSD)	0.10	(0.31)	0.16	(0.37)	-0.06	(0.11)
Psychosocial + substance use disorders (SUD)	0.15	(0.37)	0.11	(0.32)	0.04	(0.11)
Other interventions	0.15	(0.37)	0.05	(0.23)	0.10	(0.10)
<b>Control condition</b> ( <i>mutually exclusive</i> )						
Enhanced Usual Care	0.55	(0.50)	0.05	(0.23)	0.50	(0.13)***
No Treatment	0.35	(0.49)	0.37	(0.50)	-0.02	(0.16)
Treatment As Usual (Pharmacological)	0.10	(0.31)	0.58	(0.50)	-0.48	(0.14)***
<b>Panel B: Outcome measures</b>						
<b>Economic outcomes</b>						
Employment (dummy)	0.25	(0.44)	0.11	(0.32)	0.14	(0.12)
Time in work	0.25	(0.44)	0.11	(0.32)	0.14	(0.12)
Unable to work	0.15	(0.37)	0.11	(0.32)	0.04	(0.11)
Days unable to work	0.50	(0.50)	0.16	(0.37)	0.34	(0.14)**
Functioning at work	0.20	(0.41)	0.47	(0.50)	-0.27	(0.15)*
Job search	0.15	(0.37)	0.00	(0.00)	0.15	(0.08)*
Education	0.10	(0.31)	0.05	(0.23)	0.05	(0.09)
Assets	0.15	(0.37)	0.05	(0.23)	0.10	(0.10)
Income, consumption and input expenditure	0.35	(0.49)	0.00	(0.00)	0.35	(0.11)***
Subjective poverty measures	0.00	(0.00)	0.21	(0.42)	-0.21	(0.10)**
Social networks	0.05	(0.22)	0.05	(0.23)	-0.00	(0.07)
Other	0.10	(0.31)	0.05	(0.23)	0.05	(0.09)
<b>Mental health outcomes (all)</b>						
Suicide attempts or at risk of suicide	0.45	(0.50)	0.05	(0.23)	0.40	(0.13)***
Relapse (dummy)	0.30	(0.47)	0.11	(0.32)	0.19	(0.13)
Recovery (dummy)	0.15	(0.37)	0.05	(0.23)	0.10	(0.10)
Rehospitalisation	0.05	(0.22)	0.16	(0.37)	-0.11	(0.10)
Diagnosed with mental disorder	0.20	(0.41)	0.16	(0.37)	0.04	(0.13)
Overall assessment of mental disorder	0.15	(0.37)	0.21	(0.42)	-0.06	(0.13)
Substance use	0.15	(0.37)	0.16	(0.37)	-0.01	(0.12)
CMD symptoms	0.70	(0.47)	0.47	(0.50)	0.23	(0.16)
PTSD symptoms	0.15	(0.37)	0.16	(0.37)	-0.01	(0.12)
SMD symptoms	0.20	(0.41)	0.11	(0.32)	0.09	(0.12)
Overall measures of functioning	0.80	(0.41)	0.47	(0.50)	0.33	(0.15)**
Functioning in social interactions	0.05	(0.22)	0.21	(0.42)	-0.16	(0.11)
Self-regulation	0.10	(0.31)	0.11	(0.32)	-0.01	(0.10)
Self-esteem/self-efficacy	0.05	(0.22)	0.21	(0.42)	-0.16	(0.11)
Cognition	0.10	(0.31)	0.16	(0.37)	-0.06	(0.11)
Physical health	0.00	(0.00)	0.21	(0.42)	-0.21	(0.10)**

Notes: This table shows the mean prevalence for each intervention characteristic listed in the rows separately by whether the intervention reports cost data (columns 1 and 2) or not (columns 3 and 4). The mean difference in study characteristic by whether the intervention has cost data or not is calculated by OLS regression in columns 5 and 6. Each row is based on a separate regression over all N=39 interventions.